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6 november 2008. Daar sta ik, Sandra Phlippen, geboren te Kerkrade als dochter van 
José en Josef Phlippen, zusje van Stephanie Phlippen. Wauw, wat ben ik trots. De 
mijlpaal van een promotie is zo groot dat het je bij je oorsprong stil doet staan. 
Hoewel een promotie geen verrassing hoeft te zijn gezien mijn eerdere activiteiten op 
het gymnasium en de twee afgeronde studies erna, zullen de meeste mensen mij niet 
direct als academicus inschatten, maar eerder als sociale netwerker. Beide kanten 
horen bij mij en dat ze niet altijd even gemakkelijk samen gaan komt tot uiting in een 
duidelijk 2-perioden promotie model.  
 
Tijdens de eerste helft van mijn promotie overheerste mijn sociale kant. Inhoudelijke 
verkenning, verbreding en tenslotte verdieping van mijn kennis gingen prima samen 
met aio-clubjes, feestjes en vele andere avonturen. Voor de inspiratie die werd 
opgedaan tijdens talloze weekendtrips en congressen was meer nodig dan mijn luttele 
aio-salaris, waarvoor ik pappa dan ook zeer erkentelijk ben. Centrale figuren van het 
eerste uur die mijn hedonistische levensstijl ondersteunden zijn onder andere Stefano, 
Rob, Vali, Tibor, Sebi, Viktoria, Stefan, Daina en Kevin. Met Francesco Ravazzolo, 
mijn kamergenoot, heb ik lief en leed gedeeld. Met name door hem was onze kamer 
H16-10 lange tijd het sociale epicentrum van het Tinbergen Instituut. Een klein aantal 
aio’s zijn mij dierbaar. Streepje, Michiel, Francesco, Elaine, Gus, Bas, Flor en Romy 
weten dat. Met Ward en Jan Frederik heb ik gouden koffiekamertijden gedeeld, 
waarbij mijn links-liberale politieke standpunt alleen maar sterker is geworden. 
Vrouwen zijn zeldzaam bij het Tinbergen Instituut, maar Silvia en Mariëlle zijn twee 
briljantjes.  
 
In het najaar van 2004 ontstond de verdieping in mijn werk tijdens een werkbezoek 
aan de universiteit van Florence en in Lucca. Massimo Riccaboni heeft mij 
geïnspireerd en getraind in het netwerk denken. Sindsdien kijk ik gefascineerd door 
een netwerkbril naar de wereld. Andere brildragers zijn Marco van der Leij, Skye 
Bender-de-Mol, Andrea Knecht, Marielle Non, Martijn Burger, Bas Karreman, 
Ronald Wall en mijn promotor Bert van der Knaap. Mijn laatste dankwoorden voor 
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deze eerste periode zijn voor de TI staf. Maarten, Ine, Dave, de 2 Cariene’s, Jaap en 
Arianne leidden een mooi instituut.  
 
Toen kwam Robert Dur. Zijn liefde bracht rust en concentratie die nodig waren voor 
het werkelijke schrijven van een proefschrift. Maar nog belangrijker dan dat, Robert 
maakte al het andere relatief en hielp mij om twijfel om te zetten in vastberadenheid.  
Papers werden geschreven, congressen bezocht en positie genomen in het 
wetenschappelijke debat. Dit alles, en het college geven aan 800 eerstejaars economie 
studenten heeft mij gevormd tot wie ik nu ben. Mijn promotoren Bert van der Knaap 
en Harry Commandeur hebben hierin een belangrijke rol gespeeld. Bert gaf mij de 
ruimte om te groeien, hielp mij op mijn werk reflecteren en samen kregen we ideeën 
waar we enthousiast van werden. Ik heb je kamer zowel huilend als juichend verlaten, 
hoewel je dat eerste hoop ik nooit hebt gezien. Gelukkig was er na je kamer altijd 
Nita.. Ik ben je dankbaar voor alles Bert. Harry Commandeur is een fantastische 
tweede promotor. Alles wat ik schreef werd grondig gelezen en we hebben vele uren 
zitten bomen over interpretaties, ideeën en uitbreidingen. Mijn werk is beter geworden 
door zijn commentaar. 
 
Een hoogtepunt was mijn onderzoeksproject bij McKinsey & Company in Brussel en 
Louvain-la-Neuve. Van An Vermeersch en Daniel Berhin heb ik bijvoorbeeld geleerd 
dat het bottom-up denken in de wetenschap veel sneller en efficiënter kan. Amanda, 
Alain, Filip, Arlene, Natu en de anderen in de pharma practice waren fijne collega’s. 
Daarbuiten ben ik Bernard Paque, Leigh Weiss en Olivier van Rietpaap dankbaar voor 
hun bereidheid tot kennisuitwisseling en introducties. 
 
In beide perioden van mijn promotie en al ver daarvoor waren er mijn 
hartsvriendinnen die onvoorwaardelijk al mijn uitspattingen en onhebbelijkheden 
accepteren. Amber, Etje, Francesca, Johanna, Marloeschka, en Streep, wat fijn dat 
jullie er zijn. Als laatste wil ik de Commissieleden hartelijk bedanken voor hun inzet 
en het Erasmus Trustfonds voor de royale financiële bijdragen aan mijn congres- en 
werkbezoeken in het buitenland. 
 
Voorwoord (acknowledgements) 
En toen was er Elodie. Ook al heb je mijn promotie aanzienlijk vertraagd, in je 
moeder heb je je grootste fan gevonden. Hoewel het steeds vechten blijft met je vader 
om die positie. Over 2 weekjes ben je een jaar in ons leven. Het mooiste jaar.  
 
Zittend in Dudok Rotterdam schrijf ik dit voorwoord. Rotterdam is de stad waarin dit 
alles heeft plaatsgevonden. Rotterdam is mijn stad. De ruimte, de wind, de rauwheid, 
de stilte en de stedelijkheid brengen mij troost en inspireren. Het is de stad van sterke, 
individuele koppen aan wie ik dit proefschrift opdraag.  
 
 
 
Sandra Phlippen 
Rotterdam, 2 september 2008 
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Chapter 1  Introduction 
1.1 Motivation, aim, and scope  
In studying firm behavior, economists tend to have an under-socialized view of the 
firm, while sociologists tend to have an over-socialized view of the firm. Socialization 
in this respect refers to the extent to which a firm is embedded in- and affected by its 
relational environment. On the one extreme, economists building on transaction costs 
economics assume the market to be an anonymous environment where firms can 
behave opportunistically without repercussions. On the other extreme, sociologists 
argue that the market consists of a dense web of existing and previous transactions in 
which a firm is embedded, and that this embeddedness is defining the range of 
strategies a firm can pursue or even perceive1. While the former view mainly 
considers the impact of behavior on a static environment and the latter focuses on the 
impact of environment on firm behavior, this thesis provides a co-evolutionary 
perspective, wherein firm behavior and environmental structures affect each other 
mutually. This dynamic perspective on innovation strategies of firms allows us to take 
into accounts both ongoing and previous transactions, which together constitutes a 
firm’s relational environment. We study how firm behavior is affected by its network 
position and how network structures change as a result of firm behavior. We shall 
focus on the biopharmaceutical industry. Besides the network of collaborations, the 
environment in which a typical biopharmaceutical firm operates consists of a number 
of other elements as depicted in figure 1.1. This figure shows the main environmental 
elements to which a firm in the pharmaceutical industry is subject to.  
                                                 
1 The notion that firms face different ‘menus’ of technological choices because of the path 
dependent development trajectories is put forward by Nelson & Winter (1982). 
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Fig. 1.1 - The environment of the firm
 
One very important element to the firm is the technological environment, since in the 
pharmaceutical industry firms are active in a highly volatile technological 
environment, which requires them to continuously adapt and to respond to new 
technological developments. The institutional and regulatory environments in which 
the firm operates are also of great importance. While the institutional and the 
regulatory environment are evolving rather slowly over time, and are outside the 
scope of this thesis, they are of great importance for understanding the innovation 
strategy of the firm. Especially, the issue of intellectual property right protection is of 
major importance in providing firms with the freedom to manoeuvre outside their 
boundaries. However, the complexity of this latter issue deserves a dissertation of its 
own. Finally, there is the geographical environment that we consider in understanding 
innovation strategies of pharmaceutical firms. In science-based industries, such as the 
pharmaceutical industry, the physical environment of the firm is particularly 
important to understand who benefits from (mainly) public (scientific) knowledge 
spillovers.  
Within these environments, firms face the decision to either internalize their 
production, to buy from the market, or to ally with partners. For the development of 
new drugs, which is a lengthy, costly and highly uncertain process, firms develop 
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strategic portfolios in which they make, buy and ally simultaneously. Especially the 
large, established pharmaceutical firms, which dominate the industry have for the last 
decade been searching for new strategic approaches to combine in-house activities 
with boundary spanning activities2 3. The main reason being the continuous decrease 
of new drugs in their pipelines combined with expiring patent protection on 
blockbuster drugs. For other organizations in the industry, such as smaller biotech 
firms or academic organizations, the willingness of pharmaceutical firms to engage in 
boundary spanning activities provides interesting opportunities for innovation. 
Boundary spanning activities between organizations in the pharmaceutical industry 
can be depicted as a network of organizations and their inter-firm relations. Relations 
in this network represent strategies of organizations to access knowledge externally. 
This dissertation focuses on how geographical-, relational, and cognitive 
(technological) proximity between two organizations affects a firm’s access to 
external knowledge and henceforth their innovation strategies.  
In this introductory chapter we first provide a short overview of the theoretical 
discussion on firm strategy and the impact of proximities. Next, we introduce the 
reader to our empirical setting by explaining the production process of drug 
development and by providing a short historical overview. Finally the outline of the 
remainder of this book is presented to the reader.   
 
1.2 Innovation strategy of the firm 
1.2.1 Dynamic capabilities 
Firms operating in environments of rapid technological change are required to 
develop dynamic capabilities in order to survive the waves of creative destruction in 
an industry (Teece, et al., 1997, Prahalad & Hamel, 1990; Penrose, 1995; Schumpeter, 
1942). Dynamic capabilities refer to a firm’s ability to exploit its existing internal 
                                                 
2 For example Glaxo Smith-Kline has set up various centers of excellence for external drug 
discovery where specific attempts are made to align in-house R&D with external drug 
discovery efforts. Financial Times, June 8 2008. 
3 Elli Lilly, to give an example of one of the largest drug developing firms, is one of those 
firms that are continuously searching for new strategies to boost their drug discovery output. 
In 2001 it has spun out a ‘virtual’ firm named InnoCentive, which poses drug discovery 
problems on the web including fees for ‘solvers’ (Travis, 2008).  
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knowledge and simultaneously explore new (external) knowledge to address changing 
environments (Teece et al, 1997; O’Reilly & Tushman, 2004). Together exploration 
and exploitation can be seen as a cycle of innovation, where new products, new 
technologies or new applications are constantly being explored and exploited in new 
markets (Nooteboom, 2000). Ideas, institutions, and organizational routines first settle 
down in a ‘best practice’ or a dominant design. That shows up the limits of validity as 
well as indications for novel combinations, which break down existing structures. 
This leads to a next round of convergence into a dominant design.  
By analyzing a firm’s innovation strategy in terms of dynamic capabilities we 
encompass several theoretical views of the firm. The transaction costs theory of the 
firm and the resourced based view of the firm provide insights on how firms choose 
an optimal governance structure that minimizes the costs and maximizes the value of 
each individual transaction. To understand the potential complementarities between 
individual transactions in a firm’s portfolio (or a network) we further consider 3 other 
theoretical perspectives on firm strategy: the relational view of the firm, which 
emphasizes the whole portfolio of transactions as a unique resource of the firm. The 
embeddedness view of the firm, which focuses on the costs minimizing features of the 
network surrounding the firm. Finally, we consider the real options approach to firm 
strategy, which adds additional arguments to how a firm can strategize on its 
portfolio. The real options approach mainly argues that firms can capitalize on 
transaction value and simultaneously minimize transaction costs by confronting 
uncertainty with flexibility, rather than avoiding uncertainty (Kogut, 1991; Leiblein, 
2003) 
 
1.2.2 Make, buy or ally 
The strategy of a firm on how it is going to govern its transactions is one of the core 
issues in economics. Possible governance structures range from full integration, which 
means that transactions are performed internally to arms-length transactions in the 
market, which refers to a completely disintegrated structure. In between these two 
extremes are long term contracts, strategic alliances & joint ventures, and parent 
subsidiary relationships ranging from less- to more integrated governance structures 
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(Besanko, 2007). Figure 1.2 plots the range of possible transactions ranging from full 
integration to pure market transactions. 
 
Fig. 1.2 - Range of mechanisms to govern transactions
Based on Yoshino & Rangan (1995)
Dissolution of entity
Strategic alliances
Inter-firm linkages
Equity arrangementsContractual agreements
Traditional Creation of entityNon-traditional 
Technology 
acquisition
Licensing 
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By and large, these governance structures vary along three dimensions: efficiency 
(transaction value), costs (transaction costs), and the frequency of transactions.  
 
Efficiency 
According to transaction costs economics (TCE), markets are generally more efficient 
than hierarchies, since in a market a product can serve multiple customers and achieve 
scale and scope economies. On the other hand the firm (representing a hierarchy) is 
argued to have more superior coordinative attributes and information processing 
abilities (Gulati & Singh, 1998). When transactions are geared toward innovation, 
coordination and information processing becomes increasingly important. This is 
because transactions aimed at innovation contain rather large amounts of tacit 
(embedded) knowledge, which is not perfectly tradable and requires more 
coordination and processing capabilities (Kogut & Zander, 1992). While performing a 
transaction internally might be more efficient in terms of coordinating and processing 
tacit knowledge, it might be impossible to acquire these resources within the firm 
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given the difficulties of mobilizing them. Indeed, the resource based view (RBV) of 
the firm argues that firms exist because they possess valuable, rare, hard to imitate 
and immobile resources such as tacit (embedded) knowledge (Barney, 1991). Because 
these resources are sticky, firms are heterogeneous, which in turn enables rent 
creation from transactions outside the boundaries of the firm. This latter requirement 
is particularly prevailing when firms are active in technologically volatile markets. 
When transactions are focused on innovation, stickiness prevents a firm to fully 
integrate resources internally, but it also prevents the transfer of these resources in 
pure market transactions. In other words, when transactions entail rather large 
amounts of tacit (embedded) knowledge (which is sticky) strategic alliances between 
firms might be most efficient. With this intermediate form of governance a firm can 
still achieve scale and scope economies by interacting with multiple partners and at 
the same time allow sticky information to gradually be transferred between alliance 
partners. Finally, Dyer and Singh (1998) introduce the notion of how a complete 
portfolio of boundary spanning transactions can be viewed as a unique resource of the 
firm. Taken together, the portfolio of transactions (or the ego-network) can provide a 
firm with relational rents, which creates a competitive advantage in an industry. 
Relational rents are defined as “supernormal profit jointly generated in an exchange 
relationship that cannot be generated by either firm in isolation and can only be 
created through the joint idiosyncratic contributions of the specific alliance partners” 
(Dyer & Singh, 1998, p.662). While the relational view mainly emphasizes value 
creation as a competitive resource of the firm, in the following section we will 
emphasize how the portfolio of boundary spanning transactions prevents knowledge 
appropriation and thereby enables a sustainable competitive advantage.  
 
Costs 
There are two main economic hazards involved in transactions. These are the danger 
of opportunistic behavior by transaction partners, and the danger of being unable to 
overview the whole transaction process, which is referred to as bounded rationality. 
Opportunistic behavior can entail the unintended appropriation of knowledge 
(knowledge leakage) or the unwillingness to pay once a transaction has started. 
Governance structures vary in the way in which, and the extent to which they mitigate 
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the dangers of a transaction as described above. According to transactions costs 
economics (Williamson, 1975), market transactions can in principle mitigate 
opportunistic behavior through contracts that specify the mutual agreements between 
agents in a market. However, given that agents cannot oversee the complete 
transaction, contracts are by default incomplete. Moreover, when transactions are 
aimed at exploring novel information, they are often highly specific and their outcome 
uncertain or hard to determine in advance. In these cases, contracts are even more 
incomplete and this increases the danger of knowledge leakage. In addition, the 
uncertainty about the outcome of a transaction ex-ante requires renegotiation along 
the way, which given the specificity of knowledge, greatly increases the danger of 
hold-up by the market agent (Leiblein & Miller, 2003). These circumstances lead 
transaction costs economists to conclude that the transaction should be vertically 
integrated inside the firm, where “fiat rules the day” (Leiblein, 2003, p. 941). 
However, real options theory provides compelling arguments for refraining from 
vertical integration since this could become costly in the future. More specifically, 
real options theory argues that in environments where technologies change rapidly, 
vertical integration decreases the flexibility to abandon assets that turn out less 
valuable after technological change (Pindyk, 1991). If a firm governs its transactions 
through a portfolio of strategic alliances with various partners it can preserve its 
flexibility by opting to withdraw from a less promising alliance or it can obtain scope 
economies by re-applying similar technologies in different relational transactions and 
applications. This latter strategy has also been recognized as hedging against the 
dangers of knowledge appropriation because firms create unique ‘bundles’ of relation 
specific knowledge, which is hard to imitate4 (Dyer & Singh, 1998).  
Thus far we have seen that TCE considers contracting or, if impossible, 
internalization to be the answer to dealing with the risks of opportunistic behavior. By 
analyzing each individual transaction, TCE takes a dyadic view on the innovation 
strategy of the firm. The real options theory provides a broader perspective by 
analyzing the whole portfolio of transactions in which a firm is engaged. It argues that 
uncertainties from the environment can be mitigated by diversifying transactions in 
such a manner that the firm can flexibly switch between transactions if environmental 
                                                 
4 In the relational view of the firm this is referred to as inter-organizational asset 
interconnectedness (Dyer & Singh, 1998) 
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conditions change. The network perspective takes an even broader perspective by not 
only taking into account the transaction partners of a firm, but also the partners’ 
partners of the firm and their transactions. The theory argues that the more 
‘embedded’ a firm is in a ‘web’ of current, previous, and partnering transactions, the 
less it will have to spend on mitigating the risks of opportunistic behavior 
(Granovetter, 1973). More precisely, opportunistic behavior is prevented because of 
reputation information circling around in the network of transactions. Additionally, 
reputation information enables the enforcement of social norms and eventually ‘trust’ 
between transacting partners, which are recognized to be good alternatives for costly 
contracting.   
 
Transaction frequency 
In general one can say that transactions occur more frequently as the firm moves from 
more integrated (in-house) governance structures to less integrated (market) 
transactions. Furthermore, contracts are an important part of a transaction regardless 
of the type of governance structure. However, the more frequent transactions are 
likely to occur, the more difficult it becomes to make contracts complete (given 
bounded rationality and increased uncertainty) and the more important alternative 
approaches to control transaction outcomes become. Within the boundaries of the 
firm, contracts are enforced and complemented through power differences and fiat. 
Beyond the boundaries of the firm, where we distinguish arms-length transactions and 
embedded transactions (strategic alliances), it has been found that in more embedded 
transactions, contracts are complemented by trust (Uzzi, 1997). Trust builds on 
heuristics of experience, which accumulates over time (Uzzi, 1997, p.43-44). Finally, 
by transacting more frequently, partners involved in joint problem solving are better 
able to overcome asymmetric information between them. The reason for this is that 
transactions are reciprocated over time, which leads to relation-specific investments 
by both partners. Although the specificity of investments can easily lead to situations 
of small-numbers bargaining and subsequent hold-up problems, the situation is 
unlikely to generate opportunistic behavior by any partner because of mutual 
dependencies.   
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Thus far we have discussed the considerations of firms in choosing the appropriate 
governance structure to encompass their innovation activities. When firms operate in 
technologically volatile environments, there are convincing arguments for why firms 
should complement their existing in-house activities with explorative search beyond 
their boundaries. The question that has remained largely under-exposed is how firms 
should go about in achieving complementarities between the different transactions 
they engage in. Put differently, when are boundary spanning transactions usable for 
achieving innovation performance internally? 
 
1.2.3 Availability and usability of knowledge 
In order to effectively use external sources of knowledge, firms first need to gain 
access to knowledge (availability) and second they need to be able to use or absorb 
this knowledge (usability). The issue of availability and usability of knowledge has 
been analyzed by Simon (1958) and was later expanded by Cohen and Levinthal 
(1989). The strategies that firms develop in their search endeavor for available and 
usable knowledge has mainly been categorized in terms of local-, and non-local 
search (Simon, 1958; Nelson & Winter, 1982; Katila & Ahuja, 2002). Local and non-
local search represent the ends of a number of continuums that we will call 
proximities.  
 
Access to / availability of knowledge 
The strategies of organizations to acquire access to new knowledge and technologies 
depend on the type and source of knowledge and on the boundary spanning 
capabilities of the organization. The source of knowledge can be public or private, and 
the type of knowledge can be codified or rather tacit. Public, codified knowledge, 
which is non-excludable and non-rival is found to spill-over to organizations located 
within geographical proximity of the source of knowledge. Access to private 
knowledge can be obtained through vertical integration such as labor mobility or 
mergers & acquisitions or through boundary spanning activities such as strategic 
alliances or arms-length market transactions. This thesis mainly focuses on strategic 
alliances between organizations as an important means to obtain access to external 
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knowledge. Together these strategic alliances form a large network, covering all 
phases in the production process. While the network of strategic alliances is often 
claimed to be the locus of innovation, the extent to which new knowledge is actually 
generated through the alliance depends on the type of strategic collaboration. R&D 
collaborations or co-development alliances are for example most often alliances 
whereby all partners involved contribute some of their knowledge to the alliance. 
When transactions are licensing agreements, knowledge has most likely been created 
within the principal firm, as a partnering firm pays a license fee to acquire knowledge 
from the principal firm.  
 
Usability of knowledge / absorption capacity 
While access to knowledge is a necessary condition for innovation, it is not a 
sufficient one. Once a firm has obtained access to either a public or a private source of 
external knowledge, this knowledge needs to be usable within the organization. 
According to Cohen and Levinthal (1989), firms need to build a capacity to absorb 
external information. A firm’s absorption capacity is defined as its ‘relevant stock of 
prior knowledge’. ‘Prior knowledge’ refers to the knowledge that a firm has built 
internally before tapping into the external source of knowledge. A ‘relevant’ stock of 
knowledge can be interpreted as knowledge that is similar to the external knowledge 
that the firm is aiming to obtain.  
 
1.2.4 Proximities 
There are various forms of proximity, which affect an organization’s ability to access 
external knowledge and its ability to absorb this knowledge and turn it into 
innovation. While it is often stated otherwise, we argue that proximities are important 
for not only the transfer and absorption of tacit knowledge, but also for codified 
knowledge. Even when knowledge is codified, the interpretation and internalization of 
knowledge still requires tacit knowledge and therewith, proximity (Nonaka & 
Takeuchi, 1995 pp 72; Howells, 2002; Boschma, 2005). The most straightforward 
form of proximity is geographical proximity, which is the physical distance between 
two or more actors (either public of private). Cognitive proximity is defined as the 
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degree of commonality in knowledge domain between two actors. This knowledge 
domain acts as a framework by which we perceive, interpret, understand and evaluate 
new information. The cognitive framework is constantly reshaped in the process of 
interaction with others (Mead, 1934). In practice, cognitive proximity is often 
measured as technological proximity, which refers to the degree of overlap in the 
technologies two actors are specialized in.  
A third form of proximity is relational or network proximity. Relational proximity 
refers to how close two actors are in a network. Usually relational proximity is 
expressed as negative relational distance. Relational distance is a network measure. It 
starts with the notion that all organizations are nodes and each exchange of knowledge 
between these organizations is an edge between nodes. The relational distance 
between any pair of nodes is the number of edges one has to surpass to reach the 
other. At a distance of 1, two firms are partners, and a distance of 2 implies that two 
firms share a common third partner. Relational proximity comes very close to the 
notion of social proximity, which is defined as “a socially embedded relation between 
agents at the micro-level. Relations between actors are socially embedded when they 
involve trust based on friendship, kinship and experience” (Boschma, 2005 pp.66). 
The difference between social and relational proximity is that social proximity 
describes a dyadic feature of a relation, while relational proximity takes the whole 
network of previous collaborations with all partners into account. Table 1.1 
summarizes the effects of three forms of proximities on the availability and usability 
of external knowledge.  
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Table 1.1 – Effect of proximities on availability and usability of 
external knowledge 
Cognitive proximity increases a 
firms’ absorption capacity 
(Cohen & Levinthal, 1989)
Cognitive proximity is required to access 
epistemic communities with highly specified 
tacit knowledge. 
Cognitive 
proximity
Previous partner experience 
improves alliance management 
and increases knowledge 
transfer within the alliance 
(Gulati, 1995)
Socially embedded relations 
based on trust facilitate tacit 
knowledge transfer (Maskell & 
Malmberg, 1999)
Public knowledge spillovers require 
relational proximity (and geographical 
proximity enables social network formation) 
(Breschi& Lissoni, 2001)
Relational proximity creates transitivity and 
social control which, facilitates new partner 
formation (Gulati, 1995)
Relational 
(social) 
proximity
Face-to-face contacts facilitate 
the transfer of highly specific 
tacit knowledge (Zucker, 1996)
Public (codified) knowledge spillovers are 
geographically bounded (Jaffe & 
Trajtenberg, 1993)
Geographical 
proximity
Usability of knowledge 
(absorption capacity)Availability of knowledge (access)
 
 
Geographical proximity 
Patents, which are highly codified sources of public knowledge, are more likely to 
build on patents that were applied within geographical vicinity then on patents that are 
applied at distant locations (Jaffe et al, 1993). This finding is interpreted as evidence 
of geographically mediated public knowledge spillovers. It implies that firms who aim 
to access this knowledge benefit from being co-located to the source of knowledge. 
Geographical proximity has proven to be important for the transfer and absorption of 
tacit knowledge between organizations in our empirical setting; the biopharmaceutical 
industry. One obvious reason for this is that the natural excludability of knowledge in 
this industry requires scientists who have invented a new drug or a technology are 
needed for further development and exploitation of the invention. The dual occupation 
of these scientists creates human capital immobility and thereby induces knowledge 
transfer within geographical proximity. Co-located organizations are more likely to 
engage in long-term face-to-face contacts. These contacts create mutual trust, shared 
social norms, and an epistemic community that are important for successful transfer 
and absorption of tacit knowledge (Zucker, 1996).  
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Relational proximity 
While Jaffe et al (1993) found that patents are more likely to be cited by inventors that 
are geographically proximate, it seems, that relational proximity between 
organizations is even a better predictor of who cites (and accesses knowledge of ) 
whom (Breschi & Lissoni, 2001). It is generally acknowledged that geographical 
proximity alone is not sufficient for firms to enter knowledge transfer arrangements or 
to benefit from spillovers, it is most likely that co-location strengthens other 
dimensions of proximity (Zucker, 1996). For instance, a minimum amount of 
cognitive proximity is deemed necessary for absorption of external knowledge, and 
co-location is found to induce local processes of imitation and selection, which create 
cognitive proximity (Boschma, 2004). 
 
At the level of the firm, Gulati argues that relational proximity facilitates the 
formation of new collaborations between organizations. Especially when a firm’s 
network of collaborations has a clique-like structure (i.e. its existing partners 
collaborate as well), reputation information circulates and functions as a social control 
mechanism against opportunistic behavior. Social control in turn helps firms engage 
in risky undertakings such as the start of a collaboration with a new ‘unknown’ 
partner. Once collaboration has started, the actors involved may become more 
‘socially close’ as the time spent collaborating increases. This includes for example 
the formation of direct communication lines between technical staff of two 
organizations or the development of shared jargon. As a result, externally sourced 
knowledge can be more fine-tuned to the needs of the organization, which increases 
its ability to absorb external knowledge and ultimately to innovate.   
 
Cognitive proximity 
Cognitive proximity is found to positively affect an organization’s ability to access 
and use external information. Within the organizational learning literature it has been 
shown that new knowledge acquisition is more successful when internal capabilities 
are similar to new knowledge that is being sought externally (Dussauge & Garrette, 
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1999). Especially when knowledge is highly complex and tacit, specialized epistemic 
communities evolve, which require a high level of cognitive proximity to participate. 
In science, for example, epistemic communities evolve around specific sub-disciplines 
within a scientific field. Obtaining access to such communities through e.g. 
conference participation requires a very high level of knowledge similarity. 
 
Too much proximity and interaction effects  
While emphasis has mainly been on the positive effects of proximity, it is 
undisputable that too much proximity can have detrimental effects for innovation 
performance or even the likelihood of obtaining access to external knowledge. The 
negative effects of too much proximity become apparent when the interaction effects 
between different forms of proximity are taken into account. For example, firms in 
dense clusters of co-located organizations can suffer from lock-inn effects due to 
redundancy or from unintended knowledge flows if these organizations are densely 
connected through more or less formal relations. In this case, geographical proximity 
coincides with relational proximity. Additionally, the probability of lock-inn effects or 
unintended knowledge flows is even higher when organizations are also active in a 
similar knowledge domain, an argument, which adds cognitive proximity to the 
equation.  
Furthermore, the usability of external knowledge increases with the degree of 
cognitive proximity up to a certain point. A study by Wuyts (2005) reveals the 
inverted u-shaped relation between cognitive proximity between two firms and their 
ability to learn from each other. Indeed, knowledge similarity initially increases a 
firm’s ability to absorb external knowledge, but too much overlap in two actors’ 
knowledge domain reduces the newness of information and is found to negatively 
affect the ability to be innovative.  
At the level of a cluster there is empirical ambiguity about whether specialization 
(representing cognitive proximity between clustered organizations), or diversity 
amongst co-located firms induces knowledge transfer and innovation performance. 
One the one hand there are studies showing the benefits of flexible specialization 
(Amin & Thrift, 1992; Piore & Sabel, 1984). Flexible specialization means that firms 
and other actors in a cluster specialize in a product line, but have the ability to shift to 
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other related lines with similar technologies rather instantaneously. As a result, these 
clusters are rather homogeneous in terms of technologies, while complementary 
knowledge is exchanged between firms inside the cluster intensively. On the other 
hand, there are studies promoting technological diversity (Prevezer, 1997; Cooke, 
2001). Clusters in which firms are technologically diversified appear to encourage 
cross-fertilization of ideas and technologies between firms, which leads to more 
innovation and firm growth. 
Finally there is contradictory theoretical and empirical evidence about the effect of 
relational proximity on a firms’ innovation capacity. In these studies relational 
proximity and cognitive proximity have not been clearly separated and are mainly 
referred to as local-, and non-local search. Local search implies that firms search for 
new knowledge within the network of existing and previous collaborations. According 
to Cowan (2005) local search enables firms to access knowledge that it can integrate 
with its existing capabilities. In a local network, so the author argues, shared 
language, norms, and collaboration processes have developed, which are particularly 
valuable when new and tacit knowledge is to be exchanged. Non-local search through 
‘distant’ linkages in a network are considered of major importance for innovation by 
Sidhu, Commandeur and Volberda (2007). These authors provide evidence that 
distant linkages provide a firm with access to more novel information, which is 
crucial for innovation.   
 
1.3 Empirical setting: the biopharmaceutical industry 
The biopharmaceutical industry is one of the most interesting industries to study firm 
innovation. The main reason for this is that innovations occur frequently and even 
radical innovations occur regularly. For the production of a new drug there are several 
different types of organizations involved, such as biotech firms, pharmaceutical 
organizations, academic institutes and public-, and private financial organizations. 
While a large part of the production process is still being carried out within the 
boundaries of the firm, there is an abundance of empirical evidence that the 
importance of innovation taking place outside the boundaries of the firm is increasing 
(Hagedoorn, 2001; Orsenigo et al, 2001; Phlippen & Riccaboni, 2008). Boundary 
spanning innovation activity is of interest to us for two reasons. First, it allows us to 
 Chapter 1 Introduction 16
monitor innovations and their antecedents more closely. In-house R&D is often 
subject to considerable scrutiny before made public. Second, inter-organizational 
innovation activities allow us to study industrial players and their activities as a 
network of innovators, which provides valuable complementary insights to standard 
(actor-based) economic thinking about industrial organization. Furthermore, amongst 
the strategic alliances that make up our network, the two main processes of 
innovation, being explorative alliances and exploitative alliances, are clearly 
distinguishable (March, 1991; Jansen, van den Bosch & Volberda, forthcoming). 
Finally, because of the science driven features of new drug development, a large part 
of the information that is exchanged between organizations is tacit. Tacit information 
transfer is, as we have discussed in the previous section, assumed to be strongly 
affected by different forms of proximity.   
 
1.3.1 Drug development process 
The biopharmaceutical industry is strongly innovation driven, as rapid and radical 
technological innovations threaten to render existing products obsolete within a 
relatively short time. In order to compete, firms in the biopharmaceutical industry 
need to continuously develop new or improved drugs and technologies that are 
valuable and patentable. The skills required for new drug development range from 
basic research and discovery to clinical testing procedures, manufacturing, marketing 
and distribution and knowledge of and experience with the regulatory process. Basic 
research and discovery activities are aimed at exploring new chemical targets or 
molecular compounds. These exploration activities are strongly science-driven and 
are often characterized by so-called upstream collaborations between small biotech 
firms and academia. Once a new compound has been discovered, the clinical testing 
procedures range from toxicity testing on animals to large scale testing on patients in 
a controlled hospital environment. At various stages in the process of clinical testing, 
approval from the Federal Drug Administration is required in order to continue the 
testing procedures. Because these clinical testing procedures are extremely expensive, 
large pharmaceutical organizations have specialized in these so-called downstream 
drug development activities.  Once a new drug has received final approval to enter the 
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market, large pharmaceutical firms exploit the new drug in the market using their well 
entrenched marketing and distribution channels.  
 
1.3.2 Historical overview 
Traditionally, the whole process of drug development, both the exploration of new 
compounds and the exploitation of existing compounds, has been conducted in-house 
by large established pharmaceutical firms. The research laboratories of large 
pharmaceutical firms attracted the best chemists from academia worldwide and deeply 
specialized knowledge of disease areas was cultivated in these laboratories. From the 
seventies, a number of radical technological innovations such as the molecular 
biology revolution and the genomics revolution altered the process of drug 
development and the role that various organizations play in drug development. In 
what follows, we will discuss the nature of these innovations, the effect that they had 
on the drug development process and finally the strategies of organizations to cope 
with the innovations.     
 
Molecular biology revolution 
In the 70s and 80s, drug development was characterized by advancement in 
chemistry, pharmacology, microbiology and biochemistry, which together led to what 
was called the molecular biology revolution. Molecular biology potentially enables 
researchers to understand disease processes at the molecular (genetic) level and to 
determine the optimal molecular targets for drug intervention (Drews, 2000). New 
biotechnology drugs based on molecular biology were mainly recombinant proteins 
and monoclonal antibodies.  
Advances in molecular biology originated from American universities and research 
centers. The first firms exploring biotechnologies were science based dedicated 
biotechnology firms who were located closely to the academic sources of knowledge 
in the US in order to collaborate with academic researchers or because of dual 
occupations. Large pharmaceutical firms, who were at that time still only developing 
chemical based compounds, realized the potential of the new biotechnologies, and 
started collaborating with dedicated biotechnology firms. As a result, drug 
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development was no longer the sole territory of large pharmaceuticals, but was 
divided into an explorative part and exploitative part. Dedicated biotech firms (DBFs) 
and academia were collaborating to explore new biotechnology drugs while 
pharmaceutical firms were collaborating with DBFs to access and subsequently 
exploit biotech based drugs on the market. European pharmaceutical firms who were 
eager to access the new biotechnology based drugs were required to collaborate with 
DBFs in the United States. A number of reasons have been identified for the near to 
absence of dedicated biotechnology firms in Europe during the 70s and 80s (Owen-
smith et al., 2002): first, institutional barriers prevented scientists to become 
entrepreneurs as was happening in the United States. Second, while private funding 
through venture capital was not available, public funding from the government was 
too decentralized. While the National Institute of Health was funding centers of 
excellence in the US, European funding came from the national level, which could not 
lead to a critical mass of knowledge. A final reason for the absence of biotech firms in 
Europe is related to regional knowledge trajectories that were evolving in Europe. 
Although, US firms involved in biotechnologies were spatially concentrated in a few 
areas, the innovation activities within these areas were highly diversified. In contrast, 
the spatial concentration of European activities developed alongside specialized 
knowledge trajectories, which impeded cross-fertilization of knowledge (E.g. Max 
Planck institutes).  
In the 70s and 80s, access to knowledge had become an indispensable resource for 
both pharmaceutical firms and for dedicated biotechnology firms. Dedicated biotech 
firms who were aiming to access academic ‘public’ knowledge, located near academic 
centers of excellence in the US to benefit from localized knowledge spillovers. As a 
result, explorative activities in drug development were regionally concentrated in a 
few areas. Large pharmaceutical firms who aimed to exploit biotechnology based 
drugs on the market, formed strategic collaborations with DBFs to access ‘private’ 
knowledge they did not possess in-house themselves. While a large part of the drugs 
that pharmaceutical firms brought to the market still originated in-house, the amount 
of externally sourced drugs were steadily increasing. From the 70s and 80s, a large 
network of collaboration activities started to take form in the biopharmaceutical 
industry. Although European pharmaceutical firms were actively involved in these 
collaboration activities, most firms had American partners, which prevented the 
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formation of an intra-European network (Senker, 2004). In 1978, the Single European 
Act was formed to stimulate intra European research collaboration. This act later 
developed into the European framework programs.  
 
Genomics revolution 
In the beginning of the nineties the Human Genome Project was initiated by the US 
Government to identify the genes that make up the human DNA and store the genetic 
information into huge publicly available databases. While the genetic information was 
publicly available, it was hardly useful since the information came in huge unordered 
amounts. Scientists working on the decoding of the genome, started developing 
technologies to store, organize, screen, and subsequently use the genetic information 
for medical applications. These technologies, referred to as general purpose 
technologies have fundamentally altered the approach to drug development. Before 
the genomics revolution, drug research used to take a more qualitative approach, 
where many scientists worked on developing a few molecules that could effectively 
interfere with a given target. The genomics revolution suddenly enabled the 
identification of hundreds of genetic targets and the screening to thousands of 
molecular compounds simultaneously (Pammoli & Riccaboni, 2002). While this new, 
more quantitative approach to drug research has not delivered on its promises yet, in 
the beginning of the nineties pharmaceutical firms were eager to form strategic 
alliances with general purpose based firms to access these technologies. Today, 
general purpose based technologies have become fully integrated into the process of 
drug development. Also, an increasing amount of new drugs on the market are based 
on biotechnologies.     
What we have seen in this historical overview is that since the beginning of the 70s a 
division of labor took place in the process of drug development. Exploration of new 
molecular compounds was increasinlgy carried out by academia and dedicated biotech 
firms. The testing and exploitation in the market has remained the domain of large 
pharmaceutical firms. The division of labor has made access to knowledge an 
important prerequisite for firms to innovate. This is especially true during periods 
when radical innovations occur that affect the industry in fundamental ways. In figure 
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1.3 we show the relative increase in strategic collaborations in pharmaceutical R&D 
during the molecular biology revolution and during the genomics revolution. 
 
Fig. 1.3 - Percentage change in R&D collaborative agreements
(E - Edges) and organizations (V - Vertices) in the
biopharmaceutical R&D network (1976 - 2002)
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1.4 Outline of the book 
The chapters of this thesis are organized as follows. In chapter two we introduce the 
reader to the developments in the European biopharmaceutical industry over the last 
decade. We empirically explore proximities between European biopharmaceutical 
organizations from two perspectives: the regional clustering of firms in space and the 
network of strategic collaborations between organizations. The aim of this chapter is 
twofold: first, we analyze the changing features of the main regional clusters of 
biopharmaceutical activity by type of organizations present, nature of activities, and 
degree of technological specialization. The second part considers the topological 
features of the European network of strategic alliances over time. Moreover, these 
topological features are compared to theoretical predictions about the optimal network 
topology for exploration and exploitation activities. Finally, chapter two concisely 
describes the preparation process of the data we used for chapter two and chapter four.  
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Chapter three focuses on the innovation strategies of the firm with respect to 
complementarities between in-house and external R&D. At the level of the individual 
research project, we identify the main determinants of successful research projects in 
drug discovery. More specifically, we examine how cognitive proximity between in-
house research and external collaborations increases the probability of successful drug 
discovery. By doing so, this chapter analyzes how firms strategize on their portfolio of 
make, buy and ally transactions. 
In chapter four we jump two aggregation levels higher from research projects within 
the firm to regional cluster of European biopharmaceutical firms. The aim in this 
chapter is to understand the determinants of local and non-local collaboration amongst 
geographically co-located firms. In other words, we test the antecedents of 
geographical proximity co-occurring with relational proximity. One of the main issues 
that this chapter addresses is the contradicting evidence that exists about whether 
exploration activities require geographical proximity or not. If geographical proximity 
matters we expect to see mainly clusters, which are networks of local collaboration. If 
geographical proximity is not required we expect clusters to act as nodes in a global 
(or European) network of collaboration. 
Chapter five shows how radical technological change induces alliance formation of 
firms and how the structure of the network changes as a result of this. The Genomics 
revolution in the beginning of the nineties sets the stage for our analysis. In response 
to the radical innovations surrounding the human genome project, new firms enter the 
network of existing players. Being confronted with the potentially disruptive 
technologies of the newly entering firms, incumbent organizations face the challenge 
of obtaining access to the new technologies. As a result, a wave of strategic 
collaborations characterizes the industry. This allows us to test whether firms facing 
radical technological change form either local linkages or distant linkages in the 
network. Or, put differently, whether novel information is obtained through relational 
proximity or rather through relational distance. Finally, chapter 6 concludes. Table 1.2 
provides an overview of the chapters of this thesis.  
Table 1.2 - Outline of this thesis
Explorative 
social network 
analysis
NetworkHow does radical technological 
change affect alliance behavior 
and subsequent network 
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Relational 
proximity
Radical innovation 
and network evolution
5
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Chapter 2  Proximities in the European 
biopharmaceutical industry: regional clusters and 
networks1 
 
2.1 Introduction 
This chapter provides an empirical overview of biopharmaceutical innovation 
activities in Europe over the last decade (from 1996 until 2005). Our focus is on three 
forms of proximity between organizations in the European biopharmaceutical 
industry; geographical proximity, relational proximity and cognitive (technological) 
proximity. In our previous chapter we argued that these proximities help us 
understand firms’ strategies in acquiring access to external knowledge, which is 
considered to be a prerequisite for innovation in the biopharmaceutical industry. In 
this chapter we empirically explore proximities between European biopharmaceutical 
organizations from two perspectives: the regional clustering of firms in space and the 
network of strategic collaborations between organizations.  
 
We start with the identification of the main clusters of biopharmaceutical 
organizations in space, based on cluster (or regional) attributes on the one hand and on 
relational attributes on the other hand. Together these cluster-and relational attributes 
help us to identify certain ‘types’ of clusters, based on the literature of industrial 
districts (Markusen, 1996). We might for example find typical “hub-and-spokes 
clusters”, where small firms evolve around academic centers of excellence 
(representing the ‘hub’). Alternatively we might encounter clusters that resemble 
                                                 
1 This chapter builds on a previous version (co-authored by G.A. van der Knaap), which is 
published in Pharmareview, June 2006. 
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“satellite clusters” where large pharmaceutical firms form mainly marketing and 
distribution alliances with non-local partners.  
In the second part of this chapter we change our perspective towards a network view 
on innovation activities in the European biopharmaceutical industry. In order to do so, 
we ‘map’ all strategic alliances at three moments in time (1999, 2002, and 2005) as 
collaboration networks between organizations. We distinguish alliances as either 
science-driven or as market-driven. As a result the collaboration network is divided 
into an explorative- and an exploitative network. Lastly, we analyze some structural 
features of these networks over time and relate these to existing theory on innovation 
behavior of organizations.  
 
Before we start exploring, we briefly explain how our data were collected and we 
define our variables of interest.   
 
2.2 Data 
2.2.1 Data preparation 
Our information on European biopharmaceutical organizations, their relational 
activities, and their location originates from Pharmadeals alliance database between 
June 1996 and June 2005. Pharmadeals is a global monitor of alliances through press 
releases and annual reports search on a daily basis since 1996. As these concern 
alliance data, we are aware of organizations existing in Europe only if they have 
formed at least one alliance every three years. In the pharmaceutical industry, where 
external collaborations are deemed necessary for innovation, it is generally 
acknowledged that this selection criterion encompasses the majority of viable 
organizations in the industry (Arora & Gambardella, 1990).  
The identification of the main clusters of European biopharmaceutical organizations 
has been a three stage process. To start with, we selected alliances where at least one 
European partner was involved. The database did not at that time allow us to create a 
query based on the location of organizations, and we used European countries as 
keywords to search for a match in any part of the alliance announcement (including 
press release). This resulted in a hit of 2800 alliances between June 1996 and June 
2005.  
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In a second stage we have split alliances where multiple partners were involved. Of 
these 2800 alliances, some 300 appeared to involve more than 2 separate 
organizations. We decided to split those alliances into each possible combination of 
alliances. Thus, an agreement with n participating organizations was transformed into 
n x (n-1)/2 linkages. Hence, we assume that an alliance serves as a conduit of 
knowledge transfer, where information transfers between all participants in an alliance 
(whether the alliance is an R&D collaboration between multiple universities or a 
project of some pharmaceutical companies who received EU funding). Turning all 
these multiple partner alliances into dyads led to a new alliance set of 4031 alliances 
among 2500 separate organizations. 
Thirdly we manually looked up the cities where organizations are located and found 
around 650 organizations either not tractable or undisclosed by Pharmadeals or being 
a USA based firm with a USA based partner (this latter phenomenon can be explained 
by the splitting of multiple partner projects). Our final work set consists of 2566 
alliances among 1834 organizations of which 1054 are organizations located in 
Europe.  
 
To identify the whole network of collaborations at various moments in time we 
created ‘snapshots’ of the network of collaborations in June 1999, June 2002 and in 
June 2005. These ‘snapshots’ build on the assumption of alliance duration of 3 years 
(Phelps, 2003), which means that each ‘snapshot’ captures all new agreements 
announced back to three years before the ‘snapshot’ was taken.  
 
2.2.2 Cluster identification 
Regional clusters of biopharmaceutical organizations have been identified by geo-
coding each organization’s location and using a hierarchal clustering algorithm based 
on Euclidian distances between locations to define the boundaries of European 
clusters. Having identified the European clusters we aggregated the information on 
organizations and their alliances back to the regional clusters. The following 
information per cluster was obtained: 
Cluster name: city where most organizations are located 
Cluster size: number of organizations that have formed at least one alliance in the past 
three years.  
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Alliances: number of alliances formed by organizations located in a cluster. These 
alliances encompass all phases in the drug development process ranging from 
discovery collaborations through licensing deals to marketing-, and distribution 
alliances. Furthermore, we identified all alliances as either local collaboration with 
both organizations located in the same cluster, or as non-local collaborations whereby 
collaborating actors are located in different clusters.  
Company type per cluster. Our data contained information about the type of 
organizations that are involved in each alliance. This enabled us to identify the 
number of start-up firms, large established organizations, governmental organizations, 
academic organizations and finally some financial firms per cluster.  
Therapeutic focus of the alliances of organizations located in each cluster. Each 
alliance focuses on a specific therapeutic area or on a combination of therapeutic 
areas. In some cases the alliance is not therapeutically focused but rather focuses on a 
technology such as genomics, proteomics or on certain platform technologies such as 
high throughput screening or assay detection. In any case, in line with the relational 
view of the firm, we consider the whole portfolio of activities in which a firm is deal-
active as the resources of the firm (Dyer & Singh, 1998). As such, the collection of 
activities of all firms in a cluster can be considered as the resources of a cluster.  
Finally, our database contains information on the phase in the drug development 
process at which each alliance is targeted. These phases range from discovery and 
lead optimization to clinical testing and lastly marketing and distribution activities. 
We have exploited this information to disentangle explorative activities from 
exploitative activities and subsequent network structures.   
 
2.3 Geographical proximity: regional cluster development 
Most of the 1054 biopharmaceutical organizations in Europe tend to co-locate in a 
few regional clusters. In fact, our data show that 72 percent of the active 
biopharmaceutical organizations are located in the 30 largest regional clusters. While 
the remainder of this chapter focuses on the largest clusters, we first summarize 
cluster characteristics over time for all regions (where at least 2 deal-active 
organizations are clustered) in table 2.1.  
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Table 2.1 – European biopharmaceutical clusters 
in 1999, 2002 and 2005 (descriptive)
3.443.052.59Skewness of distribution of linkages
23.0015.6719.63Mean number of linkages per cluster
2.842.961.69Skewness of distribution of organizations
7.786.235.44Mean number of organizations per cluster
3.02.53.6Average number of linkages per firm
1679956942Linkages
568380261Number of organizations
Jun-05Jun-02Jun-99
 
 
In the last decade there has been a steady stream of new clusters of biopharmaceutical 
organizations in Europe. As a result, the total number of active organizations in these 
clusters has increased. Although the total number of alliances has risen, the average 
number of alliances per firm reveals a more cyclical trend. The average organization 
has become less deal-active in the first period between 1999 and 2002, while it has 
become increasingly deal-active in the second period between 2002 and 2005. The 
cyclical nature of link formation is a common feature of alliance behavior among 
firms (see Hagedoorn (2001)). When we look at the mean number of organizations 
located in a cluster, we see that on average clusters have been growing over time. This 
average growth is remarkable considering the fact that in each period there are 10 new 
(and usually small) clusters emerging on the European scene. It indicates that the 
growth in the number of active organizations has been larger than the growth in the 
number of new clusters. Lastly, we consider the distribution of clusters in terms of 
number of organizations over time. In table 2.1 we see an increased skewness in the 
distributions of cluster size in the period 1999 – 2002, which indicates an increased 
inequality in the number of organizations per cluster. In other words, in the first 
period the number of larger clusters has been growing faster than the number of 
smaller clusters. In the second period, from 2002 till 2005, we see a decreased 
skewness in the distribution of cluster size, which indicates an increased equality in 
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the number of organizations per cluster. Whereas agglomeration effects seem to be at 
work in the first period (resulting in a large-grow-larger phenomenon), the second 
period is characterized by a (light) catching up of smaller clusters in terms of number 
of organizations. In sum, table 2.1 reveals that for organizations in the European 
biopharmaceutical industry both link formation and co-location (or clustering) are not 
activities that grow linearly over time, but are cyclical. Technological changes are 
often said to underlie these cyclical patterns in link formation and clustering behavior 
of firms (Tushman and Anderson, 1986; Nooteboom, 2001). If both link formation 
and regional clustering are part of a firms’ strategy to gain access to external 
knowledge, then one could argue that in times of more radical technological change, 
the necessity for firms to access external knowledge increases and hence link 
formation (related to R&D) and regional clustering increases. In chapter 5 of this 
thesis we empirically investigate these hypotheses in detail. More specifically, we 
study the effect of radical technological change on patterns of link formation in the 
pharmaceutical R&D network.   
  
2.3.1 Identifying the main clusters and the main activities. 
Which are the main clusters of European biopharmaceutical firms? Where do 
biopharmaceutical organizations locate and which activities do they employ? To 
answer these questions we focus on the 30 largest clusters in terms of the number of 
organizations present. Within these clusters we distinguish between different types of 
organizations and different therapeutical areas in which organizations are active.  
 
Main type of organizations per cluster 
Figure 2.1 shows the 30 largest clusters in the European pharmaceutical industry by 
type of (deal-active) organization over time. We distinguish among academic 
organizations, biotech firms, and (large) pharmaceutical firms. Governmental 
organizations and financial firms are important actors in the innovation process, but 
they are hardly captured by our data of (commercial) strategic alliances.  
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Fig. 2.1 – 30 main clusters by type of organization in 1999, 
2002, 2005
 
European pharmaceutical clusters are increasing in size between 1999 and 2005. In 
the same period we see a growing dominance of London and surrounding clusters 
(including Essex, Cambridge, Oxford and Berkshire) as the largest pharmaceutical 
cluster in terms of deal-active organizations present. One might even typify the area 
around London as one giant cluster of biopharmaceutical activity, since 20 percent of 
all European biopharmaceutical organizations (211 organizations) are located in this 
area. This visual observation is confirmed as a general trend of increasing inequality 
in the distribution of organizations over European clusters (standard deviation of 
organizations per cluster more than doubles from 1999 until 2005). Indeed, clustering 
or geographical proximity is an increasingly important phenomenon in the European 
biopharmaceutical industry. The clusters that surround London can be divided into 
clusters that are driven by large pharmaceutical firms (Hertfordshire, Manchester, 
Essex) or driven by academic organizations such as Cambridge and Oxford. In both 
cases the number of start-up firms has gradually increased over time. For the rest of 
Europe, only the Madrid cluster has had a steady majority of academic organizations 
involved in alliances in the last decade. The proportion of start-up firms has increased 
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in almost every European cluster, with the extreme cases being Horsholm, Munich 
and Vienna. Finally Paris and Frankfurt stand out as the clusters with a majority of 
large established pharmaceutical organizations present. 
 
Main activities per cluster 
Therapeutic focus  
Activities in drug development are often categorized along their therapeutic focus2. 
Usually a therapeutic focus contains various disease areas and can be approached 
using different technologies. For example, Immunological is a therapeutic focus area 
which covers a number of diseases related to the immune system, such as rheumatoid 
arthritis or multiple sclerosis. Compounds to cure these diseases can be either 
chemically based or biologically based and the technologies that are available to 
screen, select and test these compounds are numerous. Since the beginning of the 
nineties, the genomics revolution has brought a set of technologies that aid the drug 
development process by being applicable to any compound without needing a specific 
therapeutic focus. As a result, alliance activities can be either focused on a specific 
therapeutic area or on a genomics related technology such as genomics, 
bioinformatics, high-throughput screening etc. For visualization purposes, we have 
grouped alliance activities around basic research, diagnostics, drug delivery, and 
around genomics related technologies for each cluster over time. Figure 2.2 visualizes 
the main activities per cluster.  
 
                                                 
2 With the exception of anti-cancer therapies. This is such a broad disease area that it has 
become a therapeutic focus area on its own.  
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Fig. 2.2 – 10 main clusters by type of activity in 1999, 2002, 
2005
 
Basic research, diagnostics and drug delivery can be seen as activities that take place 
at the beginning, the middle and the end of the drug development process. Genomics 
related technologies are so-called ‘general purpose’ technologies that are used as 
instruments to enhance the drug development process without being part of it. In 
figure 2.2 we can see that basic research is an important part of all European clusters. 
More interestingly, it seems that clusters which are dominated by either start-up firms 
(such as Cambridge Munich and Berlin) or by academic organizations (such as 
Madrid and Amsterdam in 2005), a higher proportion of activities is geared at 
genomics related technologies. This finding can be explained by the fact that the 
genomics revolution in the beginning of the nineties was sparked by global academic 
research and caused a number of waves of new firm entrance around the introduction 
of new genomics based technologies such as genomics, proteomics or bioinformatics.  
 
Regional specialization 
Based on the therapeutical or technological focus of alliances we created a measure of 
regional specialization. More specifically, we consider the portfolio of alliances of 
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organizations in a cluster as the resource of the cluster. Using the Herfindahl index 
enables us to determine to what extend a cluster is dominated by a relatively few 
therapeutical (or technological) areas. Originally the Herfindahl index is a measure of 
the size of firms in relation to the industry and an indicator of the amount of 
competition among them. In our case the Herfindahl index expresses the degree to 
which a biopharmaceutical cluster is dominated by a small number of therapeutic 
areas/technologies. The Herfindahl index is defined as follows: 
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The index is the sum of the squared share of each therapeutic area in a cluster. iN  is 
the number of deals that are based on therapeutic area i. There are k therapeutic areas 
and N deals in a cluster. The reason for squaring each share of therapeutic areas is to 
put more weight on larger therapeutic areas and less weight on smaller areas. We use 
the Herfindahl index to typify clusters as being more or less specialized in certain 
therapies or technologies in table 2.3. The exact therapeutical areas in which clusters 
are specialized are visualized in figure 2.3 
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Fig. 2.3 – Therapeutical specialization of the main 
European clusters
 
In figure 2.3 we have accumulated the therapeutic areas in which organizations in 
each cluster close many deals (10 deals or more). This leads to a network of clusters 
and therapeutic areas whereby the thickness of the ties represent the number of deals 
closed by organizations in a cluster based on that specific therapeutic area. The size of 
the therapeutic area nodes represents the number of times that the therapeutic area is 
dealt by any European organization, and the size of the cluster nodes is determined by 
the total number of deals closed by organizations in the cluster. 
 
A number of observations can be made from this network at first glance. First, 
anticancer is by far the most popular therapeutic area in Europe. Almost every big 
cluster has closed at least ten deals based on anticancer therapies. The latter 
observation however is also valid for other therapies such as neurological, 
immunological and general pharmaceuticals. The difference between anticancer and 
the other mentioned therapies lies in the extraordinary strong relation between London 
and anticancer therapies. In fact, 142 deals have been closed in London based on 
anticancer therapies. While London appears to be strongly focused on its main disease 
area we will come to see later, when we calculate the degree of therapeutical 
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specialization for each cluster, that this strong focus does not make London a 
particularly specialized cluster. Because of its large size London is an example of a 
mixed case with a number of specialized sub-clusters and at the same time a wide 
range of different types of therapeutics. Our final observation is about the similarities 
in alliance activity between Cambridge and London. From the above figure we see 
that they have closed about the same amount of deals from 1996 till 2005 (node size). 
Cambridge ranks second in terms of number of organizations after London (figure 
2.1), and while it is deal-active in fewer different therapeutic areas, it has a similar 
(though weaker) dominant tie with anticancer therapeutics as London has. 
 
2.3.2 Positioning of main clusters in the European network: 
relational attributes 
Where do organizations in a cluster search for external knowledge? Do they search 
locally within their cluster or do they search for external knowledge beyond their 
cluster? By answering this question we do not only gain information about the 
relational behavior of organizations in clusters, we also obtain insights on the 
European network of inter (and intra) regional relations in the pharmaceutical industry 
and the position of clusters in this network.   
 
Exploration network & exploitation network 
When studying the European network in terms of local and non-local search activities, 
we distinguish between explorative search and exploitative search. Our data capture 
two types of agreements between organizations: exploration alliances that are aimed 
at exchanging knowledge or technologies in the earlier stages of drug development, 
and exploitation alliances aimed at downstream drug development (see data section 
for a more detailed description). Exploration alliances are known to involve relatively 
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more tacit knowledge in comparison to exploitation alliances3. It has been argued in 
the literature that tacit knowledge transfer is more likely to require geographical 
proximity than explicit knowledge transfer (Pavit, 1987; Audretch & Feldman, 1996). 
As a result we expect to see explorative alliances to occur locally more often than 
exploitation alliances.  
 
Fig. 2.4 – Network of exploration activities in the European 
biopharmaceutical industry in 1999, 2002, and 2005. 
Node size represents the relative importance of local collaboration and ties 
represent the relative importance of non-local collaboration
1999
 
                                                 
3 The high degree of formality of the alliances in our data might over-represent exploitative 
alliances compared to explorative alliances. This is because the former are based press 
releases which capture fairly explicit terms of knowledge transfer, while the latter might be 
governed through more informal channels. Despite this potential bias, the amount of 
explorative agreements in our data is almost double the amount of exploitative agreements 
(1311 explorative agreements compared to 774 exploitative agreements)  
 Chapter 2 Proximities in the European biopharmaceutical industry 
 
36 
 
2002
 
 
2005
 
 Chapter 2 Proximities in the European biopharmaceutical industry 
 
37
Fig. 2.5 – Network of exploitation activities in the European 
biopharmaceutical industry in 1999, 2002, and 2005. 
Node size represents the relative importance of local collaboration. Ties represent 
the relative importance of non-local collaboration
1999
 
 
2002
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Table 2.2. - Local & non-local collaboration in exploration & 
exploitation networks 
255228188603164287Non-local links
0.01
2
Exploitation
1999            2002            2005
0.01
2
0.060.080.100.09Local/all links
17491829Local links
Exploration
1999            2002            2005
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Figures 2.4 and 2.5 represent the exploration and the exploitation networks over time. 
Node size represents the relative importance of local linkages while the relations 
between nodes represent inter-cluster linkages. Table 2.2 summarizes the information 
in the figures 2.4 and 2.5 over the main 30 clusters and provides information on the 
absolute number of local and non-local alliances over time. From the table we can see 
that at any point in time non-local linkages occur at least ten times more often than 
local linkages. This finding might be caused by the fact that our data capture only 
alliances above a certain deal value. If it is the case that organizations form local 
alliances as ‘informal’ or ‘supportive’ alliances rather than as formal, commercial 
deals, than this could explain the very low amounts of local alliances in our data.  
Furthermore, when we consider the amount of local linkages in both networks in table 
2.2, we see that explorative activities are much more often local than exploitative 
activities4. This finding is in line with our expectations from the literature stating that 
explorative activities contain more tacit knowledge which requires geographical 
proximity.  
In figure 2.4 we see how the exploration activities, such as R&D collaborations and 
drug discovery efforts are being undertaken by European organizations at three points 
in time. In 1999 there is a remarkable clique of mainly southern European clusters that 
are strongly dominating the European scene. The clusters in this clique (being Milan, 
Frankfurt, Lyon, Nancy, Porto and Gent) are fully connected5, which is caused by the 
fact that the organizations located in this clique were participating in one research 
project subsidized by the European Union (the so-called Eureka Peptido project). In 
2002 and 2005 it becomes clear that the main explorative activities have shifted to 
London, Brussels and Cambridge (with minor roles for Maastricht, Leverkusen and 
Munich and Madrid) 
                                                 
4 Even the share of local alliances in relation to all alliances is higher in the exploration 
network than it is in the exploitation network at any point in time.  
5 Indicating that in a clique with N actors, there are N *(N-1) / 2 linkages between actors.  
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In figure 2.5 we see how the exploitation activities, such as marketing and distribution 
activities are being undertaken by European organizations at three points in time. In 
1999, Paris was performing a central role in the exploitation of existing drugs in 
Europe. From 2002, London has again (like in the exploration network) taken over the 
lead position in the European exploitation network with Milan close behind. 
Interestingly, in 2005 Milan has gained the dominant position in the network, leaving 
London at a second place. The activities performed by organizations located in Milan 
have shifted strongly from the early phases of drug development (R&D and 
discovery) in 1999 toward late stage drug development (marketing and distribution) in 
2002 and 2005. While beyond the scope of this study, it might be worth-while to 
consider whether these changes in Milan represent cluster life cycle effects.  
 
2.3.3 Types of clusters 
Thus far, clusters have been identified in terms of the type of organizations present, 
the therapeutic focus of activities and in terms of local and non-local search activities. 
In order to see whether there exists certain ‘types’ of clusters based on the above and 
other attributes, we have sorted the main clusters along their degree of therapeutical 
specialization and added a number of other attributes6. In the following table we see 
the 3 most specialized clusters (Lyon, Milan, Horsholm) and the 3 most diversified 
clusters (London, Paris, Amsterdam) with regard to therapeutic focus. Besides the 
identification of these clusters by name we use the cluster characteristics as shown in 
the columns to describe the clusters.  
                                                 
6 Alternatively, we tried to identify cluster ‘types’ by using factor analysis of cluster attributes 
over our main (30) clusters. This did not lead to any cluster type.  
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Table 2.3. – Most specialized and least specialized 
European biopharmaceutical clusters and their attributes
0.341.6410.5952580.06Amster
0.331.130.920.58862970.07London
0.091.160.660.6715380.16Horsho
0.520.660.920.3831650.24Milano
0.740.411.060.4310280.26Lyon
R&D 
ratio
USA 
connectivity*
Openness 
cluster*
Start-
up ratioNodes
Organiza -
tionsHerfindahl
cluster 
name
*These two cluster characteristics are expressed in relation to the average score in all 
European clusters. The scores range from 0 to 2, whereby 1 indicates the average score of 
all European clusters. 
0.21.320.980.44671530.06Paris
 
 
The Herfindahl index shows that the clusters Lyon, Milan and Horsholm are on 
average four times more specialized than London, Paris and Amsterdam. Further it 
seems that the bigger clusters (number of organizations) are the more diversified ones, 
but simple correlation statistics of all clusters reveal this is not the case. What does 
matter for the specialization of a cluster is the share of deals that are closed with a 
partner from the USA. More diversified clusters have relatively more partners in the 
USA than specialized clusters have.    
As not all organizations located in a cluster are deal-active, we have added a separate 
column for deal-active firms. It is interesting to see that while for all clusters but 
Amsterdam (Amsterdam, Leiden, Rotterdam region) around 35% of the organizations 
are deal-active, 90% of the Amsterdam organizations are deal-active. Taking a closer 
look at the Amsterdam cluster we see that it is not only the most active cluster, it is 
also very ‘USA oriented’. The Amsterdam cluster has over one-and-a-half times more 
connections to the USA than other European clusters have. 
A second cluster that deserves extra attention is Horsholm in Sweden. Horsholm 
seems to be a typical neo-Marshallian district in that it is one of the most specialized 
clusters in Europe, in combination with a relatively large share of start-up firms who 
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are closing deals mainly to partners inside the Horsholm cluster. Further it seems that 
Horsholm is specialized in downstream drug development because of its few R&D 
collaborations. 
Lastly, there is the Lyon cluster which is rather exceptional. Lyon is the most 
therapeutically specialized cluster among Europe’s main clusters, and on top of that it 
has a very strong focus on R&D together with a relatively weak connection to the 
USA. Lyon can therefore be typified as a specialized R&D cluster.     
 
 
2.4 Relational proximity: inter-firm network development 
To assess empirically the importance of relational proximity as a governance 
instrument for accessing external knowledge, we take a look at the networks of 
collaborative agreements among European biopharmaceutical organizations over 
time.  
As discussed previously, organizational search for external knowledge is usually 
divided into either local or non-local search (Rosenkopf & Nerkar, 2001). In 
paragraph 3.2 of this chapter we have seen from a geographical perspective that firms 
in a cluster rather search beyond the boundaries of a cluster than within the cluster. 
Regarding relational proximity, both local and non-local search can be regarded as a 
prerequisite for knowledge access and innovation. To understand how, we shortly 
explain local and non-local search in network terms, and how they are associated with 
innovation.  
 
2.4.1 Local & non-local search in the network 
Local search manifests itself through local linkages. In network terms, a linkage is 
local if it is embedded in a relatively dense web of previous and neighboring relations. 
Together this dense web of previous and neighboring relations form a local clique of 
collaborating and knowledge exchanging organizations, which through imitation 
behavior subsequently converge toward cognitive proximity (Boschma, 2004). Non-
local search in a network leads to a distant linkage (sometimes referred to as a ‘weak’ 
linkage), which means that this link forms a bridge between two actors (or cliques) in 
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a network that would ordinarily have to surpass a large number of actors to reach each 
other (Newman, 2001). Just as local linkages are often assumed to carry more similar 
knowledge (cognitive proximity) it is also assumed that distant linkages correspond to 
high cognitive distance between actors, whom bring together new pieces of 
knowledge (Rosenkopf & Nerkar, 2001). 
 
2.4.2 Local & non-local search & innovation  
In line with the transaction costs view of the firm, which emphasizes mainly the costs 
and threats of external knowledge acquisition, Cowan (2005) argues that for the 
exploration of new knowledge and new combinations, local search is more beneficial 
than non-local search. In exploration, Cowan argues, knowledge is rather tacit and 
therefore difficult to absorb. The difficulty of absorption capacity can be overcome 
through the formation of local linkages in dense cliques where knowledge domains 
are more similar. Together the clique members are better able to create new 
knowledge and to innovate. Once a dominant design has emerged and is ready to be 
exploited, knowledge becomes more codified and hence easier to absorb. At this stage 
the organization aims to diffuse its innovation as much as possible and non-local 
search through distant linkages are most optimal to do so.  
When authors apply the resource based view of the firm, as Sidhu, Commandeur and 
Volberda (2007) do, the innovation strategy that is considered optimal reverses. These 
authors argue that in order to explore in a dynamic environment, firms are required to 
reach out to organizations that are relatively far away from their current field of 
expertise, so as to make novel combinations. Local search through local linkages, 
which provide access to similar knowledge, enable incremental improvements 
necessary for the exploitation of existing products. The main difference between these 
two studies lies in the perceived importance of a firm’s absorptive capacity. Whereas 
Sidhu et al (2007) emphasize that the gains from novel combinations (through non-
local linkages) outweigh the costs of integrating them with the internal knowledge 
base, Cowan argues that the costs of absorbing knowledge requires local 
embeddedness. In addition to these arguments, a number of other issues might play an 
important role. Regarding local search and local linkages, there might be costs 
associated with redundancy or from unintended knowledge flows, especially if 
relational proximity co-occurs with cognitive proximity (knowledge similarity). With 
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respect to non-local linkages, not only the high integration costs of new knowledge 
might be problematic, but also the danger of opportunistic behavior could be higher 
since a distant linkage cannot rely on the protection of reputation effects in the 
network. Finally, the latter potential danger might also turn into a negotiation 
advantage if this distant linkage appears to be bridging two cliques with 
complementary knowledge. The intriguing question becomes what we observe 
empirically in an extremely dynamic environment as the European biopharmaceutical 
industry, where explorative relational activities can be clearly separated from 
exploitative relational activities.  
 
2.4.3 Local linkages and non-local linkages in exploration and in 
exploitation networks 
Whereas in paragraph three on geographical proximity we explored our data at the 
level of the geographical cluster, in this section we analyze relational proximity 
(through local and non-local linkages) at the level of the network. Again we compare 
these networks over time and we look at explorative and exploitative networks 
separately. We start with some descriptive characteristics of our networks and turn our 
attention to measuring local and distant linkages.  
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255228188603164287Number of linkages
1.091.291.451.390.782.39Average degree
130 (35)
5.304
0.000
1999
EXPLOITATION
177 (19)
2.823
0.000
2002
EXPLORATION
2005200520021999
235 (26)433 (193)211 (20)120 (18)
Number of 
organizatio
ns (giant 
component 
size)
3.2465.4162.8981.862
Average 
path-length 
(d)
0.0000.2680.2321.933
Clustering 
coefficient 
(c)  
Table 2.4 – Comparing structural network features of the 
exploration and exploitation network over time
 
 
While both the exploration and the exploitation networks are growing over time (in 
number of active organizations), it is becoming sparser as the average number of 
alliances per firm decreases in both networks. Particularly in the exploration network 
there is a sharp decrease between 1999 and 2002 in the number of alliances formed 
while the number of organizations has grown. If we compare these results with figure 
1.3, which plots R&D alliance activity on a global scale, we can see that European 
organizations are behaving in line with global trends. Indeed, the wave of global 
alliance growth in figure 1.3 between 1996 and 1999 (induced by the entry of 
proteomics technologies) is fully captured by the 1999 picture in table 2.4 (as the 
1999 network is a snapshot of newly announced alliances between 1996 and 1999). 
The decreasing number of global alliances formed in the 1999-2002 period is also in 
line with our findings of the 2002 network in table 2.4. 
Based on the literature discussion above, our question at hand is the following: are 
local linkages (relational proximity) predominant in exploration networks while more 
non-local linkages characterize the exploitation network or vice versa? Underlying 
this question is the issue of whether firms develop knowledge search strategies based 
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on avoiding transaction costs or based on opportunities to create novel combinations. 
Local linkages together form local cliques in which everybody is connected to 
everyone else. The importance of the alliance behavior is typically measured by the 
clustering coefficient. The clustering coefficient of an actor is the density of its open 
neighborhood that is to say how close each actor’s neighborhood is to a fully 
connected clique. Following Watts and Strogatz (1998) we define a clustering 
coefficient as follows: assume that the ith vertex iv has 1−ik neighboring vertices. At 
most, 2/)1( −ii kk  edges can exist between them. Calculate ≡ic (number of edges of  
iv  and its neighbors) / 2/)1( −ii kk . We define the overall clustering coefficient as:  
 
∑
=
=
N
i
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CC is the average of the individual clustering coefficients ic . The weighted overall 
clustering coefficient (WCC) is the weighted mean of the clustering coefficient of all 
the actors each one weighted by its degree. 
 
Non-local linkages are measured by the average path-length or sometimes referred to 
as the diameter of the network. Non-local linkages function as bridges between 
different parts of a network and thereby they reduce the average distance between 
actors. We formally define average path-length as follows: 
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The average path-length d(N) is the average distance between any actor i and j that 
belong to the same component (giant component). Actors that are isolated from other 
actors are excluded. Thus, for a connected graph N(E,V) consisting of edges (linkages) 
and vertices (nodes), the average path-length is the sum of the distances between two 
actors (i and j) belonging to the network (N), divided by all possible edges excluding 
self-ties. 
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Table 2.4 reveals the clustering coefficient and the average path length over time for 
both networks. It becomes clear from this table that local linkages are a much more 
important phenomenon in exploration networks than in exploitation networks. This 
indeed indicates as Cowan (2005) has argued that new knowledge creation mainly 
takes place in local cliques when knowledge is still rather tacit and hard to absorb. 
The absence of clique formation in the exploitation network might indicate that more 
codified knowledge (which is transferred in exploitation networks) is preferably not 
exchanged in cliques to prevent unintended knowledge flows to other actors (e.g. 
competitors) within the clique. The extraordinary high clustering coefficient (1.93) in 
1999 can be explained by taking a look at the network visualization of 1999 in figure 
2.4 and figure 2.6. Although the nodes in figure 2.4 represent clusters and not firms, it 
is firms which form these alliances (see figure 2.6). Indeed the clique dominated by 
organizations in Milano and Gent is a full clique in which all clusters are connected.                                 
 
With respect to non-local linkages, we can say that the more predominant they are, the 
shorter the average path-length will be. An average path-length can only be calculated 
for actors that belong to the main component of a network where every actor is 
reachable. Except for the exploration network in 2005, both the exploration network 
and the exploitation network consist of very few actors belonging to the main 
component, which makes the interpretation of the average path-length dubious. While 
there is a strong growth of deal-active organizations in both networks, for the most 
part these organizations remain active in independent components without forming an 
integrated European network. Interestingly, in 2005 European organizations which are 
active in exploration have managed to connect these previously unconnected 
components to a large extend. As a result, the 2005 exploration network shows a 
relatively large giant component. To put it differently, in 2005 (almost) every second 
European organization is connected to one giant European network of firms active in 
exploring new drugs. Figure 2.6 shows how the separate components in the 
exploration network become connected in 2005.  
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Fig. 2.6 – The emergence of a giant component in the (firm 
level) exploration network
1999
2002 2005
 
 
While we cannot rely on the average path-length information to assess whether non-
local link formation has occurred, we can analyze local link formation by visualizing 
the emergence of a giant component in the exploration network. Based on figure 2.6 
we argue that the connection of previously unconnected components in 2005 into a 
large giant component can only take place when organizations form non-local 
linkages. Given our findings that a giant component has only emerged in the 
exploration network and not in the exploitation network, we can now say that non-
local link formation only plays a role in the exploration of new and relatively un-
codified knowledge. This finding is in line with the predictions of Sidhu et al. (2007) 
who argue that in exploration, non-local linkages might create novel combinations 
which outweigh the costs of integrating external knowledge.    
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2.5 Concluding remarks 
In this chapter we have provided an empirical overview of how pharmaceutical 
innovation activities have developed in Europe in the last ten years. In order to do so 
we have relied on information about alliances which cover the whole production 
process in drug development. The main actors, such as academic centers, biotech 
firms and large pharmaceuticals have been identified based on their involvement in 
these alliances. For these organizations, alliances are an important means to gain 
access to external knowledge. As previously discussed, different forms of proximities 
can have an important influence on a firm’s ability to access external knowledge. 
Geographical proximity appears to be important for the location behavior of 
organizations since more than 70 percent of the organizations in Europe are 
concentrated in the 30 largest clusters. However, when analyzing the alliance behavior 
of these clustered organizations in terms of local and non-local search, it appears that 
geographical proximity or local linkages are of minor importance to these 
organizations. In chapter 3 the determinants of local and non-local search from a 
geographical perspective are analyzed in greater detail.  
The second part of this chapter has focused on relational proximity as a means for 
organizations to access external knowledge. Also relational proximity can be 
expressed in terms of local and non-local search, be it in a network of collaborations. 
By studying the evolution of the European pharmaceutical network of collaborations 
over time, we analyzed whether organizations prefer to ally with their existing 
partners or with partners of their partners, or whether they allied with more distant 
organizations in the network. We furthermore distinguished whether this relational 
behavior is different when organizations explore new knowledge or exploit existing 
knowledge. We found that local search is clearly more prevalent when exploring new 
knowledge and that with one exception ‘distant’ knowledge search does not apply to 
the European scene. This latter finding is explained by the fact that for the most part 
the European network is highly fragmented. The exception is an interesting 
development in 2005, when about half of the European pharmaceutical actors are 
connected to an emerging giant network component. In Chapter 4 we further explore 
the impact of relational proximity on network evolution. 
 
Chapter 3  Complementarities and the R&D 
boundaries of the firm: A project level study on 
pharmaceutical R&D strategies1  
 
3.1 Introduction 
A firm’s ability to innovate is increasingly the result of both internal R&D efforts and 
external knowledge sourcing (Gambardella, 1992; Freeman, 1991). External 
knowledge sourcing can be performed through informal personal interactions, formal 
collaborations, spin-out (and later spin-in) companies and consultancy or through job 
mobility (Abramovsky et al, 2007). Especially in the biopharmaceutical industry the 
complementarities between internal R&D and external sourcing through formal 
collaborations play an important role in large pharmaceutical innovation strategies 
(Arora & Gambardella, 1990; Henderson & Cockburn, 1996; Pisano, 1990).  
Until recently, externally sourcing of R&D has been considered a substitute for in-
house R&D activities, i.e. R&D has been perceived as either a make-, or a buy 
decision of the firm. Exemplifying in this respect is the seminal work of Pisano (1990) 
on the R&D boundaries of the firm. Although the author acknowledges 
complementarity between in-house R&D activities to be important, potential 
complementarities beyond the boundaries of the firm are ignored (Pisano, 1990). 
Our study fills an important gap in the literature. While there exists a rich theoretical 
literature on complementarities between R&D activities, limited data availability has 
so far constrained empirical testing of some key features of these theories. Using 
unique data on more than 1300 early stage research projects of large pharmaceutical 
firms, we empirically study two important issues from the literature. 
First, we investigate conditions under which in-house and external research are 
complementary to one another. Complementarity between two activities is defined as 
“Adding an activity while the other activity is already performed has a higher 
                                                 
1 This chapter is based on joint work with An Vermeersch and McKinsey and Company. 
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incremental effect on performance than adding the activity in isolation” 2 (Cassiman & 
Veugelers, 2006 pp. 70) 3.  While the above definition of complementarity is elegantly 
simple, it does not provide any direction about when to expect complementarity and 
how these activities come about to be complementary. We therefore turn to Cohen 
and Levinthal’s notion of absorptive capacity, which is similar to the notion of 
complementarity. The authors state that firms with a sufficient stock of relevant in-
house R&D are better able to achieve complementarities from combining internal 
with external R&D. Internal know-how is used to effectively screen and absorb 
external knowledge and to exploit these findings internally (Cohen and Levinthal, 
1989). So far, existing empirical work has not provided any answer as to what defines, 
which knowledge is ‘relevant’ internal knowledge and how much knowledge is a 
‘sufficient’ stock of knowledge. Our results indicate, which types of pharmaceutical 
R&D knowledge are relevant to achieve complementarities and, more importantly, we 
indicate a critical mass of prior R&D that is necessary for complementarities to occur. 
Second, we investigate in detail how these complementarities occur. According to the 
theory of absorptive capacity (Cohen & levinthal, 1989; van den Bosch et al, 1999) 
there is a two-way knowledge flow between internal know-how and external 
knowledge that underlies the relationship between complementarities and 
performance. Knowledge flows or spillovers between activities cause learning effects 
and subsequently increase marginal returns on firm performance4. On the one hand, 
internal know-how is claimed to increase the marginal return to external sourcing 
through an increased ability to effectively screen and contribute to external projects 
knowledge (Lane & Lubatkin, 1998). On the other hand, external knowledge that has 
been absorbed needs to return into the organizations internal knowledge base in order 
                                                 
2 Complementarity between two activities 1A and 2A arises only if 
)0,0(),1()1,0()1,1( ∏−−∏≥∏−∏ , whereby ( )21, AA∏  represents performance, and each 
activity A either takes place (1) or does not (0). 
3 Milgrom and Roberts (1990) have first coined the term complementarity to describe 
synergies among organizational practices within the firm. In the strategy literature the concept 
of complementarity is better known as ‘strategic fit’ (Porter, 1980). Strategic fit is defined as: 
'the degree to, which the needs, demands, goals, objectives, and/or structures of one 
component are consistent with the needs, demands, goals, objectives, and/or structures of 
another component' (Nadler and Tushman, 1980: 36) 
4 Additionally it might be the case that complementarity raises competition (or tournament 
effects) between activities, which leverages efficiencies and reduces organizational slack. 
Another potential driver of the relationship between complementarities and performance 
might be that investment in one activity improves selection capabilities for other activities4 
(Veugelers, 1997). 
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to truly increase internal innovations. We will refer to the former as knowledge 
outflow and to the latter as knowledge inflow. We test both knowledge flows and their 
effect on performance directly. First, we measure how the performance of external 
R&D projects changes when the firm has generated sufficient in-house R&D in a 
similar knowledge domain. Second, we measure how internal R&D project 
performance changes when ‘sufficient’ external R&D is undertaken in a similar 
knowledge domain. Our findings are in line with the theory on absorptive capacity. 
This means that sufficient internal knowledge does not improve the performance of 
external R&D projects. External R&D projects that are selected do perform 
exceptionally well, but the main improvement occurs amongst the in-house R&D 
projects once a few (probable well screened) external projects are added to the ‘group’ 
of internal R&D projects. In other words, having a sufficient stock of internal R&D in 
a relevant knowledge domain enables the firm to screen (attract) the right external 
R&D projects from which it can learn and subsequently increase its marginal return 
on internal R&D. Finally, our findings indicate that this knowledge flow (or spillover) 
only occurs when relatively few external projects are added to the group of in-house 
R&D. We strongly suspect that the knowledge that is ultimately responsible for 
realized absorptive capacity does not flow or spill over between projects or even 
researchers, but only travels because the same people who are working on externally 
sourced projects are applying the obtained knowledge internally. This would naturally 
limit the number of external projects in relation to in-house capacity.  
3.2 Literature 
A number of elementary studies have identified complementarities and some studies 
have, what might be even more important, identified circumstances that drive 
complementarity. With our study, we hope to further our current understanding of 
why and how complementarities occur among research activities within-, and beyond 
the boundaries of the firm.  
The earliest work on complementarities between different research activities goes 
back to Coase’s (1937) work, where he argues that as a firm accumulates R&D 
experience internally the costs of internalizing new R&D decreases. More 
specifically, Nelson & Winter (1974) state that the ‘ease’ of internalizing new R&D 
depends on whether prior accumulated R&D is similar to the newly acquired R&D, 
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and that the costs of these activities are reduced because of learning curve effects 
(Pisano, 1990). Also Milgrom and Roberts (1990) have focused their work on 
complementarities within the boundaries of the firm, although their definition of 
complementarity has been applied in some of the more fundamental work on 
complementarities between internal R&D and externally sourced R&D knowledge as 
well. The seminal work on complementarities between internal R&D and external 
sourcing of knowledge is the paper by Cohen and Levinthal (1989) on the two faces 
of R&D. The authors state that firms invest in R&D primarily to generate internal 
innovations. More interestingly, they discover that a side-effect of R&D investment is 
that it enables firms to appropriate external, publicly available spillovers more easily 
than firms, which invest in R&D to a lesser extend. This side-effect is termed 
‘Absorptive capacity’. It is defined as a firm’s relevant stock of prior knowledge that 
enables it to identify, assimilate and exploit knowledge from the environment. While 
the emphasis is on knowledge influx (absorbing external knowledge in), empirical 
work that followed from this study has often looked at the effect of internal R&D on 
successful external knowledge sourcing, which implies knowledge outflow (Lane & 
Lubatkin, 1998; Arora & Gambardella, 1990). The literature review on absorptive 
capacity by Zahra and George (2002) has brought structure to a growing conceptual 
ambiguity around absorptive capacity. The authors identify three stages within the 
construct of absorptive capacity, which are essentially already incorporated in the 
original definition of Cohen & Levinthal (1989), namely: identification of external 
knowledge through external sourcing activities. Second, the assimilation or 
conversion of this knowledge back into the firm and third, the exploitation of the 
absorbed knowledge to new or improved products and processes. Based on these three 
phases, most existing work can be grouped as focusing on potential absorptive 
capacity (phase one and two) or on realized absorptive capacity (phase three) (Zahra 
& George, 2002). An interesting study that does cover all three phases of absorptive 
capacity (identification, incorporation and exploitation) is the study by Cassiman & 
Veugelers (2006). The authors find that firms, which ‘make and buy’ R&D have a 
higher marginal return on innovation than firms who only ‘make’ or only ‘buy’, 
especially if they are more heavily involved in basic R&D. More precisely, a 10% 
increase in reliance on basic R&D increases the likelihood of combining internal and 
external sourcing by 2.7 % (Cassiman & Veugelers, 2006 pp. 77). The studies 
described above have convincingly argued that complementarities exist among R&D 
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activities within and between firm boundaries. An important condition for 
complementarities to occur, as Cohen & Levinthal already mentioned, is that internal 
and external knowledge are relevant to one another. With two exceptions, existing 
contributions have largely ignored this condition of knowledge relevance. One 
exception is the work of Arora and Gambardella (1994) who test whether firms use 
their external linkages as complements. While complementarity itself is not precisely 
defined in this study, it is assumed that different types of external linkages are 
complements if they do not have overlapping (knowledge) purposes. Moreover, the 
authors argue that external linkages such as research agreements with universities and 
acquisitions of biotech firms are complementary strategies because they serve 
different purposes but are still correlated. While indeed, it is generally acknowledged 
that activities, which are completely overlapping in terms of purpose or knowledge 
domain are considered as substitutes, it is not very clear whether non-overlapping 
features defines them as complements (Besanko, 2007). A more precise investigation 
into the relevance of knowledge between R&D activities is provided in the work of 
Lane and Lubatkin (1998). These authors argue that a firm’s absorptive capacity is 
often seen as a firm-specific characteristic that determines its innovativeness vis-à-vis 
others to a large extent. However, Lane and Lubatkin (1998) state that a firm’s ability 
to absorb external knowledge depends on the ‘type’ of external knowledge (and the 
partner carrying this knowledge) the firm is absorbing. In other words, absorptive 
capacity is a relational characteristic rather that an actor characteristic of the firm, 
since it differs with each external partner. A firm’s absorptive capacity in this sense 
depends on the knowledge (cognitive) similarity between internal knowledge 
(experience), and external knowledge, and thereby becomes a relational characteristic 
of the firm. This ‘new’ notion of absorptive capacity furthermore implies that 
innovativeness, which is increased by absorptive capacity, differs for each activity 
where a firm is tapping into a new external source of knowledge. An important 
implication of this finding is that measuring absorptive capacity requires project-level 
information. 
Our study differs and enriches these existing studies in a number of ways. To start 
with, all above mentioned studies are performed at the level of the firm, while our 
study enables a direct measure of performance at project level. Having project level 
information has important advantages. Not the least advantage is that it allows us to 
circumvent the danger of firm heterogeneity driving endogenous decisions of which 
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projects are selected5. Furthermore, while being specific for the pharmaceutical 
industry in which our research is situated, we identify the type of knowledge where 
learning curve effects and subsequent complementarities occur. Most importantly 
however is that while previous studies have convincingly shown the existence of 
complementarity as a binary choice, our study allows us to treat complementarity as a 
continuous variable. More specifically, we identify a size threshold over which 
complementarities occur, which concretizes Cohen & Levinthal’s (1989) notion of the 
‘sufficient’ stock of knowledge required for achieving complementarities. Given the 
existence of complementarity, our data allow us to empirically disentangle whether 
these complementarities represent potential absorptive capacity (arising from 
improved external sourcing) or whether the firm has indeed managed to reintegrate 
and exploit external knowledge, which represents realized absorptive capacity.  
                                                 
5 For additional information on how to deal with the problem of unobserved firm 
heterogeneity we refer to Cassiman & Veugelers (2006). 
Chapter 3 Complementarities and the R&D boundaries of the firm 57
3.3 Empirical setting: the pharmaceutical industry 
A number of developments in the pharmaceutical industry over the last decade have 
made the quest for a strategy that achieves complementarities and subsequent 
innovation capacity an important and largely unanswered question in this industry. 
Within big Pharma there is an increased pressure on R&D due to decreased R&D 
productivity and approaching patent expirations. Along the pressure for big pharma to 
maximize shareholder value, strategies have shifted in the last two decades from being 
research driven to being market driven (Drews, 2003). In a research driven 
environment, emphasis of decision making was within R&D departments, where 
managers were geared at innovations originating from deep knowledge of disease 
pathways and pharmacology. While the industry was consolidating in the beginning 
of the nineties, the gravity of decision making has shifted toward marketing and 
finance departments (Drews, 2003). This strategic shift implied a more quantity based 
approach toward research whereby drug discovery was increasingly considered a 
statistical event (Booth & Zemmel, 2004). Today, it appears that this quantitative 
approach toward research is not yet paying off in terms of productivity, and analysts 
are revaluating the early days’ in vivo empiricism based on disease knowledge 
(Erickson, 2003). 
Furthermore, a series of findings suggest that alternatives to the traditional in-house 
R&D model of big pharma might be more successful. The first finding concerns the 
higher success probabilities of (new) biotechnologies. The proportion of newly 
admitted compounds using biotechnologies has increased with 20 -25% compared to 
the more traditional chemical based compounds (Reichert, 2000). Biotechnologies are 
mainly exploited by small-, and medium sized biotechnology firms, while chemical 
based compounds mainly originate from big pharma. Second, newly developed 
compounds that are discovered in-house are being outperformed by compounds that 
are produced externally or through external collaborations6. Moreover, as 
biotechnologies increase the scope of research, big pharma increasingly realize that it 
is impossible to cover the whole spectrum of technologies themselves. While research 
for new drugs was traditionally conducted in-house, large pharmaceutical firms have 
by now build research portfolios where internal R&D efforts are combined with 
                                                 
6 ‘Improving the pharma research pipeline’ McKinsey Quarterly, August 2004. 
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external R&D collaborations. Some analysts even go as far as to state that Pharma 
companies should be virtual in research, which means that they in-license all 
compounds from preclinical testing onwards. Against the background of these 
developments it has become questionable whether big pharma still has to play a role 
in research. Wouldn’t it be better if big pharma narrows down its core competences to 
downstream drug development and employ a virtual research model? Or are there still 
advantages to be obtained from in-house research? If the latter is true, which portfolio 
would generate complementarities between internal and externally sourced research 
projects?  
 
3.4 Empirical strategy 
Our empirical strategy is summarized in figure 3.1.  
Fig. 3.1 - Empirical strategy
* Number of projects that belong to same disease area (DASIZE), target (TARGETSIZE), therapeutic area (TASIZE) or pharmacological 
(PHARMACOSIZE) activity
** All stages of preclinical investigation including discovery, research, lead optimization. 
*** Following Phelps (2003)5 we assume a project duration of three years. As a result,  all projects that  started between 2000 and 2002 make 
up the 2002 research portfolio.
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  3.4.1 Data selection 
We selected the 20 highest R&D spending pharmaceutical firms in 2005 from 
Evaluate Pharma, a frequently used database in the pharmaceutical industry for 
forecasting and analysis services. Of the selected firms, we used Pharma Projects 
database to extract the whole research portfolio per firm at a certain time. 
PharmaProjects is a privately held project monitoring firm, which continuously 
searches for information on both internal and externally sourced projects of large 
pharmaceutical firms through a number of search channels. Primarily, PharmaProjects 
visits events and conferences where pharmaceutical firms meet to exchange 
information about the projects running through their pipelines. This information is 
then verified and updated with press releases, website information and annual reports. 
Telephone surveys are regularly conducted to verify the accuracy of their database. As 
a deliberate strategy, no use is made of patent information, since “often...” our 
informant claims, “...the firm files patents on anything that lies around in the lab to 
create a smoke screen and hide their actual R&D strategy” (information based on 
telephone interview with Pharmaprojects data manager). 
We focus our analysis on research projects that are active at the earliest stage of 
research before entering clinical testing7. In doing so, we follow earlier work by 
Pisano (1990) who convincingly argues that from clinical testing onwards external 
contracting is often done by technological licensing instead of R&D contracting. 
Technological licensing and R&D contracting are two fundamentally different 
contracts. R&D contracts are typically long-term agreements where knowledge 
exchange and learning effects take place, while technological licensing agreements 
are one-time exchanges to obtain rights to an already developed technology (Pisano, 
1990 pp. 163). As in our study we are interested in complementarities arising from 
learning through knowledge spillovers between and within organizations, we restrict 
our analysis to these early stage research projects. Another reason for this restriction 
is that our dependent variable (probability to enter clinical I) is more reliable when 
restricted to early stage research. If we were to measure the probability of a project to 
reach the market for example, we would be unable to distinguish complementarities 
                                                 
7 Projects only entered the database if they had a solid chemical structure and a therapeutic 
goal had been identified. 
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from many other factors affecting whether a projects survives the 12 year (or longer) 
ride through the pharmaceutical production process.  
 
  3.4.2 Building a research portfolio 
To determine each firm’s research portfolio of 2002, we summed all research project 
that were announced as annual newly entering projects in early research from 2000 
until 2002. We thereby follow a study by Phelps (2003) who shows that the average 
duration of R&D projects is three years (see also: Phlippen & van der Knaap, 2007). 
As a result, all newly announced projects in 2000, 2001 and 2002 are assumed to be 
part of a firm’s 2002 research portfolio. Our choice of constructing the 2002 research 
portfolio and not a more recent portfolio is related to our dependent variable 
‘probability to reach clinical testing’. A project in early research can take (on average) 
up to four years to reach clinical testing, which makes it necessary to track each 
project until the end of 2006 to know whether it has been successful in reaching 
clinical testing on humans. Our initial sample consisted of 1328 early stage research 
projects (before clinical testing I). Leaving out projects of which no success 
probability was known reduced our sample to 977 projects. Furthermore, we excluded 
all projects where no disease area information was given, which reduced our final 
work set to 762 projects. 
 
  3.4.3 Variables 
 
  Dependent variable: success probability 
 Each project is defined as either successful, failure or unknown in reaching the first 
stage of clinical testing (SUCCESS). If we didn’t find the project in our database for 4 
years or longer, we decided to label it as a failure. Projects were labeled unknown if 
there was no information between 1 and 3 years. We used Binary logistic regression 
analysis to model the success probabilities of a research project.  
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Control variables 
In every regression we controlled for a number of variables that are strongly 
associated with the probability of a project reaching clinical testing successfully (see: 
empirical setting). The first is the variable indicating whether a project is being 
developed in-house or through external collaboration (EXTERNAL), as previous 
work has shown external collaborations to perform better on average than internal 
projects over the whole production process8. A second control variable indicates 
whether a project involves chemicals or biotechnologies (BIOTECH), as 
biotechnology based compounds are found to outcompete compounds based on 
chemical substance. We further controlled for the effect of a project aiming at a 
reformulation of an existing drug or aiming at a new drug (FORMULATION), since 
the former are assumed to be more likely to reach clinical testing. Each project is 
focused at a certain disease area. To prevent the disease area (e.g. anticancer or 
inflammation) itself to be driving the success probabilities of our projects we included 
dummies for all disease areas in most of our regressions (ANTICAN, INFLAM etc). 
At the level of the firm, we control for firm heterogeneity simply by adding dummies 
for all firms in most of our regressions (ROCHE, GSK, etc).  
 
 Explanatory variables 
There are two main sets of explanatory variables. The first set is aimed at identifying 
the conditions for complementarity to arise, and the second set is aimed at 
understanding how complementarities occur between internal projects and external 
projects, i.e. whether they result from potential (knowledge outflow) or from realized 
absorptive capacity (knowledge inflow).  
   
Conditions for complementarity 
As we have argued in our introduction, Cohen & Levinthal (1989) and the work 
thereafter has emphasized the importance of a firm’s ‘sufficient stock of relevant prior 
knowledge’ in order to absorb external knowledge effectively. We test what 
constitutes a ‘sufficient’ stock and what knowledge is ‘relevant’ to obtain 
complementarities.  
                                                 
8 ‘Improving the pharma research pipeline’. McKinsey Quarterly, August 2004 
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Where to look for complementarities? 
Which type of knowledge similarity generates complementarities? While it is 
typically assumed that projects aiming at similar therapeutical areas might compete 
and/or learn from each other and create complementarities by doing so, we test 3 other 
potential types of knowledge areas where complementarities might occur. First we 
add disease area as a potential knowledge area that might be an alternative for 
therapeutic area. TAsize (therapeutic area) is a more broadly defined group than 
DAsize (disease area). For example the therapeutical area named ‘cognition enhancer’ 
consists among others of the disease area ‘Alzheimer’. Another knowledge area where 
complementarities might occur is the target that a drug in a project is aiming at 
(TARGETsize). A drug target can be the protein to which the drug binds, inhibits or 
activates (e.g. receptor subunits or enzymes). Finally we tested whether the 
pharmacological activity, which describes the beneficial or adverse effects of a drug 
on living matter (i.e. it describes how the drug works) might generate 
complementarities (PHARMACOsize). Based on each of these four knowledge areas 
we grouped all projects within each firm and tested whether more projects in each of 
these knowledge areas (within a firm) increases the average performance of projects. 
 
 When is a stock of knowledge sufficiently large? 
The aim is to determine the effect of the number of ‘similar’ projects in a firm’s 
research portfolio (SIZE) on the probability of a project reaching clinical testing. The 
knowledge area to which ‘similarity’ applies is to be defined as a first step in our 
analysis. This variable (SIZE) is categorized as either ‘no or just one similar project’ 
(SMALL), 2-9 similar projects (MEDIUM), or containing 10 or more similar projects 
(LARGE)9. Complementarities arise when more similar projects leads to higher 
average success probabilities. We thus expect that projects in category LARGE 
perform better than projects in category MEDIUM. Projects categorized as SMALL 
contain (nearly) isolated projects, which by definition do not measure 
                                                 
9 We explored different size categories and the currently used categories were most able to 
discriminate amongst success probabilities.  
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complementarity. However, being a relatively large group of projects, we used this 
category as our reference category to benchmark our two other categories against.   
 
How do complementarities arise between internal and external projects? 
The theory of absorptive capacity provides guidance on how complementarities are 
expected to arise between internal research and externally sourced research projects. 
While a firm’s absorptive capacity implies knowledge flowing outside in, this theory 
argues that internal knowledge is first used to screen and absorb external knowledge, 
and as a second step the firm reintegrates the absorbed knowledge internally to 
improve internal R&D. We measure both parts of this process separately by 
identifying: 
1. How the performance of external projects changes when a ‘sufficient’ amount of 
‘similar’ internal projects are running (EXTERN_SUCCESS).  
2.  How the performance of internal projects changes when a ‘sufficient’ amount of 
‘similar’ external projects are running (INTERN_SUCCESS).  
The question about ‘sufficient’ amounts of internal and externally sourced projects 
essentially asks how a firm should design its research portfolio with regard to the ratio 
of internal and external R&D investment. Surprisingly we found no study that deals 
with this question explicitly and hence we explored the ‘optimal’ external/ internal 
ratio among ‘similar’ projects ourselves. 
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3.5. Results 
 3.5.1 Effect of individual project characteristics 
Our analysis starts with the assessment of individual project characteristics that have 
in previous studies been identified as having a significant impact on the success 
probabilities of R&D. The two main characteristics are whether a project is conducted 
in-house or through external sourcing, and second whether a project builds on 
chemicals or on biotechnologies10 11.  
 
Fig. 3.2 – Individual project characteristics
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Externally sourced projects are significantly more likely to reach clinical testing (our 
indicator of success) than internal projects. While previous studies have already 
shown this differences between internal and externally sourced projects at the 
development stages in R&D (clinical I to III) (DiMasi, 2001), our findings indicate 
that the advantage of external collaboration already occurs during early research. We 
further found that projects involving biotechnologies, such as recombinant DNA 
technologies or monoclonal antibodies are also significantly more likely to be 
successful compared to projects based on chemical compounds. Figure 3.2 illustrates 
                                                 
10 See chapter 1 section 1.3 for an overview. 
11 We also tested the effect of a project being a new formulation of an existing drug or a ‘real’ 
new drug.  
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these findings by showing the differences in average success rates related to external 
collaborations and biotechnologies. 
 
3.5.2 Conditions for complementarities 
Identifying ‘relevant’ knowledge 
Our data allowed us to test four knowledge areas where complementarities might 
occur. More specifically, we grouped projects around the same disease area, the same 
target, the same pharmacological activity and around the same therapeutic area 
(within a company). For each grouping we then analyzed the effect on success 
probabilities, as is shown in table 3.1. After controlling for individual project 
characteristics we found that only disease area grouping has a positive significant 
impact on success probabilities, and that neither grouping by target, by 
pharmacological activity or by therapeutic area has a significant impact on success 
probabilities12. From here on, our analysis focuses on projects grouped around disease 
areas, as it appears to be the only relevant knowledge area for achieving 
complementarities.  
 
                                                 
12 Interestingly, grouping based on therapeutic area appears to have a significant negative 
effect on success probabilities. It might be the case that on the higher aggregation level that 
therapeutical area represent, competition outweighs learning effects. 
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Table 3.1 – Identifying relevant knowledge areas.
Effect of grouping by disease area, target, pharmacological activity and therapeutical area on a 
projects’ success probability
B S.E. Sig. Exp(B)
Step 
1(a)
BIOTECH .234 .002 2.064
FORMULATION .378 .003 3.092
EXTERNAL .195 .065
.102 .921
Constant - 1.008 .164 .000 .365
a  Variable(s) entered on step 1: BIOTECH, FORMULATION, EXTERNAL, TAsize, PharmacoclusterSize, 
DAsize, TARGETsize, DA Externals 
Notes: coefficients significant at 1%***, 5%**, 10%*
.724***
1.129***
.360* 1.434
Ta size - .016 .003 .952
PharmacoclusterSize - .015 .011 .168 .985
Da size .017 .044 1.035
TARGETsize .089 .071 .209 1.093
Da externals - .082 .050
.034**
.049***
 
 
Identifying a sufficiently large stock of knowledge 
Previous work on complementarities has provided clear evidence that adding an R&D 
project to an already existing stock of R&D has a higher incremental effect on 
innovation than adding an R&D project in isolation (Milgrom & Roberts, 1990). 
Going one step further, we analyze whether the size of the existing stock of 
knowledge matters for achieving these complementarities. Intuitively, one could 
imagine that a critical mass of relevant knowledge must be achieved in order to truly 
benefit from complementarities. In order to test whether this is indeed the case we 
categorized projects as either belonging to a large disease area group, (i.e. containing 
10 projects or more per firm), to a medium sized disease area group (containing 2 to 9 
projects within the same disease area per firm), or as focusing on a (nearly) isolated 
disease area. In the latter category success probabilities are not caused by 
complementarities. Based on the actual distribution of projects over disease areas by 
our set of firms in figure 3.3 we chose the boundary between large and medium sized 
groups.  
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Figure 3.3 reveals that the largest R&D spending pharmaceutical firms invest 46 
percent of their total research projects in disease areas with on average 10 projects or 
more (within the 2 largest disease areas). If one can speak of a critical mass of 
knowledge that drives complementarities, we expect the boundaries to be around 10 
or more projects13. 
Table 3.2 shows the binomial Logit regression results on the effect of the group size 
to which a project belongs on the probability that the project reaches clinical testing. 
 
 
                                                 
13 We also explored shifting the boundaries to 9 or more projects and to 12 or more projects. 
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.155.00.148-1.862Constant
1.640.032.230.495**INFECTION
1.893.045.318.638**Astrazeneca
2.814.000.1821.035***SMALL
1.448.079.211.371*LARGE
1.456.023.165.375**EXTERNAL
3.417.001.3631.229***
FORMULATION
1.679.009.199.518***
BIOTECHStep 2(b)
.163.000.145-1.815Constant
1.585.045.230.461INFECTION
2.773.000.1811.020SMALL
1.444.082.211.367LARGE
1.454.023.164.375EXTERNAL
3.409.001.3631.227
FORMULATION
1.689.008.198.524
BIOTECHStep 1(a)
Exp(B)Sig.S.E.B
Table 3.2. – Identifying a sufficient stock of knowledge.
Effect of the group size to which a project belongs to on its success probability
a  Variable(s) entered on step 1: INFECTION. b  Variable(s) entered on step 2: Astrazeneca.
Notes: coefficients significant at 1%***, 5%**, 10%* Notes2: N = 977.  
 
In order to exclude any effect of either firm heterogeneity or effects that are specific 
for any disease area, we added firm dummies and disease area dummies next to the 
usual project characteristics as control variables. To keep our results readable, we 
used a stepwise selection method for our variables with entry testing based on the 
significance of the score statistic, and removal testing based on the probability of a 
likelihood-ratio statistic based on the maximum partial likelihood estimates. Our main 
variable of interest is LARGE, which is offset against our base variable MEDIUM. As 
table 3.2 reveals, the variable LARGE is significant at the 10 percent level, which 
indicates that projects active in a disease area where at least 10 other projects are 
running are more likely to reach clinical testing compared to projects in a disease area 
where only 2 to 9 similar projects are running. This finding confirms that projects in 
which a firm has built a critical mass of disease knowledge have a higher marginal 
return to performance than projects in which a firm has not built such a critical mass. 
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More generally, complementarities between research projects arise once a firm has 
built a critical mass of knowledge in a similar knowledge domain.  
However, one could argue that there is a critical danger of endogeneity driving our 
results i.e., projects do not become more successful because of complementarity 
effects, but the management of a firm puts its ‘golden eggs’ in one basket, namely in 
its main disease areas. This would imply that the expected success of certain projects 
drives management to focus their attention on these projects and create a large number 
of similar projects around these ‘golden eggs’. To test whether this is the case, we 
analyze the effect of each firm’s two main disease areas14 on the success probabilities 
of projects in these DA’s. Table 3.3 shows the results of this test, whereby we 
replicated the test on size effects (table 3.2) while interchanging the categories 
LARGE, MEDIUM, SMALL with the categories DA2largest and OTHER (reference 
category) 15. 
 
                                                 
14 Again, we chose to analyze a firms two main DA’s since these represent 46 % of all 
research projects, while the third largest disease areas and beyond are strongly decreasing 
their contribution to the firms research portfolio (see figure 3). 
15 To prevent our main variable of interest DA2largest to be excluded from the results based 
on restricted entry testing used in table 2, we unconditionally let the variable DA2largest and 
the BIOTECH, FORMULATION and EXTERNAL variables enter our equation.  
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.336.000.126-1.089Constant
2.136.025.338.759**Wyeth
1.730.049.278.548**GSK
.717.052.171-.333**DA2largest
1.268.196.183.237EXTERNAL
3.472.001.3751.245***FORMULATION
1.665.021.221.510**BIOTECHStep 2(b)
.351.000.124-1.046Constant
2.020.036.336.703Wyeth
.733.068.170-.311DA2largest
1.276.183.183.243EXTERNAL
3.407.001.3741.226FORMULATION
1.665.021.221.510BIOTECHStep 1(a)
Exp(B)Sig.S.E.B
Table 3.3 – Effect of projects belonging to a firm’s 2 largest disease 
areas on success probabilities
a  Variable(s) entered on step 1: Wyeth. b  Variable(s) entered on step 2: GSK.
Notes: coefficients significant at 1%***, 5%**, 10%*
Notes2: N = 977.  
 
DA2largest measures whether a project is part of a firms two main disease areas or 
not. As becomes clear in table 3.3 projects that belong to one of the firm’s two most 
important disease areas does not increase their probability of reaching clinical testing. 
Moreover, there seems to be a negative effect from being part of a firm’s 2 main 
disease areas. This effect might be caused by the fact that the firms in our sample 
differ with respect to their R&D investment strategy. While some firms choose (or are 
able) to built a critical mass in a few disease areas, other firms rather spread their 
R&D projects over different disease areas. These strategy differences become clear 
when looking at figure 3.3. The number of projects that form a firm’s 2 largest disease 
areas range from 2 to 37 projects. Interestingly, the strategy of spreading projects over 
different disease areas, referred to as risk diversification strategies, is appearing to be 
paying off as well. Although this study investigates complementarity effects among 
projects, the highly significant positive effect of nearly isolated projects (SMALL) in 
table 3.2 raises our suspicion that aiming for complementarities by building a critical 
mass of disease knowledge is not the only rewarding strategy.  
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3.5.3 How do complementarities arise between internal and 
external projects? 
So far, we have found that complementarities arise from grouping a relatively large 
amount of research projects around a disease area. As a next step, we focus on these 
large disease area groups to find out how the ratio of internal R&D and external R&D 
affects complementarities among internal projects and externally sourced projects 
separately16. The ratio between internal and external R&D has been surprisingly little 
discussed within the literature on absorptive capacity. We argue however that it is a 
fundamental question since the capacity to absorb larger amounts of external 
information must depend greatly on a larger internal capacity to absorb this 
information. To some extend the work of Lane and Lubatkin (1998) recognizes the 
importance of this ratio by focusing on relative absorptive capacity. However, they do 
so at the level of the dyad (i.e. a relation between internal R&D and one externally 
sourced project). 
Once the ratio of internal versus external projects that generates complementarities is 
determined, we can test whether external projects or internal projects are most 
responsible for the increased success probabilities. In this part of the analysis we use a 
subsample of our data, namely only projects belonging to a firm’s large disease area 
(10 or more similar projects). Figure 3.4 below plots the number of projects that firms 
run in large disease areas at different internal / external ratios. 
                                                 
16 By reducing our sample to projects in large disease areas we are unable to control for firm-, 
and disease fixed effects. This is due to the fact that only few firms are able to create a large 
number of projects in a few disease areas (e.g. anticancer and infection).  
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Fig. 3.4 – The number of projects in large disease areas (within   
the firm) at different external/internal ratios
 
 
Based on the above plot we divided projects as either belonging to a disease area with 
few external projects and many internal projects (ratio externals 20/80 or less) or vice 
versa (ratio externals 20/80 or more)17. Dividing our projects into these to categories 
allows us to test if projects perform differently in each category. If they do, we can 
test whether internal projects benefit from a specific internal/external ratio or whether 
external projects benefit from this ratio. Projects in the ‘poor performing’ category 
serve as our benchmark. The results of these tests are displayed in table 3.4. 
                                                 
17 Obviously this choice is somewhat arbitrary. We explored different ratios and found this 
division to be discriminating our success probabilities.  
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.148.000.391-1.907
Constant
.343.3131.062-1.071
EXTERNAL by 
FEWEXTERNALS
2.829.035.4931.040**
FEWEXTERNALS
2.778.069.5611.022*
EXTERNAL
.0001.00040192.970-20.317
FORMULATION
4.120.005.5081.416***
BIOTECH
Exp(B)Sig.S.E.B
Table 3.4 - Effect of (internal) projects belonging to a large disease area
with less than 20% external R&D projects on success probability.
a  Variable's) entered on step 1: BIOTECH, FORMULATION, EXTERNAL, FEWEXTERNALS, EXTERNAL 
FEWEXTERNALS .
Notes: coefficients significant at 1%***, 5%**, 10%*
Notes2: N = 136  
 
In table 3.4 the variable FEWEXTERNALS shows that projects in a disease area with 
an external ratio of 20/80 or less perform significantly better than projects in a disease 
area with a higher externals ratio. While this variable does not distinguish among 
internal and external projects, the addition of our interaction term 
(FEWEXTERNALS by EXTERNALS) controls for the (slightly negative) effect that 
external R&D projects have in the disease areas with a low external ratio. To put it 
differently, the higher performance of projects in DAs with low externals ratio is 
mainly attributable to the improved performance of internal projects. To clarify this 
point we add a fifth table where we only consider the subsample of internal projects in 
large disease areas.  
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.228.000.254-1.479
Constant
1.788.100.353.581*
INTERNAL_SUCCESS
1.463.7481.182.380
FORMULATION
2.516.027.418.923**
BIOTECHStep 
1(a)
Exp(B)Sig.S.E.B
Table 3.5 - Internal project performance in large clusters with few externals 
compared to other internal projects.
a  Variable(s) entered on step 1: BIOTECH, FORMULATION, INTERNAL_SUCCESS.
Notes: coefficients significant at 1%***, 5%**, 10%*
Notes2: N = 182  
 
Here, in table 3.5 the variable (INTERNAL_SUCCESS) indicates the performance of 
internal projects in large disease areas with a low external ratio in comparison to other 
internal projects in large disease areas. The results confirm the findings displayed in 
table 3.4 that internal projects perform better if they are part of a large disease area 
with few externally sourced projects involved. 
 
3.6 Conclusions 
For more than a decade firms in research driven environments such as the 
pharmaceutical industry, experience an increased pressure on R&D due to decreased 
R&D productivity and approaching patent expirations (Drews, 2001). In response to 
this, firms are exploring alternative ways to organize their R&D portfolio. While 
traditionally early stage R&D has been conducted mainly inside the firm’s own R&D 
laboratories, the last decade has brought forward a huge increase in R&D 
collaborations with market based firms at all stages of the drug development process. 
This raises the question whether the make-or-buy decision of the firm should be 
replaced by a make-and-buy decision of the firm. The answer depends crucially on the 
extent towhich internal R&D (make) and externally sourced R&D (buy) can be 
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complementary, i.e. whether performing internal R&D in combination with external 
R&D generates higher marginal performance than only internal or only external 
R&D. In theory, complementarity between internal and external R&D exists if a firm 
has built a sufficient stock of relevant internal knowledge to effectively absorb 
external knowledge (Cohen & Levinthal, 1989). Our study is the first empirical work 
that has investigated the conditions for complementarity to arise, and the process 
through which it occurs. More specifically, we examined what ‘type’ of knowledge is 
relevant for complementarity, how much of this knowledge is sufficient, and lastly we 
examined how this knowledge flows between internal and externally sourced R&D. 
As it turns out, large pharmaceutical firms can achieve higher marginal returns on 
their R&D projects, if they group a relatively large number of projects (more than 10) 
around a specific disease area. By focusing on a specific disease area firms can 
develop deep in-house expertise, attract the best talent, and be a preferred partner for 
deal-opportunities outside the firm. Moreover, we conclude that if no more than 20 
percent of these projects are externally sourced, complementarity effects are highest. 
This is caused by the fact that internal projects perform better when the number of 
externally sourced projects is relatively low. The reason for this might be that 
knowledge can only be transferred from external projects to internal projects if the 
same expert scientists are involved in both internal and external partners work. This 
would naturally limit the number of externally sourced projects. This interpretation is 
in line with the notion that knowledge required for pharmaceutical drug discovery is 
highly tacit and embedded in the scientists involved, which makes transfer of this 
knowledge between people leave alone projects difficult. 
Chapter 4  When clusters become networks1: 
Alliance formation in regional clusters2  
 
4.1 Introduction 
Regional innovation, local knowledge spill-over and cluster synergy are concepts that 
have long spurred policy makers to invest heavily in the co-location of firms such as 
technology- and science parks. These investments however rely on two assumptions: 
one is that there is some sort of knowledge diffusion process going on among co-
located organizations that is beneficial to these organizations, and the other is that this 
knowledge diffusion occurs in geographically confined areas. These assumptions are 
supported by empirical and theoretical evidence where high-tech clusters with 
strongly connected organizations are recognized as engines of national economic 
performance (Storper, 1995; Scott, 1993; Saxenian, 1994). While there are examples 
of highly innovative regions where firms exchange knowledge intensively, there are 
many more regions where co-location does not induce any knowledge exchange.  
As the exchange of knowledge is considered crucial for innovation in science based 
industries, this chapter aims to bring to light what determines knowledge exchange in 
clusters of co-located firms. More specifically, we exploit empirical data from the 
European pharmaceutical industry, as it is the most science based industry today and 
we focus on one particular form of knowledge exchange, namely formal 
collaborations. 
Knowledge can diffuse through various routes, depending among others on the type of 
knowledge that is diffused (e.g. whether it concerns tacit or codified information or 
whether it is appropriable) and on the type or organizations involved. Knowledge 
diffusion can take the form of informal personal interactions, formal collaborations, 
spin-out companies and consultancy or through job mobility (Abramovsky et al, 
2007). In this study we look at formal collaborations as a means of knowledge 
diffusion. Firms in technology intensive environments transfer valuable knowledge 
through formal interactions rather than through informal social contacts (Zaheer and 
                                                 
1 This chapter is based on joint work with G.A. van der Knaap. 
2 We thank Wouter Kleijheeg, Martijn van Eckeveld and Henri van den Broek for research 
assistance. We further thank all participants of the Tinbergen PhD seminar and the Applied 
Economics seminar for valuable comments on previous versions of this chapter. 
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George, 2004). Moreover, we argue that while informal knowledge exchange can play 
an important role in innovation, it often travels along more formal interactions such as 
lunch meetings, or other social occasions with formal alliance partners. Especially in 
our empirical setting, which is the pharmaceutical industry formal collaborations have 
shown to be crucial in the organization of innovative labor and in the acquisition of 
new skills and technologies (Hagedoorn, 2002; Owen-Smith et al, 2002). 
 
Given the importance of formal collaborations, the question is: when do these 
collaborations require geographical proximity? While there is convincing evidence of 
the existence of geographically mediated knowledge diffusion in science driven 
industries (see Audretch & Feldman, 1996; Jaffe, 1989; Prevezer, 1997), less is 
known about what drives this geographically mediated knowledge diffusion or, as in 
our case, local collaboration. From a policy maker’s perspective, for whom 
geographical proximity is given, one should turn this question around by asking: when 
do co-located organizations collaborate? 
In the existing literature on firm innovation in relation to locational decision, 
emphasis is mainly on why firms cluster geographically. One important finding is that 
geographically mediated knowledge spillovers can partly explain the geographical 
clustering of innovative firms. While studies emanating from US data indeed show 
that innovative tacit knowledge transfers locally through formal alliances (Zucker et 
al, 1996), little is known about the European situation. Our study not only reveals 
partly contradicting evidence, but also indicates factors that do induce local link 
formation in European clusters. Proposed explanatory factors from the literature that 
we include in our analysis are: type of organizations present, relational embeddedness, 
nature of knowledge that is exchanged, technological diversity, and life-cycle effects. 
 
The empirical setting of this chapter is the European biopharmaceutical industry. The 
biopharmaceutical industry appears to be a very appropriate setting to test our 
research questions since it is not only a highly innovative science based industry, but 
firms active in biopharmaceuticals tend to cluster geographically (Swann & Prevezer, 
1996; Zaheer & George, 2004; Zucker, 1996). Thereby, due to the specific 
characteristics of drug development, such as high commercial values and natural 
excludability, the number of strategic collaborations is high (Hagedoorn, 2002). With 
rare exceptions, existing studies on innovative clusters are case studies of one or two 
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regional clusters and existing quantitative studies are mostly based on data from the 
United States. This chapter distinguishes itself from these existing studies by covering 
100 European clusters of deal active firms and fairly detailed information per cluster, 
such as type of organizations, type of alliances (R&D collaboration, licensing etc) and 
the therapeutic focus of alliances. Furthermore the time span of our data (1996-2005) 
allows us to first provide a preliminary longitudinal view of collaboration activity in 
Europe and finally to create clusters of firms in which alliance activity is based on 
realistic assumptions of alliance duration. Lastly, our use of longitudinal data enables 
us to significantly reduce endogeneity problems. In what follows we propose 
hypothesis based on our discussion of the literature on innovation, collaboration and 
geographical proximity (section 3). Section 4 of the chapter will discuss the data and 
research methodology, followed by the results in section 5. In the concluding section 
(section 6) of the chapter we will discuss the results, its implications and limitations 
and give some directions for future research. We will start with a preliminary view on 
the data (section 2). 
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4.2 Preliminary data view 
In figure 4.1 we have plotted the amount of annual newly announced agreements 
between organizations in the European pharmaceutical industry. We distinguish 
between local agreements and non-local agreements. Local agreements are 
agreements between organizations located in the same geographical cluster and non-
local agreements are agreements between organizations that are not located in the 
same cluster. We further define a cluster as a group of co-located organizations. The 
boundaries of our clusters are chosen in such a way that the geographical distance 
between organizations within our clusters is minimized while maximizing the distance 
between clusters. More details about the boundary setting of our clusters are given in 
section 4. Agreements, hereafter referred to as linkages, are formed at all phases in the 
production process of drug development, ranging from early stage drug discovery 
collaborations to marketing and distribution agreements. 
 
Fig. 4.1 - Annual new collaborative non-local agreements (dotted line) and local agreements
(full line)
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From 1996 till 2005 we can clearly distinguish 3 waves of link formation, with peaks 
in 1998, 2001 and 2004 respectively. While local linkages and non-local linkages 
seem to follow the same pattern in link formation, the absolute number of linkages 
that occur locally is much lower compared to non-local linkages.  To identify the 
whole network of collaborations at various moments in time we created ‘snapshots’ of 
the network of collaborations in June 1999, June 2002 and in June 2005. These 
‘snapshots’ build on the assumption of alliance duration of 3 years (Phelps, 2003),, 
which means that each ‘snapshot’ captures all new agreements announced back to 
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three years before taking the ‘snapshot’. In table 4.1 and figures 4.2, and 4.3 we show 
these snapshots of the European pharmaceutical industry. We are aware that our 
dataset is limited in the sense that we do not observe firms, which have not formed 
alliances for three years. However, we do not consider this a major problem since 
competitive firms in the pharmaceutical industry are almost always deal-active (Arora 
& Gambardella, 1990). 
 
Table 4.1 – European pharmaceutical clusters (descriptive)
609411303Organizations
1157715687Linkages
11.107.734.96
Standard dev of 
organizations per 
cluster
10.047.325.79
Mean number of 
organizations per 
cluster
June 2005June 2002June 1999
 
 
European pharmaceutical clusters are increasing in size with mean cluster sizes almost 
doubling from 1999 until 2005. In the same period we see a growing dominance of 
London in figure 4.2 as the largest pharmaceutical cluster in terms of deal-active 
organizations present. This visual observation is confirmed as a general trend of 
increasing inequality in the distribution of organizations over European clusters 
(standard deviation of organizations per cluster more than doubles from 1999 until 
2005). 
 When we look at the evolution of alliance activity of the organizations in these 
clusters in table 4.1 and Figure 4.3 it is no surprise that alongside the increasing 
number of deal-active organizations, the number of alliances has increased as well. In 
figure three, the size of the nodes represent the intensity of local collaboration (within 
clusters) and the ties between nodes reflect the intensity of non-local collaboration. 
Two observations are worth mentioning here. One is that while Milan was in 1999 
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clearly the European centre of collaboration activities, London has gained dominance 
in 2002 and even reinforced its position in 2005. While this shift from Milan to 
London is apparent in the alliance network, this is not the case in the geographical 
landscape of figure 4.2. This indicates that the regional clusters dominating the 
European landscape in terms of size (representing the number of firms) does not 
necessarily imply that these clusters are also central in terms of connectivity. A 
second observation is that it seems at all moments in time, that local link formation 
and non- local link formation are complements and not substitutes (the largest nodes 
in figure 4.3 are also the most connected nodes). This observation might hint at the 
potential of combining visions of clusters as regional growth engines through local 
collaboration (Storper, 1995; Scott, 1993) with views of clusters as competitive hubs 
in global networks through international collaboration (Porter, 1990; Batheld et al., 
2002). Although our study focuses on explaining local link formation, this preliminary 
data view informs us of the importance to regard local link formation in relation to 
link formation in general or to ‘international’ link formation more specifically. 
Fig. 4.2 – European pharmaceutical clusters in 1999, 2002 and 2005. (Node size represents the number 
of deal-active firms)
   
Fig. 4.3 – Collaboration between clusters (ties) and within clusters (node 
size) in 1999, 2002, and 2005
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4.3 Literature & Hypotheses 
The literature on local knowledge transfer through strategic collaborations is divided 
into studies emanating from economic geography and management studies focusing 
on strategic technology partnering. Within economic geography, local knowledge 
transfer is mainly analyzed as one reason why firms co-locate. Strategic collaboration 
has in this view been analyzed as an important route through which knowledge is 
transferred locally. From the perspective of management studies the emphasis is on 
strategic collaborations and partner choice, whereby geographical clusters are merely 
considered as a potential place to meet. Because interesting empirical contributions to 
our research question originate from both disciplines, we aim to integrate the findings 
under the heading of link formation and local link formation more specifically. 
 
4.3.1 Link formation 
The main argument for the formation of inter-firm linkages has been that it provides 
firms in innovation-driven industries access to new knowledge (Mowery, 1996). 
Especially in the pharmaceutical industry there is an abundance of empirical evidence 
of the increasing importance of inter-firm alliances as a way to acquire knowledge 
that is crucial for innovation (Hagedoorn, 2002; Owen-Smith et al, 2002). 
Other reasons for link formation that have been advocated are efficiency reasons (risk 
& cost sharing, mutual specialization and consolidation of production capacity) and 
strategic reasons such as the improvement of the firm’s long-term product market 
position. A relatively new argument in management studies originating from 
sociology is the embeddedness perspective on the understanding of inter-firm link 
formation. From the relational embeddedness perspective collaborations between 
organizations are more likely to occur when they are embedded in previous relations. 
Relational embeddedness creates trust and transparency among organizations, which 
in turn increases learning performances and reduces costs of mitigating opportunistic 
behavior (Gulati, 1998; Wuyts, 2003). 
With these theoretical perspectives in mind, we now turn our attention to the influence 
of geography on the process of link formation. In other words, how does ‘being in the 
neighborhood’ affect the above described reasons for strategic collaboration? 
Furthermore, related to the question of why organizations collaborate is the question 
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of when to expect local collaboration. To answer these questions we build on insights 
from economic geography, where geographical proximity between organizations and 
the effect on knowledge flows has been studied intensively. 
 
 
4.3.2 Local link formation 
The nature of knowledge 
The competence based view of the firm argues that geographical proximity is 
beneficial for firms in the process of mutual knowledge acquisition. The reason for 
this is that geographical proximity offers the possibility of face-to-face contact, which 
in turn facilitates the transmission of highly specified knowledge (Lundvall, 1992; 
Saxenian, 1994). Highly specified knowledge (as opposed to codified knowledge) is 
often embedded in routines, peoples and in machines, and therefore its transfer is 
geographically bounded (Nonaka, 1994; Blanc & Sierra, 1999; Jaffe & Trajtenberg 
1993; Zucker, 1996). In sum, the competence based view proposes that access to 
specific knowledge can be regarded as a reason for organizations to form local 
collaborations. From a transaction cost perspective of the firm, there exists however a 
danger in inter-organizational knowledge flows, that is, unintended knowledge flows 
easier within geographical proximity and can result in opportunistic behavior (Narula 
& Santangelo, 2005). From this point of view, knowledge that diffuses as a non-
excludible public good (e.g. urbanization economies) can explain the geographical 
clustering of firms since it reduces transaction costs, but it does not explain local link 
formation. Taking these arguments together we expect local link formation to occur 
only when knowledge is excludable (through patents or naturally) and commercially 
valuable. Furthermore, the expectation of local link formation should according to 
Rallet and Torre (2000) be refined, since the requirement of geographical proximity 
might be temporary and does not always necessitate co-location. These authors argue 
that as the nature of the collaboration between organizations moves from exploration 
of potential new products or technologies to the exploitation of the product or 
technology, tasks of organizations involved become more routinized and the need for 
geographical proximity decreases. The notion that the proximity requirement depends 
on the nature of activities and phase of the product life cycle is in line with Saxenian’s 
finding in Silicon Valley, where mainly small and medium sized firms explore niche 
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markets and are at the forefront of new knowledge, which is still non- routinized. 
Thus, one can say that as far as explorative and exploitative activities in new product 
development are undertaken by separate organizations, the organizations involved in 
exploration are expected to be co-located in the same cluster. 
In the pharmaceutical industry, the production process of new drug development is 
roughly divided into explorative or upstream activities aimed at the discovery of new 
drugs and into exploitative or downstream activities aimed at the development, 
marketing & distribution of drugs (Powel, 1996; Liebeskind et al, 1996). Existing 
empirical studies have mainly focused on the organization of upstream activities, 
since here, naturally excludable and highly specified knowledge is transferred 
between organizations through formal alliances. Furthermore, it has been shown that 
in the US at least, these collaborations are formed between co-located organizations 
(first academic and start-ups firms, later established firms), indicating the importance 
of geographical proximity for knowledge transfer (Zucker et al, 2002). We now can 
formulate our first hypothesis as follows: 
 
Hypothesis 1. Clusters with relatively many upstream alliance activities (focusing on 
exploration) have a higher probability of local collaboration. 
 
Technological proximity 
While the above posed hypothesis is founded in an abundance of existing empirical 
evidence, there is a recent and growing literature in management- and innovation 
studies that seems to argue otherwise. In these latter studies, partner selection (or link 
formation) is the main dependent variable that one seeks to explain and geographical 
proximity is placed next to technological proximity and relational proximity as 
potential explanatory variables for the formation of a formal alliance (Gulati, 1995; 
Sorenson & Stuart, 2002). It is argued that in order for firms to effectively collaborate, 
learn and apply the resulting knowledge in the organization, it is necessary to have a 
certain minimum level of technological proximity (Wuyts, 2003). Technological (also 
referred to as cognitive) proximity indicates a common ‘mental’ framework that 
cannot be obtained simply through intensive interaction, but requires training and 
education in the same specific knowledge domains. Given a minimum amount of 
technological proximity, it is the complementarities or variety in the knowledge bases 
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of both firms that induces the highest and most effective knowledge spillovers. 
Organizations that are after these knowledge spillovers will collaborate with partners 
in any geographical location, and they will more likely use their network of social 
relations or some professional occasion (such as a conference) to connect to these 
potential partners. While collaboration between organizations might sometimes be 
within a regional cluster, it is the technological proximity that drives the relation 
rather than geographical proximity (Breschi & Lissoni, 2001). Regional innovative 
clusters such as Silicon Valley or the Boston cluster (around MIT & Harvard) are 
examples of this latter phenomenon.  
 
When we translate the notion of technological proximity between firms back to the 
level of a regional cluster, we find that it coincides with both the notion of ‘flexible 
specialization’ (Piore & Sabel, 1984) in a cluster and with the notion of ‘related 
variety’ (Frenken, 2007). ‘Specialization’ and ‘variety’ (diversity) represent two 
opposing views in the economic geography literature as the answer to what induces 
regional knowledge spillovers. In the literature these are referred to as MAR 
externalities versus Jacobs’s externalities respectively (see Autant-Bernard (2006) for 
a discussion). By conceptually distinguishing diversity as related-, and unrelated 
variety (Frenken, 2007) these two (seemingly opposing) views come together. 
‘Specialization’ refers to the relatedness or the similarity of technologies and 
‘flexible’ refers to the benefits that accrue to co-located firms from the 
complementarities or variety in related activities. Both concepts ‘flexible 
specialization’ and ‘related variety’ basically argue that knowledge spills over 
between organizations, which are involved in complementary activities with 
minimum technological proximity. The main difference between both concepts lies in 
the level of sectoral aggregation at which knowledge spillovers are assumed to occur. 
While the ‘flexible specialization’ thesis focuses on complementarities within an 
industry, ‘related variety’ is focused on inter-sectoral complementarities. As we will 
come to see in the data section of this chapter, we propose to let go of any 
assumptions about the appropriate aggregation level at which spillovers occur and 
simply test whether complementarities pay-off in terms of local collaboration.  
 
From the above literature discussion we can conclude that being co-located does not 
in itself provide incentives for collaboration. However, if firms in a cluster are active 
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in a variety of related activities, we expect to see an increased probability to 
collaborate. Hence our second hypothesis: 
 
Hypothesis 2. Clusters with a high variety in related technological / knowledge 
domains have a higher probability of local collaboration. 
 
The type of organizations present 
The theory of neo-Marshallian districts states that regional collaborations take place 
mainly between small firms that are specialized in different parts of the production 
process of similar products. The smallness of the firms in these districts is perceived 
essential in order to provide mutual interdependence and trust (Markusen, 1996; 
Simmie & Sennet, 1999). While not related to a neo-Marshallian district, Saxenian 
(1991) also finds a more practical reason why small and medium sized firms are more 
likely to collaborate locally. Start-up firms often collaborate locally in science driven 
clusters because they are university spin-offs, whose founders stay close to university 
because of dual occupations. This leads us to a third hypothesis regarding when to 
expect local collaboration 
 
Hypothesis 3. Clusters with relatively many start-up firms have a higher probability of 
local collaboration. 
 
The work of Zucker et al (1996) has shown that biotechnology star-scientists at 
universities are rather entrepreneurial and are responsible for local alliances between 
the university and local private firms. While for US data there is convincing evidence 
of cluster formation around academic organizations, there is still very little insight in 
whether European academic organizations have the same effect. Our fourth 
hypothesis can therefore be stated as follows: 
 
Hypothesis 4.  Clusters where relatively many academic institutions are located have 
a higher probability of local collaboration. 
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(Cluster) Life cycle effects 
The above literature suggests that local collaboration is more likely to occur when 
academic and start-up organizations are co-located. However, it might be the case that 
when too many collaborating organizations are co-located, the information that is 
exchanged becomes redundant. This, in turn, may reduce the incentives for firms to 
form new collaborations. Evidence of such decreasing returns is provided by 
Fingleton et al (2005) in their study on the effect of geographical clustering on high 
technology SMEs in the computing industry. While sector specific, the commonality 
of characteristics between computing and biopharmaceuticals, such as being 
technology and innovation intensive, with rapid growth and the crucial role of SMEs 
(Fingleton et al, 2005) has been confirmed in the study on cluster evolution by Swann 
& Prevezer (1996). While redundancy is certainly a plausible explanation for 
decreasing returns to local collaboration, we will also investigate a second explanation 
for decreasing returns. It might be the case that as clusters increase in terms of number 
of organizations, their function changes from providing organizations local ‘support’ 
collaborations to being a hub from where organizations connect internationally. In this 
latter situation, decreasing returns to local link formation should be accompanied by 
increasing returns to non-local link formation. Or, to put it differently, clusters that 
grow large enough become (reaching a certain threshold) visible in the global 
network, which helps organizations to go ‘international’. We will test whether a 
growing number of deal-active organizations in a cluster causes decreasing returns to 
the propensity to collaborate locally. Additionally, we will investigate whether a 
decreasing tendency to collaborate locally is complemented by an increasing 
probability to collaborate non-locally. 
 
Hypothesis 5. There is an inversed u-shaped relation between the number of deal-
active organizations and the probability to collaborate locally, indicating decreasing 
returns to local collaboration. 
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4.4 Data and methods 
4.4.1 Data 
We used the Pharmadeals database, which globally monitors the announcement of a 
variety of strategic alliances in the biopharmaceutical industry on a daily basis since 
1996. The data preparation has been a three stage process. 
 
To start with, we selected alliances where at least one European partner was involved. 
The database did not at that time allow us to create a query based on the location of 
organizations, and we used European countries as keywords to search for a match in 
any part of the alliance announcement (including press release). This resulted in a hit 
of 2800 alliances between June 1996 and June 2005.  
In a second stage we have split alliances where multiple partners were involved. Of 
these 2800 alliances, some 300 appeared to involve more than 2 separate 
organizations. We decided to split those alliances into each possible combination of 
alliances. Thus, an agreement with n participating organizations was transformed into 
n x (n-1)/2 linkages. Hence, we assume that an alliance serves as a conduit of 
knowledge transfer, where information transfers between all participants in an alliance 
(whether the alliance is a R&D collaboration between multiple universities or a 
project of some pharmaceutical companies who received EU funding). Turning all 
these multiple partner alliances into dyads led to a new alliance set of 4031 alliances 
among 2500 separate organizations. 
Thirdly we manually looked up the cities where organizations are located and found 
around 650 organizations either not tractable or undisclosed by Pharmadeals or being 
a USA based firm with a USA based partner (this latter phenomenon can be explained 
by the splitting of multiple partner projects).  
Our final work set consisted of 2566 alliances among 1834 organizations of which 
1054 are organizations located in Europe. We geo-coded each organizations’ location 
and used a hierarchal clustering algorithm based on Euclidian distances between 
locations to define 54 European clusters. Since we are interested in local collaboration 
we define a cluster as a geographic area where at least 2 deal- active organizations are 
located. Having identified the European clusters we aggregated the information on 
organizations and their alliances back to the regional clusters. Table 4.2 summarizes 
the terminology and definitions of our clusters.   
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Table 4.2 – Definitions of cluster attributes
Phase in the production process of alliances formed by organizations located in a 
cluster (e.g. discovery, clinical testing I/II/III, marketing & distribution)
Type of alliances formed by organizations located in a cluster (e.g. R&D collaboration,
manufacturing & supply, co-development, licensing)
Therapeutical focus of the alliances of organizations located in a cluster (e.g. 
oncology, inflammation, etc.)
Company types per cluster = number of start-up firms, established firms, academic 
organizations or financial organizations located in a cluster
Alliances (linkages) = the total number of alliances formed by organizations located in 
a cluster
–Intra-cluster alliances= the number of alliances where both partners are located in a cluster
–Inter-cluster alliances= number of alliances where a partner is located outside a cluster
Cluster size = the number of deal-active organizations located in a cluster
Cluster name = the city of a cluster where most companies are located
 
 
Finally we have created three ‘snapshots’ of our clusters over time. Following an 
extensive study by Phelps (2003) on the duration of alliances, the most realistic 
assumption of alliance duration is three years. The assumption of three year alliance 
duration is however an average. While our data enable us to distinguishing different 
alliance types, we found no information on average alliance duration per alliance type.  
Based on three year alliance duration we have created the following cluster snapshots: 
• European clusters at t1 = based on the alliances announced between June 1996 
 and May 1999. 
• European clusters at t2 = based on the alliances announced between June 1999 
 and May 2002. 
• European clusters at t3 = based on the alliances announced between June 2002 
 and May 2005. 
In order to increase our observations we pooled the observations of our explanatory 
variables of t1 and t2 and our observations of the dependent variable of t2 and t3 
respectively. We performed a Wald test to make sure there is significant variation 
between the information provided by the recurring clusters, so as to treat them as 
independent observations. This increases our number of observations to 108, as shown 
in the descriptive statistics (table 4.3) below. 
Table 4.3 – Descriptive statistics
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4.4.2 Dependent variable 
As our aim in this chapter is to explain the determinants of collaboration within a 
geographical cluster, our dependent variable is intra-cluster collaboration 
(Local_coll_Y). Intra-cluster collaboration is measured as the number of alliances 
where both partners are located inside the cluster. While this measure captures only 
formal alliances that are publicly announced, we argue, following Zaheer and George 
(2004) that firms in technology intensive environments can only transfer valuable 
knowledge through formal interactions and not through mere physical presence in a 
cluster or through informal social contacts. We also argue that possible knowledge 
spillovers or more informal interaction travels along these formal alliances (during 
lunch meetings, dinners or other occasions with alliance partners). In order to 
minimize reversed causality we lagged the dependent variable. 
 
4.4.3 Independent variables 
Control variables 
Local collaboration at t-1 (Intraclusx). While the issue of reversed causality has been 
taken into consideration through the lagging of the dependent variable, network 
studies show that there is another danger, which is autocorrelation. Within the 
network literature there is general agreement that new alliance formation is a path-
dependent process, where firms are likely to partner with previous partners or with 
partners of previous partners (Gulati, 1995; Coleman, 1988; Granovetter, 1985). 
Given this feature of alliance behavior, lagging a dependent variable doesn’t 
completely solve the issue of causality, because local collaboration at time t can be 
driven completely by its local collaborations at time t-1, which could in turn drive our 
explanatory variables. In order to control for this effect we inserted the number of 
local collaborations at time t-1 (intraclusX) as control variable. 
 
Cluster size (Nodes). We controlled for size effects of clusters by counting the number 
of deal-active organizations. 
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Explanatory variables 
Start-up. Number of deal-active start-up firms located in a cluster 
Financial. Number of deal-active financial firms located in a cluster 
Established. Number of deal-active established firms located in a cluster 
Academic. Number of deal-active academic organizations located in a cluster 
Upstream alliances (Linksup).With this variable we aim to capture explorative 
knowledge transfer (including highly specified knowledge). For each cluster we have 
counted the number of alliances aimed at drug discovery or R&D. We further 
included alliances that involved academic organizations, and alliances that were 
funded by the government (as basic science collaborations often are). 
Downstream alliances (linksdown). With this variable we aim to capture exploitative 
knowledge transfer (including codified knowledge). For each cluster we have counted 
alliances that where active in marketing, distribution, manufacturing & supply or in 
co-promotion activities. 
 
(Related) variety. In our second hypothesis we proposed that clusters in which there is 
a higher variety of related technological- or knowledge domains, we expect a higher 
probability of local collaboration. Since the information of our clusters is build upon 
alliance information and not upon organizational information, we have to rely on a 
proxy for technological proximity. We used the therapeutic focus of an alliance 
formed by organizations located in a cluster as if it were an organizational 
characteristic. Our justification for this strategy is that organizations can only 
collaborate in a therapeutic area where they are knowledgeable. We are however 
aware of the misinterpretation

 danger of this measure, since organizations could also 
collaborate in knowledge domains, which are complementary to them. Support for our 
approach can be found in the relational view of the firm, which states that a firms’ 
portfolio of alliances can be regarded as an important resource of the firm and a major 
source of competitive advantage (Dyer & Singh, 1998). Following a number of 
previous studies that aim to measure technological proximity or related variety in a 
geographic area, we calculated the degree of entropy of each cluster (Frenken 2007; 
Boschma & Iammarino 2007). While Boschma & Iammarino (2007) further specify 
their definition of variety to capture related variety, we can measure related variety 
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using their variety measure. The reason for this is that our data are based on alliance 
information, which by definition already ensures relatedness. Furthermore, alliances 
are aimed at fulfilling a part of the drug development process, which implies some 
degree of technological or cognitive proximity. Variety within these activities is 
caused by linkages focusing on different therapeutical areas and even on technologies 
originating from different sectors such as informatics (e.g. bioinformatics), or 
mechanical engineering (e.g. medical devices). Formally we measure (related) variety 
as entropy, which we define as: 
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pi represents the share of linkages formed in therapeutic area i, with i ranging from 1 
to N in each cluster. As the range of therapeutic areas in a cluster is partly driven by 
the size of a cluster, we weighted our clusters by size. Variety thus measures the 
weighted sum of therapeutical areas in which organizations are deal-active whereby 
therapeutical areas with relatively fewer linkages are weighted stronger.  
 
Nodes & Squared nodes. Measuring the effect of cluster size (nodes) and the squared 
cluster size (squared nodes) on local link formation enables us to see whether there 
are decreasing returns to local collaboration. The interpretation of decreasing returns 
to link formation can be twofold: First, it might be that the cluster has become so 
crowded with interacting organizations that the information they transfer has become 
redundant. Second, the number of organizations in a cluster may increase up to a point 
where the cluster becomes ‘internationally visible’ and, as a result, induce firms to 
collaborate internationally instead of locally. If the latter scenario holds, we expect to 
see decreasing returns to local link formation in combination with increasing returns 
to non-local link formation. Variables that were distributed non-normally have been 
transformed to logarithms. 
 
Non-local linkages. While our aim is to understand what causes local link formation, 
there are two reasons to take non-local link formation into account. First, if we want 
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to be sure that factors, which we find to induce local link formation are specifically 
local or whether these factors induce link formation in general, we need to compare 
the effect of our predictors on local and on non-local link formation. Second, as we 
have seen from our preliminary data view, regional clusters may perform a dual role 
in an economy, namely they may be locally embedded and at the same time function 
as nodes in a global network. While the investigation of this dual role is beyond the 
scope of this chapter, it would be naive to confine our view on inter-firm 
collaborations to local collaborations, especially given the global scope of the 
pharmaceutical industry. 
4.4.4 Analysis 
We test our hypotheses using negative binomial regressions. While Poisson models 
are often used with count data, these models require the mean to be equal to the 
standard deviation. As the descriptive statistics in table 4.3 show, this latter 
requirement is not fulfilled in our dependent variable. As our dependent variable 
contains a high number of zero values (indicating that no local collaboration takes 
place), we performed a Vuong test to see whether using a zero-inflated negative 
binomial regression model would better fit our data. This was not the case. 
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4.5 Results 
Table 4.4 shows the regression results, which are presented separately for each 
hypothesis. 
Dependent Variable: 
local link formation
Coefficient
Std. 
Error
Z-
StatisticProb.  Coefficient
Std. 
Error
z -
Statistic Prob.  
C -5.280936 0.95 -5.55 0 0.720072 0.15 4.855 0
LOG(LINKSUP+1) -0.263489 0.23 -1.13 0.26 0.465 0.04 12.81 0
LOG(LINKSDOWN+1) -0.006921 0.24 -0.03 0.98 0.449 0.06 7.985 0
LOG(NODES+1) 2.630704 0.5 5.215 0 0.371713 0.1 3.812 0.0001
C -7.5182 1.99 -3.78 0.00 0.52756 0.24 2.14 0.03
variety 1.025551 0.60 1.70 0.08 -0.174492 0.04-3.53 0.00
VARIETY*LOG(NODES+1) -0.461937 0.30 -1.52 0.12
LOG(NODES+1) 3.548979 1.22 2.89 0.00 1.359283 0.17 7.89 0.00
Effect of organization type in a cluster on local (&non-local) link formation
Decreasing returns to local (&non-local) link formation
USA effect on local (&non-local) link formation 
Dependent Variable: non-
local link formation
Effect of up- & downstream activity in a cluster on local (& non-local) link formation 
Effect of related variety in a cluster on local (& non-local) link formation 
C -3.293152 0.68 -4.88 0 1.348962 0.16 8.614 0
LOG(ACADEMIC+1) 0.624843 0.36 1.747 0.08 0.649114 0.12 5.489 0
LOG(STARTUP+1) 1.108469 0.26 4.258 0 0.348737 0.1 3.634 0.0003
LOG(ESTABLISHED+1) 1.161943 0.31 3.798 0 0.588432 0.09 6.237 0
C -6.796358 1.65 -4.12 0 0.618971 0.35 1.761 0.0782
LOG(NODES) 5.016013 1.54 3.258 0 1.710182 0.51 3.344 0.0008
LOG(NODES)^2 -0.748472 0.38 -1.95 0.05 -0.25505 0.17 -1.54 0.1238
INTRACLUSX 0.078268 0.13 0.587 0.56 0.106859 0.04 2.444 0.0145
C -0.741031 0.34 -2.19 0.03
CENTERED_USA -0.016835 0.05 -0.32 0.75
CENTERED_NODES 0.24071 0.07 3.681 0
LOG(ACADEMIC+1) 0.027102 0.42 0.065 0.95
LOG(INTRACLUSX+1) -0.190417 0.43 -0.45 0.66
Table 4.4 – Negative binomial regression results using maximum 
likelihood estimations
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4.5.1 The nature of knowledge 
The first set of variables relate to our hypothesis that upstream alliance activity, which 
entails the exchange of highly uncertain and specified knowledge (such as drug 
discovery) is positively related to local link formation. To see whether this relation is 
specific to upstream alliance activity, we compared the effects of upstream alliance 
activity to the effects of downstream alliance activity. Further we tested whether our 
hypothesized effects are specific to local link formation by comparing the effects of 
each of our explanatory variables on local link formation with their effect on non-
local link formation. Our findings lead us to reject our 1st hypothesis indicating that 
upstream, explorative knowledge exchange does not have a significant effect on local 
link formation. However, we do find that upstream knowledge exchange strongly and 
positively (z = 12.81) predicts expected non-local link formation. This result seems to 
indicate that valuable and highly specified knowledge is sourced from any location. 
However, we have to be very careful since not only upstream alliance activity but also 
downstream alliance activity is positively correlated with non-local link formation. 
 
4.5.2 Related variety 
Our second hypothesis stated that clusters with a higher variety in related technologies 
(therapeutic areas) have a higher probability of local link formation. The more variety 
in a cluster, the higher the potential knowledge spillovers and learning effects would 
be. While we found no significant effect of variety on local link formation for the 
whole sample, we found a positive and significant effect of variety for relatively small 
clusters. We distinguished between variety effects in small clusters and large clusters 
by adding an interaction variable between variety and cluster size. The positive effect 
of variety in smaller clusters is in line with the intuition that small clusters provide 
organizations with local support while large clusters function as global hubs. Local 
support in these clusters could be provided through inter-organizational collaboration 
if these organizations’ activities are of a complementary nature (indicating a high 
variety). Further support for the above described intuition arises when we take a look 
at the effect of variety on non-local link formation. Variety has a negative significant 
effect on non-local link formation. This means that in clusters where activities are 
more specialized (less variety), there is more ‘international’ (non-local) link 
formation. Again, the intuition seems in place that clusters, which function as global 
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hubs search for complementary knowledge through ‘international’ alliances and do 
not benefit from a local variety of knowledge or technologies. In sum, we can say that 
in small clusters firms form more local ‘support’ collaborations when there is more 
therapeutical variety. When firms in a cluster are active in similar therapeutic areas 
(specialization) they are capable of forming more non-local or international 
collaborations.  
 
4.5.3 Type of organizations present 
Hypotheses 3 and 4 relate to the type of organizations present and whether or not to 
expect local link formation from their presence. Table 4.4 shows the estimated effects 
of academic organizations, start-ups firms and established pharmaceutical firms on 
local link formation. Financial organizations are treated as a reference category. 
Academic organizations are the least strong drivers of local collaborations, while they 
are the strongest drivers of non-local (‘international’) linkages. This finding leads us 
to reject hypothesis 3, which stated that academic organizations collaborate locally. 
This result is in line with our previous finding that explorative activities, which are 
often carried out by academic organizations are non- local. Our fourth hypothesis, 
regarding the positive effect of startup firms can be confirmed. Startups are more 
likely to collaborate locally and local collaborations are more likely to occur than non-
local collaborations. Finally, while we did not hypothesize on the effect of established 
firms based on previous literature, established firms do perform an interesting role in 
link formation. While academic organizations mainly induce non-local collaborations 
and startups are more likely to collaborate locally, established firms are the drivers of 
both local and non-local linkages. In other words, established firms can be said to 
exert a bridge function in connecting a cluster locally and ‘internationally’. 
 
4.5.4 Cluster life cycle 
Our last hypothesis (5) deals with the issue of the life cycle of a cluster. The 
assumption in the literature is that as the number of active organizations in a cluster 
grows, there will be decreasing returns to local link formation. We proposed two 
testable views to explain this phenomenon. One is that congestion effects occur 
because the information exchanged through collaborations is becoming more and 
more redundant as the cluster grows. A second scenario we investigated is one where 
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larger clusters are more globally ‘visible’, enabling firms to collaborate non-locally 
rather than locally. If this latter scenario is indeed true, we expect to find increasing 
returns to non-local link formation. Based on our findings in table 4.4 we confirm 
decreasing returns to local link formation, but reject increasing returns to non-local 
link formation3. We interpret this finding as evidence of local congestion effects. In 
other words, as the number of organizations in a cluster grows, the number of new 
collaborations, both local and non-local, decreases.  
 
4.6 Discussion & conclusion 
The primary aim of this chapter was to help policy makers understand why some 
regional clusters are networks of intense collaboration while most clusters are mere 
co-located firms. Behind this aim lies an extensive literature that claims these 
networks of intense collaboration are a crucial factor for the innovative performance 
of firms that make up these clusters. Our findings suggest that indeed only very few 
regional clusters can be described as networks of intense collaboration. However, this 
skew distribution of linkages over clusters is not specific to local link formation but 
characterizes alliance activity in general. In other words, there are some clusters that 
are networks of internal collaboration, which are at the same time important hubs in 
non-local networks while most clusters are merely co-located firms. Moreover, most 
other cluster characteristics that we investigated are also skewly distributed, which 
indicates the high diversity of European pharmaceutical clusters. This might explain 
the prevalence of case studies in this area focusing on one or two specific clusters. 
There are two main lessons that policy makers can take from our analysis. The first 
lesson is a rejection of the most common ideas about when to expect local link 
formation, and the second contains some clear evidence of factors that do induce 
knowledge exchange through local collaboration. 
First, it is rather striking and counterintuitive that whereas in the US highly specified 
explorative knowledge spills over from universities into US clusters through formal 
collaborations, in Europe this appears not to be the case. Instead, explorative R&D 
activities such as early stage drug discovery induce non-local alliance formation. This 
                                                 
3 Decreasing returns to local link formation is indicated through a switching coefficient 
(positive to negative) for nodes and squared nodes respectively. A simple scatter plot 
(appendix I) shows that the probability to collaborate locally does not become negative within 
our range of organizations. 
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finding is in line with what Adams and Jaffe already found in 1996, namely that 
pharmaceutical R&D spillovers do not decrease as much with distance as other 
industries’ R&D does. One reason for the non-stickiness of pharmaceutical R&D in 
Europe could be that research centers and start-ups with ‘forefront’ knowledge are 
located in the US, thus making global link formation more important than local link 
formation for acquiring access to valuable new knowledge. To see whether alliance 
activity with US partners functions as a substitute for local knowledge transfer, we 
briefly tested the effect of ‘USA connectivity’ (number of alliances of firms in a 
cluster with US partners) on local link formation (see table 4.4). As the table shows, 
there is no significant effect of USA connectivity on local link formation, and hence 
we can not speak of a substitution effect between knowledge sourcing from the US 
and local knowledge spillovers (through alliances) in Europe. 
 
Second, we found clear positive effects of (related) variety in small clusters, of start-
up firms and of established pharmaceuticals on local knowledge exchange. These 
findings support a resource based view on strategic alliances, where local alliances are 
formed by firms to obtain access to complementary knowledge. While clusters are 
small and contain relatively many start-ups firms, resource interdependence 
outweighs the danger of unintended knowledge flows. The danger of unintended 
knowledge flows, which might increase the transaction costs of collaborating, is 
further mitigated through the technological variety amongst the collaborating 
organizations. The positive effect of variety is however specific for local collaboration 
in relatively small clusters. As we have seen in figure 4.3, the pharmaceutical industry 
is a truly global industry in which explorative new knowledge is mainly sourced non-
locally. For policy makers, this implies that clusters can be growth engines through 
local collaborations, but need to be present as hubs in non-local networks as well. Our 
findings suggest that large established pharmaceutical firms are important for 
achieving this dual goal since they induce both local and non-local collaborations.  
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Chapter 5  Radical innovation and network 
evolution1: the effect of the genomic revolution on the 
evolution of the pharmaceutical R&D network2  
 
 
5.1 Introduction 
Networks of collaborative relationships among firms are an important form of 
organization of innovative activities (Powell et al., 1996; Kogut, 2000). Especially in 
innovative-, and technology intensive industries, firms increasingly realize that, in 
order to tap into new technologies and know- how, internal development needs to be 
complemented with strategic collaborations (Gulati, 1998; Verspagen & Duysters, 
2004). In the biopharmaceutical industry, the emergence of an expanding network of 
R&D collaborations has been studied intensively (Pisano, 1991; Arora and 
Gambardella, 1994; Powell et al., 1996; Stuart et al. 1999; Orsenigo et al., 2001; 
Pammolli et al. 2001; Riccaboni and Pammolli 2002).  
In this chapter we study the network of innovators in the biopharmaceutical industry 
to provide a deeper understanding of the underlying mechanisms that drive network 
structures. We argue that real world networks do not evolve in isolation, but co-evolve 
along technological paradigms. Our data cover a time frame of 20 years in the 
biopharmaceutical industry in which a new technological paradigm is established over 
an old one. The technological transition has been induced by a radical scientific 
innovation. This has given us the opportunity to explore the effect of radical 
technological change on structural network evolution.  
While radical technological change occurs regularly and has an important influence 
on the structure of high technology industries and networks (Anderson & Tushman, 
1986), we have found that most inter-firm network studies assume the underlying 
technology base to be stable. Through this assumption, the majority of these studies 
assume network evolution to be an endogenous process where network structures 
                                                 
1 This chapter is based on joint work with Massimo Riccaboni.  
2 Forthcoming in Annals of Economics and Statistics. 
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guide organizational action and vice versa. In this chapter we provide additional 
insights into network evolution, because exogenous influences can lead to relational 
behavior that cannot be explained from an endogenous perspective on network 
evolution. Another, more theoretical contribution of this chapter relates to the notion 
of small worlds in complex networks. While most recent studies on small-world 
networks reveal the existence and topology of such a network structure, this chapter 
is, as far as we know, the first study to look at influences that might induce the 
relational behavior that leads to a small-world structure.   
We find that the genomic revolution, representing an exogenous shock, leads to an 
expansion of the network through a wave of firm entry and a wave of alliance 
formation. When looking more specifically at the partners of new alliances, we find 
that it requires an exogenous shock like the genomic revolution, for firms to leave 
their embedded path of existing collaborations and ally with new partners. For 
managers of new firms or peripheral firms, knowledge about such network changes 
creates an opportunity to potentially improve one’s position in the network. Especially 
in industries characterized by hierarchical structures and low turnover, where large 
incumbent firms are dominant and newcomers are usually specialized niche players, 
knowledge about such structural breakthroughs can be crucial. While it is interesting 
for firms to be able to anticipate the effect of radical innovation on their and their 
competitors’ position in a network, policy makers can also benefit from this 
knowledge. Since radical scientific innovation is often induced by government-led 
R&D programs, policy makers should know about the potential effect of publicly 
financed R&D projects on firm behavior and network development. 
In what follows we first elaborate rather extensively on the existing literature, because 
our aim is to connect insights from organization-, and strategic management literature 
to issues in complex network theory. At the intersection of these two strands of 
literature we find relational behavior that can only be explained when taking 
exogenous influences into account. In section 2, we introduce our measurement 
techniques for measuring structural network change, such as the clustering coefficient 
and the average path-length. Section 3 focuses on exogenous influences on the 
network. In this section we introduce the reader to our empirical setting, the genomic 
revolution. We apply and extend a theoretical framework developed by Koka et al. 
(2006), which enables us to hypothesize on the effect that the genomic revolution has 
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had on the pharmaceutical R&D network in section 4. We divide this section into 
hypothesized structural change at the level of the network, and into structural change 
at the level of the firm, whereby this latter part touches upon specific relational 
behavior that is associated with small worlds.  After describing the data and 
methodology in section 5, we present the results in section 6 and a discussion and 
conclusion in section 7 and 8 respectively.  
 
5.2 Network evolution 
The understanding of how networks evolve has been a topic of interest to both social 
scientists and natural scientists. Both scholars realize that relational behavior and 
network structure are intertwined. An actors’ relational strategy depends for some part 
on the structure of relationships it had before. At the same time, the actors’ new 
relationships contribute to a changed network structure that again influences its 
actions (Gulati, 1998). Social scientists and natural scientists differ in regard to the 
way they study network evolution. Social scientists assume that actors conduct 
strategic relational behavior, while natural scientists, studying complex network 
theory, often assume actors to be non-human (e.g. proteins).  Amongst the latter, the 
process of link formation is based on certain ‘rules of attachment’. Recently, a number 
of authors such as Goyal et al. (2006), Uzi & Spiro (2005), Wilwhite (2001), 
Verspagen & Duysters (2004), and Jackson (2006) have combined insights from both 
strands of literature and increased our understanding of network evolution. This 
chapter aims to contribute to this understanding. 
 
Network change consists of changes in the number of actors (exit and entry), and 
changes in numbers-, and patterns of link formation (Koka, 2006). Structural network 
change is a form of network change whereby new linkages are formed with new 
partners. Studies on new partner search in networks have broadly focused on two 
issues. One issue is about distribution of linkages among actors in a network, which 
represents the inequality of access that firms have to various resources. In many real 
world networks the distribution of linkages among actors is highly unequal 
(Dorogovtsev and Mendez, 2003; Goyal, et al.2005; Barabasi et al., 2002). Barabasi 
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(1998) shows how actors accumulate new linkages in proportion to the number of 
linkages they have already (preferential attachment). Following from this ‘rich get 
richer’ principle of growth, the resulting network structure consists of a few highly 
connected actors called ‘stars’ in combination and many weakly connected 
‘peripheral’ players. The second issue in new partner search concerns the process of 
local link formation and the process of distant link formation, which will be the focus 
of this study.   
 
5.2.1 Local link formation 
Local link formation implies that new partners are found through an actors’ existing 
network (which is called an ego network), and that the new partner is already known 
to other partners ‘in the neighborhood’. The overall network structure resulting from 
local link formation is a network composed of dense ‘cliques’ of actors, which 
indicates that they are highly connected to each other. Local link formation of an actor 
and the degree of clique formation in a network can be measured by calculating the 
clustering coefficient, which will be explained in section 2.  
Within the organization-, and strategic management literature, network studies mainly 
focus on the effect that a given network structure has on the relational behavior and 
performance of firms (Burt, 1992; Granovetter, 1985; Gulati et al., 2000). Having a 
more central and autonomous structural position in a network provides firms with 
access to resources, learning opportunities, and reduces uncertainty (A notion first 
coined by sociologists like Bourdieu (1980) and Coleman (1990) as ‘social capital’). 
Regarding the formation of new linkages, Gulati (1995) finds that the process of new 
tie creation is heavily embedded in an actors existing network (consisting of previous 
alliances). This means that new ties are often formed with prior partners or with 
partners of prior partners (Gulati, 1995), indicating network growth to be a ‘local’ 
process, where strategic collaborations are path-dependant (Noria, 1992). Particularly 
when considering inter-firm alliances, new link formation is considered ‘risky 
business’ and actors prefer alliances that are embedded in a dense clique were norms 
are more likely to be enforceable and opportunistic behavior to be punished (Gulati 
1995; Powell et al., 1996; Koka et al., 2006; Granovetter, 1985). 
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5.2.2 Distant link formation 
Distant link formation implies that new linkages are created with partners whom are 
not known to the existing partners of an actor. In the social sciences, Granovetter 
(1985) was the first to differentiate between local ties in dense cliques (strong ties) 
and distant ties that bridge these cliques (weak ties). More precisely, the author argues 
that distant linkages “serve as crucial functions in linking otherwise unconnected 
segments of the network” (Granovetter, 1983: 217). At the level of the firm, Burt 
(1992) shows that distant linkages that serve as bridges between dense local cliques of 
firms, can provide access to new sources of information and favorable strategic 
negotiating positions (termed ‘structural holes’), which improves the firms’ position 
in the network and industry. 
 
5.2.3 Small worlds 
The first network studies that combine local- and distant link formation originate from 
complex network studies. Watts and Strogatz (1998) model the process of local link 
formation and find that, with the addition of just a handful of distant linkages, a 
specific network structure is generated, which they call a small world. This means that 
although large networks have relatively few linkages compared to the number of 
actors, the reach is higher than expected (Newman, 2001). While solely local link 
formation results in dense cliques of connected actors, the average distance to reach 
all actors in a network is very large. The distance between two actors is indicated by 
the number of other actors one has to surpass in order to reach the other. Watts & 
Strogatz (1998) found that the average distance between all actors in a network is 
sharply reduced when a relatively small number of distant linkages (referred to as 
random linkages) are added to the network that serve as shortcuts between these local 
cliques. Examples of small world networks are the electronic power grid network, 
high-school friendship networks, or the neural network of a worm (see for an 
overview Watts (1999) or Newman (2001)). Recently, insights from the social 
sciences regarding network evolution and new link formation have been combined 
with the more theoretical findings as described above (see Goyal, et al., 2006; Uzi & 
Spiro, 2005; Wilwhite, 2001; Verspagen & Duysters, 2004). Verspagen & Duysters 
(2004) explain how firms that try to build ‘social capital’ can be seen as drivers of 
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local link formation, and firms that strategically aim to bridge structural holes in a 
network can be seen as drivers of distant link formation. Together, these two drivers 
of new partner search add up to small world structures in networks of technology 
alliances. A recent study by Jackson & Rogers (2006) focuses on link formation with 
new partners in social networks. They find that large social networks evolve into 
small worlds, because people meet friends of friends and strangers. The process of 
link formation is generated by an algorithm that makes actors form both local linkages 
and random linkages (distant linkages), while implying that random link formation 
resembles the ‘meeting of strangers’. While the latter implication seems feasible in 
friendship networks, random partner search by firms seems rather unlikely. A 
plausible assumption made by Verspagen & Duysters (2004), is that firms are aware 
of the structural features of the network surrounding them and that this induces these 
firms to deliberately form distant linkages that bridge local cliques. However, a 
number of studies such as the work of Cowan et al. (2004) and Powell (1990) 
emphasize the risks involved in new partner formation, and the strong tendency of 
these firms to use their existing network as a source of information for new partner 
search, implying local link formation. 
In this chapter we aim to contribute to the understanding of local-, and distant link 
formation in inter-firm alliance networks. Moreover, we investigate the effect of a 
radical exogenous innovation on structural network change. This chapter differs from 
the studies mentioned above, in that these studies analyze the effect of link formation 
on the emergence of a small-world. Our study investigates whether radical exogenous 
change induces link formation, which potentially leads to a small world. We use the 
theoretical framework of Koka et al. (2006) to measure structural change, and we will 
expand their framework by introducing local-, and distant link formation.  
 
5.3 Structural change  
Koka et al. (2006) have combined multiple indicators of relational behavior into four 
different types of network change (see figure 5.1). The network can expand, churn, 
strengthen or shrink. Each network change is brought about by a specific combination 
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of changes in tie creation, tie deletion, and by changes in an actor’s portfolio size 
(number of links) and portfolio range (number of partners).  
 
Fig. 5.1 – Environmental effects on patterns of network exchange
Source: Koka et. al (2006)
Fig. 5.1 – Environmental effects on patterns of network exchange
 
 
While Koka et al. (2006) present four types of network change they find that only an 
expanding network and a churning network are a reflection of structural change, 
because new alliances are formed with new partners. An expanding network is 
brought about by an increase in new alliances without deletion of old alliances 
(meaning a larger average portfolio), together with an increasing portfolio range 
(more different partners). A churning network reflects the formation of new alliances 
and the deletion of existing alliances. While the average portfolio remains stable in 
terms of the number of partners, there is an increasing variety in identity of partners. 
We will use this framework to hypothesize on the ‘type’ of network change to expect 
after a given exogenous or environmental change. While changes in the number of 
linkages (tie creation/deletion) and changes in the number and identity of partners 
already provides important insights into structural changes in the network, we will 
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further distinguish between local link formation and distant link formation when 
studying new link formation with new partners. Local link formation and distant link 
formation are measured through the calculation of the clustering coefficient and the 
average distance between actors respectively.  
 
 5.3.1 Clustering coefficient 
The clustering coefficient of an actor is the density of its open neighborhood, that is to 
say how close each actor’s neighborhood is to a fully connected clique. Following 
Watts and Strogatz (1998), we define a clustering coefficient as follows: assume that 
the ith vertex iv has 1−ik  neighboring vertices. At most, 2/)1( −ii kk  edges can exist 
between them. Calculate ≡ic  (number of edges of iv  and its neighbors) 
/ 2/)1( −ii kk . Then, the overall clustering coefficient is defined as: 
 
∑
=
=
N
i
icN
CC
1
1
 
 
CC is the average of the individual clustering coefficients ic . The weighted overall 
clustering coefficient (WCC) is the weighted mean of the clustering coefficient of all 
the actors each one weighted by its degree. This last figure is exactly the same as the 
transitivity index of each transitive triple expressed as a percentage of the triples in 
which there is a path from i to j3. The cluster coefficient tends to 1 if most of the 
partners of each biopharmaceutical institution are directly related by formal R&D 
collaborations. On the contrary, the clustering coefficient tends to 0 if the network is 
hierarchical and the partners of each biopharmaceutical actor are not related.  
Clustering coefficients are often applied to detect small-world networks and the 
degree of hierarchy of local relational structures. At the level of the network, the 
degree of hierarchy of local relational structures is called transitivity. If an actor’s 
                                                 
3 To calculate C it is important to notice that there are no loops attached to a vertex (no self-
ties) and that multiple relationships between two vertices are identified as one edge. 
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ego-network is a clique, meaning the absence of hierarchy, the actor and its partners 
all have equal structural power and the network as a whole becomes more transitive.   
Because the clustering coefficient (CC) essentially measures the situation whether an 
actor’s partners are connected to each other, an increasing CC measures new alliances 
being created with partners that are already known to the partners in the clique. We 
can visualize this alliance behavior as follows: 
Vk
Vj
Vi Vk
Vj
Vi
t = 1 t = 2
Fig. 5.2 – Visualization of local link formation
 
 
In figure 5.2 we can easily see that whereas at t = 1 vertex i’s partners are 
unconnected, the alliance between vertex i and vertex k at time 2 indicates that i has a 
new partner who already was a partner of j. The clustering coefficient has risen from 0 
(0/3) to 0.167 (1/6). To account for the size of a firms’ ego network, we will use 
changes in the weighted clustering coefficient as an indicator of structural network 
change, because it reflects the formation of new alliances with new ‘local’ partners 
whom are already known to the actors in a clique.    
 
   
5.3.2 Average path-length 
To measure structural network change that is caused by new link generation between 
local clusters, we use the average path-length in the network. Following Goyal et al. 
(2006), we define the average path-length between reachable pairs in our network as 
d(N), being the average distance between any actor i and j that belong to the same 
component. Actors that are isolated from other actors are excluded. Thus, for a 
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connected graph N(E,V) consisting of edges and vertices, the average path-length is 
the sum of the distances between two actors (i and j) belonging to the network (N), 
divided by all possible edges excluding self-ties:  
 
( )
)1(
;,
)( −=
∑ ∑∈ ∈
vv
Njid
Nd Vj Vi  
The above definition of average path-length is only useful when most actors in a 
network under study do indeed belong to the same component. To verify this, we 
plotted the number of actors within the main component of our network in relation to 
the all actors in the network in figure 5.3. Clearly, this figure shows that at any 
moment in time, most actors belong to the main component in which every actor is 
connected. 
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Fig. 5.3 - Size of the main component (dotted line) in relation to the 
whole network (full line)
 
 
While average path-length is an indicator of the overall network structure, the change 
in average path-length over time provides information of structural network change at 
the intermediate level. Moreover, in social networks where the majority of link 
formation occurs within the neighborhood, only the occurrence of a relatively few 
number of distant linkages between neighborhoods can cause the average path-length 
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in a network to fall. This is because a connection (bridge) between to isolated clusters 
of actors suddenly increases the reach between those clusters and thus decreases the 
path-length. The above described argument originates from Watts and Strogatz (1998) 
in their seminal paper on small-worlds. In this chapter we turn this argument around 
by assuming that a decreasing average path-length is a structural indicator that some 
actors in our network have been able to form distant linkages with new partners who 
are not familiar to the actors existing partners. The average path-length is thus an 
indirect measure of distant linkages, and one could argue that it would be better to 
measure distant linkages directly. We argue however, that the usage of average path-
length has the great advantage of only measuring ‘distant linkages’ that are effective 
in providing positional benefits to the firms involved. In order to explain why, we 
have visualized the ego networks of two vertices (hypothetical firms) Vi and Vj as 
follows: 
 
Vi Vj
Fig. 5.4 – Visualization of (non effective) distant link 
formation 
 
 
If we were to measure distant link formation ‘directly’, we would say that a link 
between two firms is a distant link, if the ego networks of both partners are non-
overlapping. When using this definition the link between i and j in figure 5.4 can be 
defined as a distant link. However, we can also see that both firms are part of the same 
clique because their partners’ partners are highly connected. This would make the 
‘distant link’ between i and j much less valuable in terms of improvement of their 
structural network position or in terms of spreading information through the net. In 
figure 5.4, the dotted line between i and j represents such a ‘less informative’ distant 
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link. While i and j do not share partners, their link is not likely to bring new 
information to the group.   
 
At the level of the network, the average path-length only decreases when distant 
linkages are formed that provide real shortcuts in the network, meaning that they 
connect cliques that where unconnected before. Linkages (dotted) that connect parts 
of a network in a way which reduces the average distance have been visualized in 
figure 5.54. 
 
Fig. 5.5 – Visualization of effective distant link formation (dotted 
lines)
 
 
In order to understand why actors are sometimes able to create these distant linkages, 
and thus shorten the average distance in the network, we explore the influence of 
exogenous forces on the evolution of the network. 
                                                 
4 This visualization is merely intended to clarify the difference between two ways of 
measuring distant link formation. The Authors are aware that this visualization cannot occur 
empirically because only connected actors are included in graph N(E,V). 
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5.4 Exogenous influences on structural network change 
Various studies focusing on structural network change have argued that real structural 
change only occurs after an exogenous shock (Barley, 1986; Piore & Sabel, 1984; 
Glasmeier, 1991). There are few networks studies in the organization- and 
management literature which take exogenous influences on network evolution into 
account. One important contribution comes from Madhavan, Koka, and Prescott 
(1998) with their study on the effect of a technological and regulatory ‘event’ on 
structural network change. Madhaven et al. (1998) find that it requires a radical 
technological change to enable relatively peripheral players in the network to 
significantly improve their network position and consequently cause a ‘loosened’ 
network structure. Koka et al. (2006) have expanded and generalized their work by 
providing a framework to assess the effects of exogenous events on structural network 
change (figure 5.1). 
 
Exogenous or environmental changes are expressed in terms of changes in uncertainty 
and munificence instead of specific industry events, which makes the framework a 
useful meta-tool for broader applications. Following Dickson & Weaver (1997) the 
authors define uncertainty as “the inability of a firm’s managers to accurately assess 
the external environment of the organization or the future changes that might occur in 
that environment”. Uncertainty induces alliance activity (Nohria & Garcia-Pont, 1991; 
Powell, et al., 1996). But, whereas some authors argue that new alliances are used to 
reinforce a firm’s relationships with existing partners during uncertainty (see 
Granovetter (1982) and Krackhardt (1992)), others, such as Kogut (1991), find that 
firms might create new alliances with new partners in order to expand its number of 
strategic options as a means to cope with uncertainty. To resolve the issue of either 
reinforcement of existing relations or the formation of new relations with new 
partners, the authors introduce to concept of munificence. Munificence refers to the 
“extend to which resources available to a firm are plentiful or scarce, after taking into 
account the number of firms competing for those resources” (Koka et al.2006:725). 
While uncertainty increases the array of actions firms can potentially make in the 
changing environment, the opportunities to do so are limited by the resources 
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available to the firm. In short, we can say that while uncertainty represents the 
opportunity for alliance formation with new firms, munificence represents the ability 
for alliance formation with new firms, given the opportunity to do so.  
We use the concepts of uncertainty and munificence to hypothesize on how the 
genomic revolution in the beginning of the nineties has induced structural change in 
the pharmaceutical R&D network. In the next section, we will analyze the genomic 
revolution in terms of its influence on uncertainty and munificence. From there we 
derive our hypothesis on how we expect genomic revolution to induce relational 
behavior that causes structural network change.    
 
5.4.1 The genomic revolution 
The genomic revolution represents the radical scientific innovations related to the 
identification and understanding of the human genome and the technologies to store 
and analyze genetic information5.  
Our aim is to provide insight in how radical technological change such as the genomic 
revolution has caused structural network change. Before getting to the question of 
‘how’, we need to defend the causal order of the question. The relational behavior of 
network actors could after all have created the genomic revolution and not vice versa. 
In order to disentangle the genomic revolution from the changes in the pharmaceutical 
R&D network, we show that the genomic revolution was sparked by a government led 
R&D program that had started long before structural changes in the network became 
apparent. Second, in order to be sure that government-led or government-financed 
R&D is not driving the structural network change, we excluded government and 
academic actors from the R&D network we study, thereby focusing on the industrial 
R&D network.  
 
                                                 
5 See the website of the U.S. Department of Energy Office of Science for information on the 
genomic revolution and the Human Genome Project. 
(http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml) 
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Human Genome project  
The Human Genome Project is a government led research project to unravel the 
human genetic code. The very first initiatives for the project were undertaken in 1983 
by the US energy department laboratory, with the creation of DNA clone libraries 
representing single chromosomes. At least until 1988, the only active institutions that 
were involved in the setup of the human genome project were the US department of 
energy and the National Institute of Health. The main aims of the project were the 
identification of all genes and determination of sequences of chemical base pairs in 
human DNA, the development of storage capacity and analysis tools of genetic 
information, and the transference of related technologies to the private sector. The 
project has been completed in 20036.  
 
General purpose technologies 
While the Human Genome project had brought forward huge amounts of new 
information on genetic targets, new tools for drug discovery were needed to deal with 
the available genetic information. These new drug discovery tools such as 
combinatorial chemistry, high throughput screening and bioinformatics are not only 
different from conventional medicinal chemistry because they enable the testing of 
larger amounts of chemical entities against more drug targets, they are also much 
more broadly applicable in terms of disease areas and biological targets (Orsenigo, et 
al., 2001). Based on these new tools known as general purpose technologies (GPT), a 
wave of new firms specializing in GPT had been founded. In figure 5.6 we show how 
the proportion of alliances based on general purpose technologies has overtaken the 
proportion of alliances based on conventional medicinal chemistry (co-specialized 
technologies) in the beginning of the nineties. 
                                                 
6 See for the timeline of developments of the Human Genome project: 
www.http://doegenomes.org/ 
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Fig. 5.6 – Proportion of alliances based on General Purpose Technologies 
(genomics, proteomics, bioinformatics, combinatorial chemistry, high-throughput 
screening)
 
 
The activities of general purpose technology based firms (GPT based firms) differ 
from other firms’ activities in drug development because they provide tools for drug 
development instead of developing a specific drug (Kaplan et al., 2003). According to 
business analysts, such as Longman (2000) and Lytton (1999), the different relational 
behavior of GPT firms compared to ‘traditional’ (co-specialized) firms, can be partly 
attributed to the specific characteristics of general purpose based technologies.  
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5.5 Effects of the radical technological change 
In this section of the chapter we first investigate the effect that the genomic revolution 
has had on changes in munificence and uncertainty. Through these changes we 
hypothesize on the effects of the genomic revolution on structural network change. In 
the second part of the section we expand the concept of structural change by 
distinguishing new alliances with new ‘local’ partners from new alliances with new 
‘distant’ partners. Through this approach our findings contribute to the literature on 
small-world networks and to the notion of the factors driving a small-world.  
 
5.5.1 Structural change: uncertainty and munificence after the 
genomic revolution 
The genomic revolution encompasses a number of radical scientific and technological 
innovations that have and are altering existing practices of drug development 
(Uppenbrink & Mervis, 2000; Gassmann et al.2004). While traditional approaches of 
medicinal chemistry and sequential experimentation have by no means become 
redundant, they have been complemented and intensified by general purpose 
technologies of which high-throughput screening, combinatorial chemistry, bio-
informatics, proteomics, genomics, pharmacogenomics, and molecular design are the 
most important. Although these technologies are very heterogeneous in their function, 
together they are responsible for the alteration of drug development into a more 
automated, mass production process based on trial and error (Gassmann et al.2004; 
Nightingale, 2000; Drews, 2000). GPT are poised to improve the process of drug 
discovery in revolutionary ways, but there are also concerns about the increased 
complexity and diversity that these technologies bring to the drug development 
process (Longman, 2000; Orsenigo et al., 2001; Drews, 2000). Burckhardt & Brass 
(1990) and Hannan & Freeman (1989) find that technological change creates 
uncertainty, because of increased heterogeneity and complexity. Following this line of 
reasoning, we assume that the genomic revolution has increased environmental 
uncertainty.  
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Munificence has also increased after the genomics revolution7. Munificence reflects a 
firms’ capacity (Dess & Beard, 1984). By using various new tools, general purpose 
technologies have greatly increased the number of possible strategies for drug 
discovery. This can be considered as an increase in technological resources. Adding to 
the notion of increasing munificence is the favorable investment climate after the 
Human Genome Project proved successful. Mainly general purpose based firms 
benefited from the willingness of investors to put their money in start-up companies 
that take no risks in drug development itself, but only provide the tools (Longman, 
2001). The availability of technological resources together with the financial capacity 
to develop or invest in these resources, accounts for an increase in munificence. The 
increase in munificence is somewhat moderated by the wave of entrance of general 
purpose based firms which increases competition and lowers the average increase in 
munificence per firm. However, we consider firm entry to be a consequence of 
increasing munificence rather that a potential cause of reduced munificence. 
Concluding, we assume that both uncertainty and munificence have increased after 
the genomic revolution in the beginning of the nineties. Following the framework of 
Koka et al. (2006; see figure 5.1), we arrive at the following hypothesis on the effect 
that the genomic revolution has had on the structural changes in the pharmaceutical 
R&D network.  
  
Hypothesis 1 
Because the genomic revolution has increased both environmental uncertainty and 
munificence, we expect to see an expansion of the pharmaceutical R&D network, 
which we measure through a higher average portfolio size of alliances per firm in 
combination with an increased average range of partners per firm.   
 
                                                 
7 The authors realize that while munificence clearly increased in the beginning of the nineties 
with the general believe that genomic based technologies would revolutionize drug 
development, later there has been some doubt about the revolutionizing effect of genomics. 
So far, drug development has mainly become more complex through all these new 
alternatives for development (Drews, 2000). Some analysts even say that the genomics 
revolution has decreased efficiency of drug development because of the decreasing number of 
scientists working together on one disease target. The increase in genetic targets has caused 
spreading of researchers over the different targets which slows down the discovery process 
(Longman, 2000). 
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5.5.2 Structural change: local clustering and distant linkages 
In order to be able to hypothesize on which type of relational behavior (local link 
formation and/or distant link formation) to expect of firms after the genomic 
revolution, we first need to explain the relational behavior of firms before the 
genomics revolution.  
Before the genomic revolution, drug development has been based on molecular 
biology, biochemistry, pharmacology and other disciplines for many years. Orsenigo 
et al. (2001) have established a connection between the nature of knowledge 
advancement in these years and the inter-organizational network structure in the 
pharmaceutical industry. They found that parallel to research in drug discovery, which 
develops as a branching process of older more general research hypothesis toward 
more specialized sub-hypothesis, a similar hierarchal branching structure unfolded in 
the collaborative R&D network between organizations. More specifically, the authors 
find that large, incumbent pharmaceutical firms manage more general knowledge in 
the network while new entrants (mainly dedicated biotechnology firms) specialize in 
specific sub-hypothesis of drug research in specialized disease areas and collaborate 
with the incumbent players. Over time this network evolves into a hierarchal R&D 
network consisting of fairly ‘isolated’ branches which represent specialized fields or 
disease areas.  
After the genomic revolution, firms entered the network through unusual relational 
behavior. The GPT that these entering firms relied on, do not obey to the ‘traditional’ 
logic of knowledge advancement, because they contribute tools to the drug 
development process instead of developing drugs. With the purpose of being an aid to 
drug development, GPT are more broadly applied in terms of number of disease areas 
and biological targets. As a result, these firms mostly form non-exclusive alliances 
with a large variety of firms and are by definition not bound to any specific research 
field or disease area (Longman, 2000; Lytton, 1999). According to Orsenigo et al. 
(2001) GPT based firms “pertubate the structure of the network” (Orsenigo et al., 
2001:490). Given the relational behavior of existing firms in the pharmaceutical R&D 
network in combination with the relational behavior of general purpose based firms 
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entering the network after the genomic revolution, we expect the network structure to 
be affected in the following way: 
Fig. 5.7 – Simplified network topologies 
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The first picture in figure 5.7 represents a simplified topology of the pharmaceutical 
R&D network before the genomic revolution. Within each branch (disease area A and 
B), specialized biotech firms collaborate with large pharmaceutical firms. It is clear 
that the network is organized in a hierarchal manner within isolated branches of 
disease areas. While this is obviously an under-representation of the complexity of the 
real pharmaceutical network structure, it gives us the opportunity to envision what 
happens when general purpose based firms enter the network with different relational 
behavior. The second picture in figure 5.7 shows the entrance of general purpose 
based firms (red nodes). The linkages they form are based on the notion that they 
form non-exclusive alliances with a large variety of firms and that they are by 
definition not bound to any specific research field or disease area. Every linkage 
formed by newly entering general purpose based firms, is a new linkage with a new 
partner, and these linkages thus cause structural change according to our definition of 
structural network change. The results from the new link formation of general purpose 
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based firms become apparent when we look at the black triangles and red (dotted) 
lines. The black triangles indicate that new alliances are formed locally and result in 
dense cliques. The red lines indicate distant linkages because they connect to distant 
partners from different disease areas. We can now formulate our hypothesis as 
follows: 
 
Hypothesis 2 a 
The genomic revolution has induced new partner search through local link formation. 
This relational behavior results in an increased clustering coefficient in the 
pharmaceutical R&D network from the beginning of the nineties.  
 
Hypothesis 2 b 
The genomic revolution has led to firms forming distant linkages between disease 
areas which are otherwise relatively unconnected. This relational behavior results in a 
decreasing average path-length of the pharmaceutical R&D network from the 
beginning of the nineties.  
 
Summarizing our analytical approach in figure 5.8, we can say that exogenous change 
induces relational behavior that is reflected in a changed network structure. More 
specifically, we argue that the genomic revolution is a radical scientific innovation 
that is exogenous to our network. This innovation has increased environmental 
uncertainty and munificence for firms, who respond by increasing their portfolio size 
and range, leading to network expansion. In more detail, we expect that GPT based 
firms connect both local players within a disease area into more dense cliques 
(clustering coefficient), and that they connect these cliques through ‘distant linkages’ 
between disease areas (average path-length).  
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5.6 Data and methods 
For our empirical analysis we have used a comprehensive and original data set that 
encompasses information about collaborative agreements in the biopharmaceutical 
industry worldwide. As a whole, the Biotech Industry Database (referred as BID) 
covers 20,182 collaborations subscribed by 7,407 institutions including dedicated 
biotech companies, established companies, specialized biotech suppliers and non-
industrial research organizations since 1976. The BID has been created at the 
University of Siena, and was previously used by Orsenigo, Pammolli, and Riccaboni 
(2001) to analyze the biopharmaceutical network. As this chapter focuses on the 
pharmaceutical R&D network our sample consists of 10.580 collaborations among 
3800 agents. For each transaction, BID includes information about: 
− Date of signing (1976-2002); 
− Partners (classified according to their role in the collaboration); 
− Stage of development at signing (i.e. discovery, preclinical, clinical…); 
− Technological content (i.e. gene therapy, genomics, combinatorial chemistry…); 
− Therapeutic category (i.e. Oncology, Metabolic disorders, Central Nervous 
System…); 
− Typology (viz. license, joint venture, co-development…); 
− Deal value and terms of payment (equity, upfront, milestones, royalties…). 
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The structure of the network of R&D collaborations can be represented by a graph 
N(E,V), where V is the set of vertices (firms), and E are edges (R&D collaborations). 
Every edge e within the graph (industry network) is defined as a link between two 
partners. The graph N can also be represented by an adjacency matrix N ⇔ A(N) = 
[ae]. Matrix entry ae equals 1 if and only if an edge e does exist, and 0 otherwise. In 
order to analyze the evolution of our network over time, we took ‘snapshots’ of the 
network by labeling each connection with the date of signing. The overall graph 
N(E,V) is decomposed in time specific sub-graphs Nτ(E,V), which include all 
collaborations up to period t. 
 
The first part of the analysis is based on simple count statistics, which reveal the 
changes in firm entry and alliance formation over time, to see whether the R&D 
network has expanded as our first hypothesis predicts. To test hypotheses 2a and 2b 
we calculate the clustering coefficients and average path-length respectively over time 
using Ucinet (Borgatti et al., 1999). Based on the adjacency matrix for each time 
periodτ, we calculate the clustering coefficient and the average path-length. In order 
to facilitate interpretation of the results we calculate the clustering coefficients and 
average path-lengths of a random network with the same number of nodes (V) and the 
same number of linkages (E) at each time periodτ.  
 
 
5.7 Results  
5.7.1 Structural change 
Figure 5.9 shows the number of deal-active firms entering the network (V) and the 
number of new alliances (E) in the R&D network from 1967 until 2002. Deal-active 
firms are firms, which close at least one new alliance in periodτ. Until 1992, the 
number of new alliances formed has been twice as high as the amount of deal-active 
firms entering the network in each period. After 1992 the grey line in our plot 
indicates that the amount of new alliances has more or less tripled the number of new 
deal-active firms. In other words, the average number of new alliances per firm has 
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increased from two to three, which means that the average size of a firms’ portfolio of 
alliances has increased starting in the beginning of the nineties.   
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Fig. 5.9 – Number of new R&D collaborative agreements (E – Edges) and 
institutions (V – Vertices) in the network of R&D collaborations in 
biopharmaceuticals (1976-2002)
 
 
In figure 5.10 we have plotted the new alliances and new firms in the network in 
relation to the existing actors and their alliances. We can clearly see that there are 
various waves of firm entry and alliance growth over time, and the beginning of the 
nineties marks the start of a new wave of entry and collaboration activity.  
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institutions (V – Vertices) in the biopharmaceutical R&D network, (1976-2002)
 
 
Unless newly entering firms form alliances exclusively amongst each other, a 
situation which is highly unlikely considering the complementary nature of their 
technologies, we argue that with an increased average alliance portfolio (figure 5.10), 
in combination with a wave of firm entrance, the average number of different partners 
in a firms portfolio has grown. After all, these newly entering firms are deal-active 
and, given the complementarities of their new technologies, they have found new 
partners in the existing network. In sum, we can conclude that from the beginning of 
the nineties, firms have on average expanded their portfolio size and range. This leads 
us to confirm hypothesis 1, stating that the pharmaceutical R&D network has 
expanded from the beginning of the nineties. From figure 5.9 and 5.10 it becomes 
clear however, that the average portfolio size of firms does not increase further after 
the beginning of the nineties and that the entrance of new firms into the network is 
also temporary. We can therefore conclude that although the R&D network appears to 
keep growing over time, the overall structural network expansion is temporary. This 
finding is in line with similar findings from the steel industry where technological 
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change leads to a temporary ‘reshuffling’ of relational behavior, causing temporary 
structural change in the network (Madhaven et al.,  1998). 
 
Local link formation 
The second part of the analysis concerned a more detailed investigation of these new 
alliances that have been formed with new partners. We have argued that, depending 
on the new partner being active in ‘the neighborhood’ or being a ‘distant’ partner (or 
both) we expect to see different structures emerge. We start with the hypothesis of 
local link formation. If firms are oriented toward local link formation, we should 
witness an increasing clustering coefficient from the beginning of the nineties. 
 
Fig. 5.11 – Weighted  overall clustering coefficient in the pharmaceutical 
R&D network (full line) and of a random network (dashed line)
 
 
Figure 5.11 shows the weighted clustering coefficient from 1982 till 2002. Between 
1991 till 1995 there is a sharp increase in the weighted clustering coefficient, while it 
starts to decrease slightly afterwards. This feature supports our hypothesis of an 
increased clustering from the beginning of the nineties, but in order to value the 
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increase we have added the clustering coefficient of a simulated random network 
(Erdös-Renyi random network). A simulated random network is a much used tool in 
network analysis to indicate the meaning of a certain network value. The clustering 
coefficient of a random network with the same amount of actors and the same average 
degree (portfolio size) serves as a bench-mark to compare observed relational 
behavior with random relational behavior. When comparing the clustering coefficient 
of a random network in figure 5.11 with the observed clustering coefficient in our 
network, the impact of the genomics revolution on local clique formation becomes 
even more apparent. Before the beginning of the nineties, relational behavior of firms 
led to less clustering compared to random relational behavior, while after the 
beginning of the nineties there was more clique formation then was to be expected 
from random relational behavior. When considering the fact that a clustering 
coefficient is also used in the literature as a measure of local hierarchy, our relatively 
low clustering coefficient before the beginning of the nineties seems to support the 
results of Orsenigo et al. (2001). They argue that the pharmaceutical R&D network 
developed as a hierarchal branching process before the nineties. Finally we can 
confirm hypothesis 2a through an increasing clustering coefficient after the genomics 
revolution, which indicates that firms have found new partners through local link 
formation. 
 
Distant link formation 
Did the genomic revolution bring forth (new) firms that were able to bridge some of 
the ‘hierarchal branches’ of the pharmaceutical R&D network? Given the hierarchal 
branching structure of the R&D network together with the inherent characteristics of 
GPT we expect general purpose technology based firms, who have entered the 
network in the beginning of the nineties, to be able to bridge these hierarchies. If so, 
these bridges or distant linkages would function as shortcuts in the network and 
shorten the average path-length. Figure 5.12 reports the average path-length of our 
network and the average path-length of a simulated random network over time. 
  The average path-length declines from 1986, reaching its lowest point in 1995. This 
indicates that the reach between actors in the network has improved. After 1998 the 
average path-length slightly starts to increase again. At first, it seems counterintuitive 
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that the path-length shortens while the network grows. In our hypothesis we have 
argued that this shortening of the path-length has been triggered by the genomic 
revolution at the beginning of the nineties. Although the path-length indeed decreases, 
there is no indication that this decreasing trend was triggered by the genomic 
revolution, since the declining path-length clearly starts much earlier (from 1986). In 
order to value the decrease in path-length we have simulated a random network based 
on the exact same network size and connectivity at each time period τ. The dashed 
line in figure 5.12 reports the average path-length of our simulated random network. 
In our random network an actor has to surpass 3.5 other actors on average to reach 
every other reachable actor in the network. As the network grows and becomes more 
connected this path-length remains stable but eventually will grow according to 
ln(n)/ln(k) (k = average degree) for very large networks (see Watts, 1999). Starting 
from 1986, our empirical network and the random network slowly converge, which 
means that the reach between actors in the network improves despite a growing 
number of actors. 
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Fig. 5.12 – Average path-length of the pharmaceutical R&D network (full line) 
and of a random network (dashed line)
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In sum, we can conclude that hypothesis 2b predicting a falling average path-length 
from the beginning of the nineties cannot be confirmed. However, the fact that the 
path-length of our random network remains relatively stable indicates that there is 
non-random relational behavior causing an improvement in the reach between actors.  
 
5.8 Discussion & Interpretation 
How can we interpret these results and what are its implications? To begin with we 
have clearly seen that the genomic revolution in the beginning of the nineties has 
caused structural network change. More specifically the network has expanded 
through an increasing average portfolio size and portfolio range, there has been a 
wave of firms entering and the technological focus of alliances has shifted from 
conventional medicinal chemistry to GPT. A second question was about the relational 
behavior that has caused this structural change, more specifically we studied whether 
firms find new partners through local linkages or whether these new partners are 
‘distant’ partners. With this question we have extended the framework of Koka et al. 
(2006) on structural network change into more detail, but also we have combined the 
issue of partner choice in alliance networks with the study of small-world network 
structures. Our argument was that the relational behavior that causes a small-world 
structure in social networks is a combination of local link formation with relatively 
few distant linkages between different cliques. Together these two types of relational 
behavior image the combination of a regular network with a handful of random 
linkages, which defines a small-world according to Watts & Strogatz (1998). Thirdly, 
we tried to find answers to what causes this specific relational behavior which in turn 
causes this specific structural change. There is basic agreement among network 
researchers that exogenous events, which increase uncertainty, cause an increase in 
alliance formation, but theories differ about the partner choice following from the 
decision to enter an alliance. Some network researchers (e.g. Powell, 1996; Burt 
1991) argue that if firms enter into new alliances with new partners, they will use their 
network to find these new partners, which implies structural network change to be a 
local growth process. This argument leaves the empirical finding of small-world 
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network structures unanswered however, because it fails to provide an explanation for 
the formation of distant linkages. We have argued that only a radical exogenous shock 
such as the genomic revolution can convince firms to leave their embedded path and 
form distant linkages with unknown partners. Following from this we hypothesized 
that after the genomic revolution, we would witness both local link formation and 
distant link formation, resembling a small-world. Although the evolution of the 
pharmaceutical R&D network does show a decreasing average distance and increased 
clustering, which are indicators of a small-world, we find no evidence for our 
hypothesis that the genomic revolution has induced this structural change. One 
explanation for this result could be that general purpose based firms, whom we 
expected to form distant linkages between disease branches, do not perform these 
alliances. The fact that we witness the increase in clustering after the genomic 
revolution indicates that general purpose based firms find new partners through local 
linkages. This latter finding confirms the structure action dynamics in network 
evolution, where firms choose their alliance partner using their existing network. This 
chapter contributes an important detail to the structure action dynamics, namely that 
while the underlying technological base is stable (before the genomic revolution) new 
alliances are formed mainly with existing partners (given the low clustering 
coefficient) and that it requires an exogenous radical change for firms to engage into 
new alliances with new partners. But even when they do, they use their network to 
find these partners.  
Although we find no evidence for our hypothesis that the genomic revolution has 
caused a decreasing average distance in the network, we do witness a temporary 
decreasing distance between 1986 and 1998, indicating that there are firms in the 
network who form distant linkages that shorten the distance between other 
organizations. The fact that these firms already performed this relational behavior 
before the genomic revolution might indicate that the network structure was not 
composed of relatively isolated branches as we assumed, but already consisted of 
some organizations that improved the overall reach in the network. Jackson (2006) 
proposes that not only distant linkages, but also highly connected actors called ‘stars’ 
or ‘hubs’ can cause a path-length to decrease. While it is beyond the scope of this 
chapter to re-investigate the structure of the R&D network before the beginning of the 
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nineties, we did look for a simple indication to check Jackson’s (2006) idea. Figure 
5.13 plots the number of alliances for each ‘type’ of firm. 
Fig. 5.13 – Number of alliances per firm type.
(Genomics based firms (T-DBF), established firms (EC), 
and co-specialized biotech (DBF))
 
 
What becomes clear in this plot is that while there are quite some highly connected 
‘stars’ amongst general purpose based firms (referred to as T-DBF), there are some 
pharmaceutical firms (EC) who are even more connected than general purpose based 
firms are. If these pharmaceutical ‘stars’ already connected different disease areas 
before the genomic revolution, then the addition of a few distant linkages by general 
purpose based firms would not cause a significant decrease in the average distance of 
the network. While being highly speculative, we feel these indications could provide 
an interesting start for further research.  
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5.9 Conclusion 
The genomic revolution in the beginning of the nineties has increased environmental 
uncertainty and munificence, and this has led to structural changes in the 
pharmaceutical R&D network. The network has expanded in terms of both number of 
firms and number of alliances. Since alliance activity outperformed the growth in the 
number of firms entering the network, we can conclude that the average number of 
deals and the average number of different partners has increased. On a firm level this 
means that new alliances have been formed with new partners, causing structural 
network change. The formation of new alliances with new partners can take to forms, 
implying different structural outcomes at the level of the network. First, firms can 
choose their new alliance partner through their existing network, which leads to local 
link formation and network clustering. Second, firms can form distant linkages with 
unknown partners. These linkages can potentially improve a firms’ position in a 
network if it manages to connect previously unconnected parts of the network. Taken 
together, local linkages and distant linkages form a small-world network which has 
been a popular subject of recent network studies. While we argued that a radical 
exogenous shock would be required for firms to be forming distant linkages, we found 
no evidence of this alliance behavior. We found that firms, when confronted with 
radical technological change keep their existing alliances and form new alliances with 
partners of their partners. This result is consistent with previous studies on alliance 
strategies and network formation. The question of what relational behavior causes a 
small-world in social networks remains unanswered, but some suggestions for further 
research are given in the discussion.  
 
Chapter 6  Conclusion 
 
The aim of this thesis has been to understand the strategies of firms to obtain access to 
relevant external knowledge that is required for innovation. Access to external 
knowledge has become an increasingly important part of a firm’s innovation strategy. 
Firms are operating in markets that are more and more volatile, meaning that the 
underlying technologies and organizational processes are continuously changing. As a 
result existing products and technologies are threatened to be rendered obsolete more 
rapidly. Volatility induces environmental uncertainty. Firms respond to this 
uncertainty by building portfolios in which internal R&D and boundary spanning 
R&D activities are combined. By doing so, firms can exploit there existing 
competencies within the firm and transact with external partners to explore novel 
technologies without necessarily binding to them. Together, the combination of make- 
and-buy strategies enables a firm to flexibly adapt to a continuously changing 
environment1. However, the downside of this strategy, which is referred to as dynamic 
capabilities, is that external transactions are costly and risky (with respect to 
knowledge leakage or opportunistic behavior). But, most importantly, the knowledge 
that is accessed externally is not automatically usable because it can be hard to 
integrate with existing capabilities and to turn into new products or processes.  
The decision of a firm regarding how to access external knowledge involves a trade-
off between the ability to understand and integrate external knowledge on the one 
hand and the newness of knowledge, which is necessary to be innovative on the other 
hand. The newest knowledge has the highest potential for innovation, but it also 
entails the greatest difficulties of understanding and integrating it within the firm. By 
choosing a level of proximity between themselves and their external sources, firms try 
                                                     
1 Another reason for external sourcing that has not been highlighted in the economic literature 
is that new entrants (in our case small biotech firms) might possess more innovative and 
immobile resources than established firms do. The reason for this is that in established firms, 
researchers are limitedly liable for their actions while researchers in start-up firms or those 
who found their own firms are more liable or even fully liable. As a result of this liability 
difference, employees with more innovative knowledge will choose full liability (including 
full rewards), while less competent researchers will choose to be employed by established 
firms where they are limitedly liable for their actions. Start-up firms thus might possess more 
innovative and immobile resources, which forces established firms to form strategic alliances 
with start-ups in order to access more innovative resources. Future co-authored work will 
shed more light on this issue.  
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to optimize the trade-off between newness and usability. This thesis is about the three 
dimensions of proximity which firms use to enhance their innovation capabilities: 
geographical proximity, cognitive proximity and relational proximity. As firms 
choose a level of proximity between themselves and external partners for every 
dimension of proximity, each firm can be positioned in a 3-dimensional action-space 
of geographical, relational and cognitive proximity. Moreover, this thesis addresses 
two main research questions: 
What is the effect of different forms of proximity on a firm’s ability to access relevant 
external knowledge? 
How do these proximities affect each other in relation to a firm’s ability to access relevant 
external knowledge? 
 
6.1 Geographical proximity 
Existing studies that address the relation between geographical proximity and 
innovation find that geographical proximity between organizations is mainly required 
to access and transfer tacit knowledge. (Zucker, 1996; Audretch & Feldman, 1996; 
Jaffe & Trajtenberg, 1993). Furthermore, tacit knowledge is found to play a more 
important role in exploring new knowledge that in exploiting existing capabilities. In 
the pharmaceutical industry the exploration of new drugs in basic research, discovery 
and lead optimization can indeed be said to involve much intangible tacit knowledge. 
Once a drug is ‘discovered’, testing procedures and marketing and distribution rather 
involve more explicit knowledge such as procedural knowledge, paper work 
experience and knowledge of legal issues. In Europe, almost all of the drug 
development activities (both explorative and exploitative) take place in a few regional 
clusters, while it is mainly explorative (discovery) activities that occur in the most 
densely clustered region surrounding London. The regional clusters surrounding 
London such as Cambridge, Oxford, Hertfordshire and others have emerged in the last 
decade as the dominant regions regarding biopharmaceutical activities (with 20 
percent of all European organizations located in the area). Moreover, this region is 
characterized by a high proportion of start-up firms and a relatively strong focus on 
basic research in anti-cancer therapies. 
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While formal strategic alliances are recognized as crucial vehicles for knowledge transfer 
between pharmaceutical organizations, they are not being used by organizations to source 
knowledge locally. Moreover, alliances aimed at exploring new drugs such as R&D 
collaborations between universities and biotech firms are highly unlikely to occur locally. In 
fact, these explorative alliances are more likely to span larger geographical distances.  
In sum, European biopharmaceutical organizations, especially those that are involved in 
exploration of new drugs, have a strong tendency to co-locate. Being co-located does however 
not induce knowledge transfer through formal collaboration activities among these 
organizations. One possible explanation is that these firms co-locate because of location-
specific features such as agglomeration externalities. The emergence of the London region as 
the dominant region for pharmaceutical innovation activity in the last decade hints at 
agglomeration effects indeed. Another possible explanation could be that geographical 
proximity plays a more important role in informal alliances. In line with the findings of 
Batheld et al. (2002) our data might show only alliances that represent ‘global pipelines’ and 
not ‘local buzz’, as the latter consist of more informal alliances. Finally, while our findings 
suggest that explorative formal alliances do not require geographical proximity, it might be 
the case that science-based knowledge, which is known to involve relatively large amounts of 
tacit information, is rather accessed through other forms of proximity such as cognitive 
proximity or relational proximity. Geographical proximity might be relevant temporarily and 
thus does not necessitate co-location. Research visits or conference meetings could suffice. 
 
6.2 Relational proximity 
Relational proximity refers to how ‘close’ an alliance partner is within the network of inter-
firm collaborations. At a distance of 1, two firms are partners, and a distance of 2 implies that 
two firms share a common third partner. 
Relational proximity can be expressed in terms of local-, and non-local search (linkages). 
Local search in a network implies that alliances are formed with previous partners or with 
partners of previous partners. Non-local-, or distant search implies that the path of previous 
relations connecting two alliance partners in a network is relatively long. In this thesis we 
examined the long-term evolution of local and non-local alliance formation in the European 
and in the global network. 
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From 1996 until 2002, the European network of R&D collaborations is highly 
fragmented into small subgroups2 where firms form only local linkages. Between 
2002 and 2005 a wave of new alliances causes the clustering of these subgroups into a 
giant network component in which about 50 percent of all active European 
organizations are connected. The emergence of a giant component reveals that non-
local linkages have been formed that connect previously unconnected subgroups in 
the network. This finding raises questions about the causes of this giant component 
emergence in Europe. In other words, what induces firms to leave their embedded 
path of existing-, and previous collaboration partners to form new alliances with 
unknown partners? One possible explanation has been examined in chapter 5: the 
effect of radical technological change. Other possible explanations are new- or 
abolished legislation, or a change in investment climate. 
 
When we consider the global network of R&D collaborations from 1975 until 2002, 
similar structural network features become visible (as in the European network). 
During this period a number of radical technological changes occur, which induce 
changes in the alliance behavior of firms and subsequent network structures. Previous 
studies on alliance behavior of firms suggest that firms form mainly local alliances 
with partners that are already ‘close’ in the network of collaborations. By forming 
local alliances firms can benefit from being embedded in a dense local network. This 
embeddedness creates several advantages such as reputational effects, shared social 
norms, and similarity of knowledge (cognitive proximity). However, at times of 
radical technological change, access to radically new knowledge through distant link 
formation is claimed to outweigh the benefits of being locally embedded.  
The genomic revolution in the beginning of the nineties can be characterized as such a 
radical technological change. However, even when radically new technologies that are 
potentially competence destroying are introduced into a market of R&D collaborators, 
firms are inclined to mainly collaborate within the local neighborhood of their 
network. At the same time, a relatively small number of firms (both large incumbents 
and new entrants) become highly central actors in the network by forming large 
                                                     
2 One subgroup is the ‘Peptido’ project, which is comprised of universities and private firms 
that jointly work on peptides and have received considerable long-term subsidy from the 
European Union. An interesting future research question would be to understand what the 
effect of subsidies or other institutional incentives is on the emergence of a more coherent 
R&D network in Europe. 
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amounts of linkages (both local and non-local). These central firms (referred to as 
‘stars’) connect previously unconnected parts of the network. As a result of the non-
local linkages, the average distance between firms in the global R&D network is 
decreasing. A network structure that combines dense local ‘neighborhoods’ with 
distant (non-local) linkages is referred to as a ‘small world’. A ‘small world’ network 
structure facilitates the diffusion of innovation in a network and prevents redundancy.  
 
6.3 Cognitive proximity 
Cognitive proximity refers to the degree of commonality in knowledge domain between two 
actors. The main question that we aim to answer is: to what extend is the transfer of relevant 
knowledge between two firms dependent on cognitive proximity between them?  
While cognitive proximity has mainly been measured as a firm-level construct, more recent 
work has shown that it is a relational attribute, meaning that it varies with each transaction 
partner (Lane & Lubatkin, 1998). Cognitive proximity has therefore been analyzed at project 
level. In theory, a firm is better able to extract the rents from external transactions if it has 
built a sufficient stock of similar knowledge internally (Cohen & Levinthal, 1989). Through 
this stock of similar internal knowledge, a firm can better understand and integrate external 
knowledge and turn it into new products. Building on these insights, we further examined the 
following issues in this thesis: For which type of knowledge does cognitive proximity 
between projects generate innovation? How much of this ‘similar’ knowledge is required to 
generate these effects? And how does knowledge flow between internal projects and external 
projects in similar knowledge domains?  
First of all, none of the 20 largest R&D spending global pharmaceutical firms that we 
investigated is performing better in research that the other firms. At the level of individual 
research projects, it turns out that projects are more successful if they are active in a disease 
area in which the firm has a critical mass of similar projects (representing high cognitive 
proximity). We interpret this finding as learning effects arising from cognitive proximity, 
although other factors could reinforce these learning effects, such as the ability of a firm to 
attract the best talent, and be a preferred partner for deal-opportunities outside the firm. 
Additionally, in-house research projects are more likely to be successful if they are active in a 
disease area where just a few external research projects are going on (no more than 20 
percent). This finding can be interpreted as knowledge flow from external projects to internal 
projects. Knowledge flow occurs only when relatively few external projects are ongoing. The 
reason for this might be that knowledge can only be transferred from external projects to 
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internal projects if the same expert scientists are involved in both internal- and external 
projects. This would naturally limit the number of externally sourced projects. This 
interpretation is in line with the notion that knowledge required for pharmaceutical drug 
discovery is highly tacit and embedded in the scientists involved, which makes transfer of this 
knowledge between people leave alone projects difficult. 
 
6.4 Interaction effects 
Firms are positioned in a three dimensional action-space, which consists of 
geographical proximity, relational proximity and cognitive proximity. Any position of 
a firm in this action-space implies a level of proximity in all proximity dimensions. At 
the level of a regional cluster for example, firms that are geographically co-located 
(geographical proximity) are also more- or less connected through strategic alliances 
(relational proximities) and they are active in more- or less similar knowledge 
domains (cognitive proximity). In Europe, most biopharmaceutical organizations are 
geographically clustered but do not form linkages within these clusters. However, 
when clusters are relatively small (containing few organizations) co-located 
organizations are more likely to collaborate with each other, but only when they are 
active in a diverse set of technologies (preventing knowledge leakage). This finding is 
in line with the notion that geographical clusters evolve over a life cycle in which they 
grow to maturity. While local ‘support’ collaborations among interdependent 
organizations are valuable in the earlier stages, toward maturity non-local linkages 
become more valuable as organizations evolve into international players in a global 
network. At the level of the firm we can further conclude that firms are more likely to 
collaborate with partners from (or close to) their existing network, while location does 
not play an important role. Finally cognitive proximity appears to be an important 
criterion for pharmaceutical firms when choosing which research projects to invest in, 
both within the firm and with external partners.  
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Policy implications 
Prevent a one-dimensional focus on geographical proximity 
Policy makers often emphasize the synergy effects that arise in certain locations from the 
coming together of people, firms, or ideas. Policy makers should realize that while 
emphasizing location as the crucial element that generates synergy and innovation, implicitly 
they make assumptions about other forms of proximity as well. For example, our Dutch 
minister of education Ronald Plasterk recently argued3 that radical innovations require the co-
location of people with innovative ideas. When elaborating on this statement, he explained 
that these people should be specialized in different but related areas of expertise, so as to 
bring together complementary knowledge. In this example, the minister combines 
geographical proximity with cognitive proximity and assumes interaction between these 
people. In other words, only when the various forms of proximity between people (or firms) 
interact, radical innovation is claimed to occur. Numerous initiatives in the formation of 
science parks, creative clusters and the like are unjustly based on merely geographical 
proximity while the innovativeness of these regions depend for a large part on the interaction 
effects of multiple forms of proximity.   
 
Creating a European small-world 
An explicit aim of the European Union is to promote innovation through knowledge exchange 
between innovative European organizations. Our findings regarding the emergence of a small-
world structure in the global network entail some insights that are useful for European policy 
makers that aim to stimulate diffusion of innovation through inter-organizational collaborative 
agreements. Our findings suggest that large pharmaceutical firms and platform technology 
based firms are crucial actors for European knowledge diffusion. These firms act as highly 
connected ‘stars’ that can combine local relationships with relations that connect local 
networks throughout the whole European network. For policy makers, the role of platform 
technology firms might be particularly interesting. Platform technology firms are also referred 
to as general purpose technology firms, which indicate that their technologies can be applied 
to multiple therapeutical areas. As the high degree of specialization in biopharmaceutical 
organizations (e.g. research labs) often forms a barrier for inter-organizational collaboration, 
platform technology firms can potentially break these barriers by functioning as an 
intermediary between otherwise unconnected organizations. Ideally, platform technology 
                                                     
3 Ronald Plasterk in ‘Zomergasten’ television program. Sunday July 27.  
http://www.vpro.nl/programma/zomergasten/ 
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firms can act as brokers and stimulate cross-fertilization of knowledge between different 
therapeutical areas.  
 Thus far, we know from this thesis that the European network until 2005 is highly 
fragmented into local networks. Firms within these local networks are usually not co-located 
in a geographical sense. In order for platform technology firms to function as bridges between 
fragments in the network, further research is required to see whether these fragments (or local 
networks) are based on cognitive proximity. Only when fragments in the European network 
represent islands of therapeutical specialization (cognitive proximity), platform technologies 
can be useful to bridge these islands.  
 
To summarize, this thesis has focused on how different forms of proximity affect a firm’s 
ability to access relevant knowledge for innovation. We have considered the influence of 
being co-located in space, of being embedded in a network, and of being active in similar 
knowledge domains. By integrating these three proximity perspectives we contribute to 
various disciplines such as economic geography, organizational sociology and innovation 
studies. Further, this thesis investigates the make, buy or ally strategies that pharmaceutical 
firms employ to maximize the probability of innovation (finding new drugs). Our findings 
suggest that firms employ multiple governance structures simultaneously, even when 
targeting similar innovations. These insights contribute to our understanding of the boundaries 
of the firm.  
While the findings in this thesis are generalizable over time and in geographical space, they 
are specific to the pharmaceutical industry. Nevertheless we argue that the growing 
importance of this industry in the future deserves a great deal of attention.  
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Nederlandse samenvatting (Dutch summary) 
 
In dit proefschrift worden de strategieën geanalyseerd die bedrijven hanteren om 
toegang te krijgen tot relevante externe kennis die benodigd is voor innovatie. 
Toegang tot externe kennis speelt een steeds belangrijkere rol in de 
innovatiestrategieën van het bedrijfsleven. Bedrijven opereren in markten die steeds 
veranderlijker worden, waarbij de onderliggende technologieën en 
organisatieprocessen aan voortdurende verandering onderhevig zijn. Het gevolg 
hiervan is dat bestaande producten en technologieën het risico lopen sneller te 
verouderen. Veranderlijkheid leidt tot onzekerheid over de omgeving. Bedrijven 
reageren op deze onzekerheid door portefeuilles samen te stellen waarin interne en 
externe onderzoek- en ontwikkelings activiteiten (O&O-activiteiten) worden 
gecombineerd. Hierdoor kunnen bedrijven gebruikmaken van de bestaande 
competenties die ze in huis hebben, en tegelijkertijd in samenwerking met externe 
partners nieuwe technologieën verkennen zonder dat ze zich hier meteen aan hoeven 
te binden. Deze combinatie van maak- en koopstrategieën stelt bedrijven in staat om 
flexibel in te spelen op een voortdurend veranderende omgeving1. Een nadeel van 
deze strategie, de zogeheten dynamic capabilities approach, is dat de externe 
samenwerking kostbaar en riskant is vanwege mogelijke kennislekkage of 
opportunistisch gedrag. Het belangrijkste nadeel is echter dat de door externe 
samenwerking gegenereerde kennis niet automatisch inzetbaar is, omdat het vaak 
                                                 
1 Een andere reden voor externe kennisverwerving, die in de economische literatuur weinig 
aandacht krijgt, is het feit dat nieuwkomers (in ons geval kleine biotechnologiebedrijven) 
vaak over méér innovatieve en niet-mobiele medewerkers beschikken dan gevestigde 
bedrijven. Dit komt doordat onderzoekers in gevestigde bedrijven slechts in beperkte mate 
aansprakelijk zijn voor hun handelen, terwijl onderzoekers in nieuwe bedrijven en oprichters 
van startende bedrijven een grotere aansprakelijkheid hebben of zelfs volledig aansprakelijk 
zijn. Het gevolg van dit verschil in verantwoordelijkheid is dat personen met een grotere 
innovatieve kennis de voorkeur geven aan volledige verantwoordelijkheid (met de daarbij 
behorende beloning), terwijl minder competente onderzoekers eerder geneigd zijn te kiezen 
voor een dienstverband bij gevestigde bedrijven, waar ze slechts gedeeltelijk aansprakelijk 
zijn voor hun handelen. Hierdoor hebben startende bedrijven vaak méér innovatieve en niet-
mobiele medewerkers in huis, zodat gevestigde bedrijven gedwongen worden strategische 
allianties met startende bedrijven aan te gaan om toegang te krijgen tot wetenschappers met 
grotere innovatieve competenties. In latere publicaties zullen we, in samenwerking met 
andere auteurs, meer aandacht aan dit aspect besteden.  
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moeilijk is deze met bestaande kennis en vaardigheden te integreren en naar nieuwe 
producten of processen te converteren. 
Bij de beslissing van een bedrijf over de strategie om toegang tot externe kennis te 
krijgen, wordt een afweging gemaakt tussen enerzijds het vermogen om de externe 
kennis te begrijpen en te integreren, en anderzijds de nieuwheid van de kennis, die 
immers een voorwaarde is om innovatie te realiseren. De nieuwste kennis biedt de 
meeste mogelijkheden voor innovatie, maar ook de grootste problemen met begrip en 
integratie. Bedrijven proberen de optimale afweging tussen nieuwheid en 
bruikbaarheid te vertalen in een geschikte mate van nabijheid tussen het eigen bedrijf 
en de externe kennisbronnen. Dit proefschrift behandelt de drie dimensies van 
nabijheid die bedrijven hanteren om hun innovatieve vermogen te optimaliseren: 
geografische nabijheid, cognitieve nabijheid en relationele nabijheid. Aangezien 
bedrijven voor elk van deze dimensies een mate van nabijheid tussen zichzelf en hun 
externe partners kiezen, kan elk bedrijf worden geplaatst in een driedimensionale 
actieruimte van geografische, cognitieve en relationele nabijheid. Hierbij staan twee 
onderzoeksvragen centraal: 
 
1 Wat is het effect van de verschillende soorten nabijheid op het vermogen van 
een bedrijf om toegang tot relevante externe kennis te verkrijgen? 
2 Welke interacties spelen zich af tussen deze vormen van nabijheid? 
 
6.1 Geografische nabijheid 
Eerder onderzoek naar de relatie tussen geografische nabijheid en innovatie laat zien 
dat deze vorm van nabijheid tussen organisaties vooral van belang is voor de 
toegankelijkheid en overdracht van impliciete kennis (tacit knowledge), de kennis die 
is ingebed in personen, machines of organisaties (Zucker, 1996; Audretch & Feldman, 
1996; Jaffe & Trajtenberg, 1993). Bovendien blijkt impliciete kennis belangrijker te 
zijn bij het verwerven van nieuwe kennis dan bij het gebruikmaken van bestaande 
competenties. In de farmaceutische industrie speelt ontastbare, impliciete kennis 
inderdaad een belangrijke rol in de eerste ontwikkelingsfasen van nieuwe 
geneesmiddelen (fundamenteel onderzoek, 'ontdekking' en lead-optimalisatie). Nadat 
een geneesmiddel eenmaal is 'ontdekt', berusten de testprocedures en de processen 
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voor marketing en distributie echter vooral op explicietere kennis, zoals kennis van 
procedures en wettelijke aspecten en ervaring met administratieve processen. In 
Europa vinden vrijwel alle activiteiten voor de ontwikkeling van geneesmiddelen 
(zowel de onderzoeksfase als de latere exploitatiefasen) plaats in een beperkt aantal 
regionale clusters, terwijl met name de onderzoeksactiviteiten (de 'ontdekking' van 
geneesmiddelen) zich afspelen in de regio met de sterkste concentratie: de regio rond 
Londen. Het afgelopen decennium hebben regionale clusters in de omgeving van 
Londen, zoals Cambridge, Oxford en Hertfordshire, zich ontwikkeld tot de dominante 
regio bij uitstek voor activiteiten op het gebied van biofarmaceutica (circa 20 procent 
van alle Europese organisaties is in dit gebied gevestigd). Bovendien wordt deze regio 
gekenmerkt door een hoog aandeel startende bedrijven en een relatief sterke nadruk 
op fundamenteel onderzoek naar behandelwijzen tegen kanker. 
 
Hoewel formele strategische allianties worden erkend als essentiële factoren voor 
kennisoverdracht tussen farmaceutische organisaties, worden deze allianties niet door 
organisaties ingezet om lokaal kennis te verwerven. Bovendien zullen allianties die 
gericht zijn op het ontwikkelen van nieuwe geneesmiddelen, zoals O&O-
samenwerkingsverbanden tussen universiteiten en biotechnologiebedrijven, in het 
algemeen geen lokaal karakter hebben, maar zich afspelen over grotere geografische 
afstanden. 
 
Al met al hebben biofarmaceutische organisaties in Europa, met name organisaties die 
zich bezighouden met onderzoek naar nieuwe geneesmiddelen, sterk de neiging tot 
geografische concentratie (co-location). Deze concentratie leidt echter niet tot 
kennisoverdracht via formele samenwerkingsactiviteiten tussen de verschillende 
organisaties. Een mogelijke verklaring hiervoor is dat deze bedrijven zich in een 
geografische regio concentreren vanwege locatiespecifieke kenmerken, zoals externe 
eigenschappen van de agglomeratie. De opkomst van de regio rond Londen als de 
dominante regio voor innovatieve activiteiten in de farmaceutische sector in de 
afgelopen tien jaar, lijkt inderdaad op agglomeratie-effecten te wijzen. Een andere 
mogelijke verklaring is dat geografische nabijheid vooral een belangrijke rol speelt bij 
informele samenwerking. Mogelijk komen, in lijn met de conclusies van Batheld et al. 
(2002), uit onze gegevens alleen bovenregionale allianties (global pipelines) naar 
voren en niet zozeer de regionale (local buzz), aangezien de laatstgenoemde 
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betrekking hebben op meer informele samenwerkingsverbanden. Ten slotte: hoewel 
onze bevindingen suggereren dat formele onderzoeksgerichte allianties geen 
geografische nabijheid vereisen, kan het wel zo zijn dat wetenschappelijke kennis (die 
zoals bekend relatief veel impliciete kennis bevat) vooral toegankelijk wordt gemaakt 
via andere vormen van nabijheid, zoals cognitieve nabijheid of relationele nabijheid. 
Geografische nabijheid is vaak alleen tijdelijk van belang, zodat geografische 
concentratie niet noodzakelijk is. Onderlinge bezoeken door onderzoekers of 
bijeenkomsten op congressen zijn vaak voldoende. 
 
6.2 Relationele nabijheid 
De relationele nabijheid is een maat voor de 'afstand' tussen twee alliantiepartners 
binnen een netwerk van samenwerkingsverbanden tussen bedrijven. Een afstand van 1 
houdt in dat twee bedrijven partners van elkaar zijn, de afstand 2 betekent dat twee 
bedrijven een gemeenschappelijke partner hebben, enzovoort. 
Relationele nabijheid kan worden uitgedrukt in termen van lokale en niet-lokale 
verbanden (linkages). Lokale verbanden in een netwerk houden in dat er allianties 
worden gevormd met voormalige partners of met partners van voormalige partners. 
Bij niet-lokale verbanden zijn twee alliantiepartners in een netwerk met elkaar 
verbonden via een relatief lang pad van voormalige relaties. In dit proefschrift hebben 
we onderzoek verricht naar de evolutie op lange termijn van lokale en niet-lokale 
alliantievorming in het Europese en het mondiale netwerk. 
 
In de periode tussen 1996 en 2002 kent het Europese netwerk van O&O-
samenwerkingsverbanden een sterke fragmentatie in kleine subgroepen2, waarbij 
bedrijven alleen lokale verbanden vormen. Tussen 2002 en 2005 zorgt een golf van 
nieuwe allianties ervoor dat deze subgroepen samenclusteren tot een kolossale 
netwerkcomponent waarin circa 50 procent van alle actieve Europese organisaties met 
                                                 
2 Een van deze subgroepen is het Peptido Project, dat bestaat uit universiteiten en bedrijven 
die samenwerken aan de ontwikkeling van peptiden en die hiervoor een aanzienlijke 
langlopende subsidie van de Europese Unie hebben ontvangen. Een interessant onderwerp 
voor nader onderzoek is het effect dat subsidies of andere institutionele prikkels hebben op de 
ontwikkeling van een meer coherent O&O-netwerk in Europa. 
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elkaar verbonden zijn. Uit het ontstaan van deze kolossale component volgt dat er 
niet-lokale verbanden zijn gevormd die subgroepen op het netwerk aansluiten die 
voorheen niet verbonden waren. Deze conclusie werpt vragen op over de oorzaken 
van het ontstaan van deze kolossale component in Europa. Met andere woorden: wat 
drijft bedrijven ertoe hun ingebedde paden van huidige en voormalige 
samenwerkingspartners te verlaten om nieuwe allianties te vormen met nog 
onbekende partners? Een mogelijke verklaring is geanalyseerd in hoofdstuk 5: het 
effect van ingrijpende technologische ontwikkelingen. Andere mogelijke verklaringen 
zijn de invoering of afschaffing van wet- en regelgeving en veranderingen in het 
investeringsklimaat. 
 
Wanneer we kijken naar het mondiale netwerk van O&O-samenwerkingsverbanden 
tussen 1975 en 2002, worden soortgelijke netwerkstructuren zichtbaar als in het 
Europese netwerk. In deze periode heeft zich een aantal ingrijpende technologische 
veranderingen voorgedaan, die hebben geleid tot wijzigingen in het alliantiegedrag 
van bedrijven en de hieruit voortvloeiende netwerkstructuren. Eerdere onderzoeken 
naar alliantiegedrag van bedrijven suggereren dat bedrijven vooral lokale allianties 
vormen met partners die zich al 'dichtbij' bevinden in het netwerk van 
samenwerkingsverbanden. Door lokale allianties te vormen, kunnen bedrijven 
profiteren van inbedding in een dicht lokaal netwerk. Deze inbedding biedt 
verschillende voordelen, zoals reputatie-effecten, gedeelde sociale normen en 
gelijkaardigheid van kennis (cognitieve nabijheid). Blijkens onderzoek weegt in tijden 
van ingrijpende technologische veranderingen de toegang tot radicaal nieuwe kennis 
via de vorming van niet-lokale verbanden echter zwaarder dan de voordelen van een 
lokale inbedding. 
 
De genoomrevolutie aan het begin van de jaren 1990 kan als een dergelijke 
ingrijpende technologische verandering worden aangemerkt. Maar zelfs wanneer 
radicaal nieuwe technologieën (die in potentie kunnen leiden tot 
competentievernietiging) hun intrede doen op de markt van O&O-partners, hebben 
bedrijven de neiging om hoofdzakelijk samen te werken in de lokale omgeving van 
hun netwerk. Tegelijkertijd groeit een relatief klein aantal bedrijven (zowel grote, 
gevestigde bedrijven als startende bedrijven) uit tot belangrijke centrale actoren in het 
netwerk, doordat ze grote aantallen verbanden vormen (zowel lokaal als niet-lokaal). 
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Deze centrale bedrijven (sterren in het netwerk) vormen verbindingen tussen 
voorheen niet-verbonden segmenten van het netwerk. Ten gevolge van de niet-lokale 
verbanden neemt de gemiddelde afstand tussen bedrijven in het mondiale O&O-
netwerk af. Een netwerkstructuur die zowel lokale, intensief verbonden segmenten 
(neighborhoods) als niet-lokale verbanden herbergt, wordt een small world genoemd. 
Een dergelijke netwerkstructuur vergemakkelijkt de verspreiding van innovatieve 
kennis binnen een netwerk en voorkomt redundantie. 
 
6.3 Cognitieve nabijheid 
Cognitieve nabijheid is de mate van gemeenschappelijkheid in de kennisdomeinen 
van twee actoren. De belangrijkste vraag die we willen beantwoorden, luidt als volgt: 
in hoeverre is de overdracht van relevante kennis tussen twee bedrijven afhankelijk 
van de cognitieve nabijheid tussen deze bedrijven? 
 
Cognitieve nabijheid werd meestal geanalyseerd als een grootheid op het niveau van 
bedrijven, maar recent onderzoek heeft aangetoond dat het een relationeel attribuut is, 
dat mede afhangt van de transactiepartner (Lane & Lubatkin, 1998). We hebben 
cognitieve nabijheid daarom geanalyseerd op het niveau van projecten. In theorie kan 
een bedrijf een beter rendement uit externe transacties behalen wanneer het bedrijf 
intern een kritische massa van soortgelijke kennis heeft opgebouwd (Cohen & 
Levinthal, 1989). Dankzij deze interne kennis kan een bedrijf de externe kennis beter 
begrijpen, integreren en converteren naar nieuwe producten. Aan de hand van deze 
inzichten hebben we in dit proefschrift de volgende aspecten nader geanalyseerd: 
- Voor welk type kennis wordt innovatie gegenereerd door cognitieve nabijheid 
 tussen projecten? 
- Hoeveel van deze 'soortgelijke' kennis is vereist om deze effecten te 
 genereren? 
- Hoe verlopen de kennisstromen tussen de interne en externe projecten in 
 soortgelijke kennisdomeinen? 
 
Om te beginnen: geen van de door ons onderzochte 20 farmaceutische multinationals 
met de hoogste O&O-uitgaven presteert op onderzoeksgebied beter dan de andere 
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bedrijven. Op het niveau van individuele onderzoeksprojecten blijkt dat projecten 
succesvoller zijn indien ze betrekking hebben op een ziektegebied waarop het bedrijf 
een kritische massa van soortgelijke projecten heeft opgebouwd (en daarmee een 
grote cognitieve nabijheid). We verklaren dit resultaat uit leereffecten die 
voortvloeien uit cognitieve nabijheid, hoewel ook andere factoren deze leereffecten 
kunnen versterken, zoals het vermogen van een bedrijf om de beste talenten aan te 
trekken of om een gewilde partner te zijn voor potentiële samenwerkingsverbanden 
met derden. Bovendien zijn interne onderzoeksprojecten vaker succesvol als ze 
betrekking hebben op een ziektegebied waarop slechts weinig externe 
onderzoeksprojecten gaande zijn (niet meer dan 20 procent). Dit resultaat kan worden 
verklaard door een kennisstroom van externe naar interne projecten. Deze 
kennisstroom treedt alleen op als er relatief weinig externe projecten gaande zijn. Een 
mogelijke oorzaak hiervoor is dat kennis alleen van externe naar interne projecten kan 
worden overgedragen indien dezelfde wetenschappers betrokken zijn bij zowel de 
interne als de externe projecten. Dit houdt uiteraard een praktische beperking in voor 
het mogelijke aantal projecten met externe kennisverwerving. Deze interpretatie sluit 
aan op de gedachte dat de voor het ontdekken van geneesmiddelen vereiste kennis een 
sterk impliciet karakter heeft en in de betrokken wetenschappers is ingebed, waardoor 
de overdracht van deze kennis tussen personen en vooral ook tussen projecten wordt 
bemoeilijkt. 
 
6.4 Interactie-effecten 
Bedrijven kunnen worden gepositioneerd in een driedimensionale actieruimte, 
gekenmerkt door de dimensies van geografische, relationele en cognitieve nabijheid. 
De positie van een bedrijf in deze ruimte bepaalt een mate van nabijheid in elk van 
deze drie dimensies. Op het niveau van een regionaal cluster geldt bijvoorbeeld dat 
bedrijven die in een bepaalde regio geconcentreerd zijn (geografische nabijheid), ook 
in meerdere of mindere mate verbonden worden door strategische allianties 
(relationele nabijheid) en actief zijn in min of meer soortgelijke kennisdomeinen 
(cognitieve nabijheid). In Europa zijn de meeste biofarmaceutische organisaties 
geografisch geclusterd, maar ze vormen geen verbanden binnen deze clusters. 
Wanneer clusters echter relatief klein zijn (met een gering aantal organisaties), is de 
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kans groter dat bedrijven uit dezelfde regio met elkaar samenwerken, maar alleen 
wanneer ze op uiteenlopende technologische gebieden actief zijn (zodat 
kennislekkage wordt verhinderd). Deze conclusie sluit aan op de gedachte dat 
geografische clusters binnen een zekere levenscyclus tot rijping komen. Terwijl 
lokale, 'ondersteunende' samenwerking tussen gerelateerde organisaties in de 
beginstadia waardevol is, worden tijdens de volwassenwording van het cluster de niet-
lokale verbanden belangrijker, wanneer de organisaties zich ontwikkelen tot 
internationale spelers in een wereldwijd netwerk. Op bedrijfsniveau kunnen we 
concluderen dat bedrijven eerder geneigd zijn tot samenwerking met partners uit (of 
op korte afstand van) hun huidige netwerk, waarbij geografische locatie geen 
belangrijke rol speelt. Ten slotte blijkt cognitieve nabijheid voor farmaceutische 
bedrijven een belangrijk criterium te zijn bij de selectie van onderzoeksprojecten om 
in te investeren, zowel binnen de eigen organisatie als met externe partners. 
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Implicaties voor het beleid 
Eendimensionale focus op geografische nabijheid vermijden 
Beleidsmakers benadrukken vaak de synergie-effecten die op bepaalde locaties 
ontstaan uit het bijeenkomen van mensen, bedrijven en/of ideeën. Hierbij dienen ze 
zich echter te realiseren dat ze door de nadruk te leggen op locatie als doorslaggevend 
element voor het genereren van synergie en innovatie, impliciet ook aannames maken 
over andere vormen van nabijheid. Ronald Plasterk, de Nederlandse minister van 
onderwijs, heeft onlangs betoogd3 dat het voor radicale innovaties noodzakelijk is dat 
er co-location plaatsvindt van mensen met innovatieve ideeën. Hij beschreef 
vervolgens dat deze mensen gespecialiseerd dienen te zijn in verschillende, maar 
onderling gerelateerde expertisegebieden, zodat er complementaire kennis bijeen 
wordt gebracht. In dit voorbeeld combineert de minister geografische nabijheid met 
cognitieve nabijheid en veronderstelt hij een interactie tussen deze mensen. Met 
andere woorden: radicale innovatie zal alleen optreden als er interactie plaatsvindt 
tussen verschillende vormen van nabijheid tussen mensen (of bedrijven). Veel 
initiatieven voor de vorming van science parks, creatieve clusters en dergelijke zijn 
ten onrechte uitsluitend gebaseerd op geografische nabijheid, terwijl de innovatieve 
kwaliteit van deze regio's voor een groot deel afhankelijk is van de effecten van de 
interactie tussen de verschillende soorten nabijheid. 
 
Een Europese ‘small world’ 
Een expliciete doelstelling van de Europese Unie is het bevorderen van innovatie door 
kennisuitwisseling tussen innovatieve Europese organisaties. Onze conclusies over het 
ontstaan van een small world-structuur in het mondiale netwerk bieden een aantal 
inzichten die waardevol zijn voor Europese beleidsmakers die streven naar diffusie 
van innovatieve kennis door middel van samenwerkingsovereenkomsten tussen 
organisaties. Uit onze conclusies komt naar voren dat grote farmaceutische bedrijven 
                                                 
3 Ronald Plasterk in het televisieprogramma Zomergasten, 27 juli 2008. 
http://www.vpro.nl/programma/zomergasten/ 
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en leveranciers van platformtechnologieën een cruciale rol spelen bij de diffusie van 
kennis in Europa. Deze bedrijven fungeren als sterk verbonden 'sterren' in het 
netwerk, die lokale relaties kunnen combineren met relaties tussen lokale netwerken 
binnen het Europese netwerk als geheel. Voor beleidsmakers is de rol van 
platformtechnologieleveranciers waarschijnlijk van extra belang. Leveranciers van 
platformtechnologieën worden ook wel algemeen-technologische bedrijven genoemd, 
omdat hun technologieën kunnen worden toegepast op verschillende therapeutische 
deelgebieden. De sterke mate van specialisatie bij biofarmaceutische organisaties 
(denk aan onderzoekslaboratoria) vormt vaak een barrière voor samenwerking tussen 
organisaties, maar platformtechnologieleveranciers kunnen deze barrières helpen 
doorbreken door te fungeren als schakel tussen organisaties die verder geen verbanden 
hebben. In het ideale geval kunnen platformtechnologieleveranciers als 
tussenpersonen optreden en de kruisbestuiving van kennis tussen de verschillende 
therapeutische deelgebieden bevorderen. 
 
We weten uit dit proefschrift dat het Europese netwerk tot 2005 sterk is 
gefragmenteerd in lokale netwerken. Bedrijven binnen deze lokale netwerken zijn 
doorgaans niet geografisch geconcentreerd. Om platformtechnologieleveranciers een 
brugfunctie tussen de netwerkfragmenten te kunnen laten vervullen, is nader 
onderzoek nodig om te zien of deze fragmenten (of lokale netwerken) zijn gebaseerd 
op cognitieve nabijheid. Alleen indien de fragmenten in het Europese netwerk 
samenvallen met eilanden van therapeutische specialisatie (cognitieve nabijheid), 
kunnen platformtechnologieën een nuttige brugfunctie tussen deze eilanden vervullen. 
 
 
Samengevat kunnen we zeggen dat dit proefschrift aandacht besteedt aan de invloed 
van verschillende vormen van nabijheid tussen bedrijven op het vermogen van 
bedrijven om toegang te krijgen tot kennis die nodig is voor innovatie. We hebben 
gekeken naar de invloed van (1) geografische concentratie, (2) inbedding in een 
relatienetwerk en (3) actief zijn in soortgelijke kennisdomeinen. Door integratie van 
deze drie nabijheidsperspectieven kunnen we een bijdrage leveren aan verschillende 
vakgebieden, zoals economische geografie, organisatorische sociologie en innovatie 
studies. Verder wordt in dit proefschrift onderzoek gedaan naar de maak-, koop- of 
alliantie-strategieën die farmaceutische bedrijven hanteren om de waarschijnlijkheid 
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van innovatie (het ontdekken van nieuwe geneesmiddelen) te maximaliseren. Uit onze 
resultaten komt naar voren dat bedrijven gelijktijdig meerdere beheersstructuren 
toepassen, zelfs bij het nastreven van soortgelijke innovaties. Deze inzichten 
verhelderen ons inzicht in de grenzen van de onderneming. 
 
Hoewel de conclusies in dit proefschrift over de tijd en de geografische ruimte 
gegeneraliseerd kunnen worden, zijn ze wel specifiek voor de farmaceutische 
industrie. 
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